Pyrazinone derivative and application thereof in medicine
Patent Information
- Application Number
- CN202380030067.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-01-12
- Filing Date
- 2023-04-21
- Publication Date
- 2024-11-26
AI Technical Summary
Existing anti-cancer drugs are difficult to effectively inhibit PARP7 activity, causing cancer cells to evade the immune system and affecting the therapeutic effect.
Develop a pyrazinone derivative compound as a PARP7 inhibitor that interacts with PARP7 through a specific chemical structure and inhibits its activity, thereby inhibiting the growth of cancer cells and restoring interferon signaling.
Effectively inhibits PARP7, significantly inhibits the growth of cancer cells, restores the immune system's ability to recognize and attack cancer, and provides a potential new anti-cancer treatment plan.
Smart Images

Figure CN119032092A_ABST
Abstract
Description
A pyrazinone derivative and its application in medicine Technical Field
[0001] The present invention relates to a compound of general formula (I) or its stereoisomers, deuterated compounds, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals, as well as intermediates and preparation methods, and their use in preparing drugs for treating diseases related to PARP7 activity or expression. Background Art
[0002] PARP, short for poly-ADP-ribose polymerase, is involved in a range of cellular processes, including DNA repair and genomic stability. This protein family consists of 17 members, divided into polyPARPs and monoPARPs. The MonoPARP protein family plays a role in various stress responses associated with the development of cancer, inflammatory diseases, and neurodegenerative diseases. Its member PARP7 has been shown to be overactive in tumors and plays a key role in cancer cell survival.
[0003] Studies have found that many cancer cells rely on PARP7 for intrinsic cell survival, which in turn enables cancer cells to "hide" from the immune system. Inhibiting PARP7 can effectively suppress cancer cell growth and restore interferon signaling, effectively releasing the "brakes" that cancer uses to evade the immune system and suppress innate and adaptive immune mechanisms. In several cancer models, PARP7 inhibitors have demonstrated persistent tumor growth inhibition, potent antiproliferative activity, and restoration of interferon signaling, making them promising targets for the development of new anticancer drugs.
[0004] Summary of the Invention
[0005] The present invention aims to provide a class of heterocyclic compounds or pharmaceutically acceptable salts thereof for use as PARP7 inhibitors. The compounds of the present invention can effectively inhibit PARP7 and can be used to treat diseases such as tumors.
[0006] The present invention provides a compound of general formula (A) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein
[0007] In some embodiments, W is selected from a bond, C(=O);
[0008] In some embodiments, W is selected from a bond;
[0009] In some embodiments, W is selected from C(═O);
[0010] In some embodiments, the compound of formula (A) is selected from the compounds of formula (I),
[0011] In some embodiments, the compound of formula (I) is selected from the compound of formula (II),
[0012] In some embodiments, Selected from
[0013] In some embodiments, Selected from
[0014] In some embodiments, Selected from
[0015] In some embodiments, Ring B is selected from is a single bond or a double bond;
[0016] In some embodiments, Selected from
[0017] In some embodiments, Selected from
[0018] In some embodiments, Z is selected from N, C, or CH;
[0019] In some embodiments, Y is selected from a bond, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)2N(R y )-、-N(R y )-、C 1-4 Alkylene, -OC 1-3 Alkylene-, -C 1-3 Alkylene O-, -C 1-2 Alkylene OC 1-2 Alkylene, -C 1-3 Alkylene S-, -C 1-3 Alkylene S(=O)-, -C 1-3 Alkylene S(=O)2-, -N(R y )C 1-3 Alkylene-, -C 1-3 Alkylene N(R y )-、-C 1-2 Alkylene N(R y )-C 1-2Alkylene, wherein the alkylene is optionally substituted by 1 to 4 groups selected from halogen, =O, =S, OH, cyano, C 1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 substituted by a cycloalkyl substituent;
[0020] In some embodiments, Y is selected from a bond, -O-, -N(R y )-、C 1-3 Alkylene, -OC 1-2 Alkylene-, -C 1-2 Alkylene O-, -C 1-2 Alkylene OC 1-2 Alkylene, -C 1-2 Alkylene S-, -C 1-2 Alkylene S(=O)2-, -N(R y )C 1-2 Alkylene-, -C 1-2 Alkylene N(R y )-、-C 1-2 Alkylene N(R y )-C 1-2 Alkylene, wherein the alkylene is optionally substituted by 1 to 4 groups selected from halogen, =O, =S, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a cycloalkyl substituent;
[0021] In some embodiments, Y is selected from a bond, -O-, -N(R y )-、-N(R y )C(=O)-、-C(=O)N(R y )-, -CH2-, -CH2CH2-, -CH2CH2CH2-, -OCH2-, -OCH2CH2-, -CH2O-, -CH2CH2O-, -CH2OCH2-, -CH2S-, -CH2CH2S-, -CH2S(=O)2-, -CH2CH2S(=O)2-, -N(R y )CH2-、-N(R y )CH2CH2-、-CH2N(R y )-、-CH2CH2N(R y )-、-N(R y )C(=O)CH2-、-CH2C(=O)N(R y )-, wherein CH2 is optionally substituted by 0 to 2 groups selected from H, =O, =S, OH, cyano, C 1-4 Alkyl, halogen-substituted C1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a cycloalkyl substituent;
[0022] In some embodiments, Y is selected from a bond, -O-, -NHC(=O)-, -C(=O)NH-, -CH2-, -CH2CH2-, -CH2CH2CH2-, -OCH2-, -OCH2CH2-, -CH2O-, -CH2CH2O-, -NHCH2-, -NHCH2CH2-, -CH2NH-, -CH2CH2NH-, -NHC(=O)CH2-, -CH2C(=O)NH-, -N(CH3)C(= O)-, -C(=O)N(CH3)-, -CH2C(=O)NH-, -CH2C(=O)N(CH3)-, -N(CH2CH3)C(=O)-, -N(CH(CH3)2)C(=O)-, -N( CH2CH(CH3)2)C(=O)-, -N(cyclopropyl)C(=O)-, -N(CH2-cyclopropyl)C(=O)-, -C(=O)N(CH2CH3)-, -C(=O)N(CH(CH3)2)-, -C(=O)N(CH2CH(CH3)2)-、-C(=O)N(cyclopropyl)-、-C(=O)N(CH2-cyclopropyl)-、-C(=O)N(CD3)-、-C(=O)N(CH2-oxetanyl)-、-C(=O)N(CH2-oxolanyl)-、-C(=O)N(CH2-azetidinyl)-、-C(=O)N(CH2-pyrrolidinyl)-、-C(=O)N(CH2-cyclopentyl)-、-C(=O)N(C H2CH2CH3)-, -C(=O)N(CH2CH(CH2CH3)2)-, -C(=O)N(CH2CH2CH2CH3)-, -C(=O)N(CH2CH2CH(CH3)2)-, -C( =O)N(CH2CH(CH3)CH2CH3)-, -C(=O)N(n-octyl)-, -C(=S)N(CH3)-, -C(=S)N(CH2CH3)-, -C(=S)N(CH2-cyclopropyl)-, -CH2S(=O)2-;
[0023] In some embodiments, R y Each independently selected from H, C 1-6 Alkyl or C 3-6 Cycloalkyl, wherein the alkyl or cycloalkyl is optionally substituted by 1 to 4 groups selected from deuterium, halogen, CF3, OH, cyano, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, 3 to 8 membered heterocyclic group or C 3-6The heterocyclic group is substituted by a cycloalkyl substituent, wherein the heterocyclic group contains 1 to 3 heteroatoms selected from O, S, and N;
[0024] In some embodiments, R y Each independently selected from H, C 1-4 Alkyl or C 3-6 Cycloalkyl, wherein the alkyl or cycloalkyl is optionally substituted by 1 to 4 groups selected from deuterium, halogen, CF3, OH, cyano, NH2, C 1-4 Alkyl, C 1-4 Alkoxy, 3 to 8 membered heterocyclic group or C 3-6 The heterocyclic group is substituted by a cycloalkyl substituent, wherein the heterocyclic group contains 1 to 3 heteroatoms selected from O, S, and N;
[0025] In some embodiments, R y Each independently selected from H, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, wherein the methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl is optionally substituted by 1 to 4 groups selected from deuterium, halogen, CF3, OH, cyano, NH2, C 1-4 Alkyl, C 1-4 Alkoxy, 3 to 8 membered heterocyclic group or C 3-6 The heterocyclic group is substituted by a cycloalkyl substituent, wherein the heterocyclic group contains 1 to 3 heteroatoms selected from O, S, and N;
[0026] In some embodiments, R b Each independently selected from H, halogen, cyano, OH, =O, C 1-6 Alkyl, C 1-6 Alkoxy, -(CH2) q -C 3-6 Cycloalkyl, wherein the -CH2-, alkyl, alkoxy or cycloalkyl is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, NH2, C 1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy or C 3-6 substituted by a cycloalkyl substituent;
[0027] In some embodiments, R b Each independently selected from H, halogen, cyano, OH, =O, C 1-4 Alkyl, C 1-4 Alkoxy, -(CH2) q -C 3-6 Cycloalkyl, wherein the -CH2-, alkyl, alkoxy or cycloalkyl is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, NH2, C 1-4 Alkyl, halogen-substituted C1-4 Alkyl, C 1-4 Alkoxy or C 3-6 substituted by a cycloalkyl substituent;
[0028] In some embodiments, R b Each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl or isopropyl, wherein the methyl, ethyl, propyl or isopropyl is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, NH2, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 substituted by a cycloalkyl substituent;
[0029] In some embodiments, R b Each is independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl or isopropyl;
[0030] In some embodiments, Ring A is selected from C 6-10 aromatic ring, 5-10 membered heteroaromatic ring or 5-10 membered heterocyclic ring, wherein the heteroaromatic ring or heterocyclic ring contains 1 to 5 heteroatoms selected from O, S, and N; in some embodiments, ring X is selected from C 6-10 Aromatic ring, 5-10 membered heteroaromatic ring, C 3-10 A carbocyclic ring or a 5-10 membered heterocyclic ring, wherein the heteroaromatic ring or heterocyclic ring contains 1 to 5 heteroatoms selected from O, S, and N;
[0031] In some embodiments, ring X is selected from a 5-6 membered heteroaromatic ring, a 5-6 membered heterocyclic ring, an 8-10 membered fused heteroaromatic ring or an 8-10 membered fused heterocyclic ring, wherein the heteroaromatic ring or heterocyclic ring contains 1 to 5 heteroatoms selected from O, S, and N;
[0032] In some embodiments, ring X is selected from a 5-6 membered heteroaromatic ring or a 5-6 membered heterocyclic ring, wherein the heteroaromatic ring or heterocyclic ring contains 1 to 5 heteroatoms selected from O, S, and N;
[0033] In some embodiments, ring X is selected from an 8-10 membered cyclic heteroaromatic ring or an 8-10 membered cyclic heterocyclic ring, wherein the heteroaromatic ring or heterocyclic ring contains 1 to 5 heteroatoms selected from O, S, and N;
[0034] In some embodiments, ring X is selected from C 3-10 Cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl, 5- to 6-membered heteroaromatic ring, 5- to 6-membered heterocycle, 8- to 10-membered paracyclic heteroaromatic ring, or 8- to 10-membered paracyclic heterocycle, wherein the heterocycloalkyl, heteroaromatic ring, or heterocycle contains 1 to 5 heteroatoms selected from O, S, and N;
[0035] In some embodiments, ring X is selected from C3-6 Monocyclic cycloalkyl, C 5-10 Cycloalkyl, C 5-11 Spirocyclic cycloalkyl, C 5-11 Bridged cycloalkyl, 4-7 membered monocyclic heterocycloalkyl, 5-10 membered cyclic heterocycloalkyl, 5-11 membered spirocyclic heterocycloalkyl, 5-11 membered bridged heterocycloalkyl, phenyl, 5-6 membered heteroaromatic ring, 8-10 membered cyclic heteroaromatic ring, wherein the heterocycloalkyl, heteroaromatic ring or heterocycle contains 1 to 5 heteroatoms selected from O, S and N;
[0036] In some embodiments, ring X is selected from phenyl, a 5-6 membered heteroaromatic ring, a 5-membered and 5-membered heteroaromatic ring, a 5-membered and 6-membered heteroaromatic ring, wherein the heteroaromatic ring contains 1 to 5 heteroatoms selected from O, S, and N;
[0037] In some embodiments, ring X is selected from a pyridine ring, a pyrimidine ring, a pyrazine ring, a pyridazine ring, a thiophene ring, a thiazole ring, a furan ring, an oxazole ring, a pyrrole ring, a pyrazole ring, or an imidazole ring;
[0038] In some embodiments, ring X is selected from a triazine ring, a benzothiazole ring, a pyridothiazole ring, a pyrimidothiazole ring, a pyridazinothiazole ring, a pyrazinothiazole ring, a benzoxazole ring, a pyridotoxazole ring, a pyrimidotoxazole ring, a pyridazinotoxazole ring, a pyrazinotoxazole ring, a pyridopyrrole ring, a pyridopyrazole ring, a pyrimidothiphene ring, a pyrimidopyrazole ring, a pyrimidopyrrole ring, a pyrimidoimidazole ring, a pyrimidotriazole ring, a pyrimidofuran ring, a pyrimidopyrrole ring, Quinoline ring, isoquinoline ring, pyrimidopyridine ring, triazole ring, triazole pyridine ring (), triazole thiazole ring (such as), triazole oxazole ring, triazole imidazole ring, triazole pyrazole ring,
[0039] In some embodiments, ring X is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclobutylspirocyclobutyl, cyclobutylspirocyclopentyl, cyclobutylspirocyclohexyl, cyclopentylspirocyclopentyl, cyclopentylspirocyclohexyl, cyclohexylspirocyclohexyl, cyclobutylspiroazetidinyl, cyclobutylspiroazetidinyl, cyclobutylspiroazetidinyl, cyclobutylspiroazetidinyl, cyclopentyl ... Hexylazaspirocyclohexyl, azetidinylspiroazacyclohexyl, azetylspiroazacyclopentyl, azetylspiroazacyclohexyl, azetylazaspirocyclohexyl, cyclobutylcyclobutyl, cyclobutylcyclopentyl, cyclobutylcyclohexyl, cyclopentylcyclopentyl, cyclopentylcyclohexyl, cyclohexylcyclohexyl, cyclobutylazetidinyl, cyclobutylazetyl, cyclobutyl Azacyclohexyl, cyclopentylazacyclopentyl, cyclopentylazacyclohexyl, cyclohexylazacyclohexyl, azetidinazacyclohexyl, azacyclopentylazacyclopentyl, azacyclopentylazacyclohexyl, azacyclohexylazacyclohexyl, azetidinyl, azacyclopentyl, azacyclohexyl, oxetanyl, oxolanyl, oxetanyl, triazine ring, benzothiol azole ring, pyridothiazole ring, pyrimidothiazole ring, pyridazinothiazole ring, pyrazinothiazole ring, benzoxazole ring, pyridothiazole ring, pyrimidothiazole ring, pyridazinothiazole ring, pyrazinothiazole ring, pyridopyrrole ring, pyridopyrazole ring, pyrimidothiphene ring, pyrimidopyrazole ring, pyrimidopyrrole ring, pyrimidoimidazole ring, pyrimidotriazolyl ring, pyrimidofuran ring, pyrimidopyrrole ring, Quinoline ring, isoquinoline ring, pyrimidopyridine ring, triazole ring, triazolopyridine ring, triazolothiazole ring, triazolooxazole ring, triazoloimidazole ring, triazolopyrazole ring, a pyridine ring, a pyrimidine ring, a pyrazine ring, a pyridazine ring, a thiophene ring, a thiazole ring, a furan ring, an oxazole ring, a pyrrole ring, a pyrazole ring or an imidazole ring;
[0040] In some embodiments, Selected from
[0041] In some embodiments, R x 、R a Each independently selected from H, halogen, cyano, OH, =O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, -SO2-C 1-6 Alkyl, -C(=O)C 1-6 Alkyl, -(CH2) q -C 3-10 Carbocyclic ring or -(CH2) q-3 to 12 membered heterocyclic ring, wherein said -CH2-, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, =O, NH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 substituted by a cycloalkyl group or a 3- to 10-membered heterocyclic ring containing 1 to 3 heteroatoms selected from O, S, and N;
[0042] In some embodiments, R a Selected from R a1 、R a2 ;
[0043] In some embodiments, R a1 、R a2 Each independently selected from H, halogen, cyano, OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, -SO2-C 1-6 Alkyl, -C(=O)C 1-6 Alkyl, -(CH2) q -C 3-10 Carbocyclic ring or -(CH2) q -3 to 12 membered heterocyclic ring, wherein said -CH2-, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, =O, C 1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 substituted by a cycloalkyl group or a 3- to 10-membered heterocyclic ring containing 1 to 3 heteroatoms selected from O, S, and N;
[0044] In some embodiments, R x 、R a1 、R a2 Each independently selected from H, halogen, cyano, OH, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 1-4 Alkylthio, -SO2-C 1-4 Alkyl, -C(=O)C 1-4 Alkyl, -(CH2) q -C3-6 Carbocyclic ring or -(CH2) q -3 to 6 membered heterocyclic ring, wherein said -CH2-, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, =O, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a cycloalkyl group or a 3- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms selected from O, S, and N;
[0045] In some embodiments, R x 、R a1 、R a2 Each independently selected from H, F, Cl, Br, I, cyano, OH, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, -SCH3, -SCH2CH3, -SO2CH3, -S O2CH2CH3, -C(=O)CH3, -C(=O)CH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl, phenyl, pyridyl, thiazolyl, thienyl, oxazolyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, the methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, -SCH3, -SCH2CH3, -SO2CH3, -SO2CH2CH3, -C(=O)CH3, -C(=O)CH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl, phenyl, pyridyl, thiazolyl, thienyl, oxazolyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, the methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, -SCH3, -SCH2CH3, -SO2CH3, -SO2CH2CH3, -C(=O)CH3, -C(=O)CH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl, phenyl, pyridyl, thiazolyl, thienyl, oxazolyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a cycloalkyl substituent;
[0046] In some embodiments, R xEach independently selected from H, F, Cl, Br, I, cyano, OH, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, -SCH3, -SCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, said methyl, ethyl, propyl, isopropyl, vinyl, ethynyl, methoxy, ethoxy, -SCH3, -SCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl, phenyl, pyridyl, thiazolyl, thienyl, oxazolyl, furyl, pyrrolyl, pyrazolyl, imidazolyl is optionally substituted with 1 to 4 substituents selected from F, OH, cyano, methyl, ethyl, methoxy or ethoxy;
[0047] In some embodiments, R x Each is independently selected from H, F, Cl, Br, cyano, isopropyl, CD3, CF3, CHF2, CH2F, cyclopropyl, cyclobutyl;
[0048] In some embodiments, R a1 is selected from H, F, Cl, Br, I, cyano, CF3, CHF2, CH2F, methyl, ethyl, propyl, isopropyl, ethynyl, methoxy, ethoxy, -SCH3, -SCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
[0049] In some embodiments, R a1 is selected from F, Cl, Br, CF3, CHF2, CH2F, methyl, cyano, cyclopropyl, isopropyl;
[0050] In some embodiments, R a2 Selected from H;
[0051] In some embodiments, L is selected from -Q1-Ak1-Q2-Ak2-, the right side of which is connected to ring B;
[0052] In some embodiments, L is selected from -N(R q )-Ak1-O-Ak2-, -O-Ak1-O-Ak2-, -O-Ak1-N(R q )-Ak2-、-N(R q )-Ak1-N(R q )-Ak2-, the left side is directly connected to the pyridazinone ring;
[0053] In some embodiments, L is selected from The left side is directly connected to the pyridazinone ring;
[0054] In some embodiments, L is selected from The left side is directly connected to the pyridazinone ring;
[0055] In some embodiments, L is selected from
[0056] In some embodiments, Ak1 and Ak2 are each independently selected from C 1-4 Alkylene, C 2-4 Alkenylene, C 2-4 Alkyne group, wherein Ak1 is optionally substituted by 0 to 4 R k1 The Ak2 is optionally substituted with 0 to 4 R k2 replace;
[0057] In some embodiments, Ak1 and Ak2 are each independently selected from C 1-3 Alkylene, C 2-3 Alkenylene, C 2-3 Alkyne group, wherein Ak1 is optionally substituted by 0 to 4 R k1 The Ak2 is optionally substituted with 0 to 4 R k2 replace;
[0058] In some embodiments, Ak1 and Ak2 are each independently selected from methylene, ethylene, propylene, vinylene, propenylene, ethynylene, and propynylene, wherein Ak1 is optionally substituted by 0 to 4 R k1 The Ak2 is optionally substituted with 0 to 4 R k2 replace;
[0059] In some embodiments, R k1 、R k2 Each independently selected from halogen, cyano, OH, =O, NH2, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -OC 3-6 Carbon ring, C 3-6 Carbocyclic or 4 to 7 membered heterocyclic rings, wherein the alkyl, alkenyl, alkynyl, alkoxy, carbocyclic or heterocyclic rings are optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, -OC 3-8 Carbon ring, C 3-8 substituted by a carbocyclic or 4- to 10-membered heterocyclic substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;
[0060] In some embodiments, R k1 、R k2 Each independently selected from halogen, cyano, OH, =O, NH2, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Carbocyclic or 4 to 7 membered heterocyclic rings, wherein the alkyl, alkoxy, carbocyclic or heterocyclic rings are optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, NH2, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 is substituted by a carbocyclic or 4- to 6-membered heterocyclic substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;
[0061] In some embodiments, R k1 、R k2 Each independently selected from F, Cl, Br, I, cyano, OH, =O, NH2, NH(CH3), N(CH3)2, methyl, ethyl, propyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, azetyl, azetyl, oxetyl, oxetyl, pyridine, phenyl, the methyl, ethyl, propyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, azetyl, azetyl, oxetyl, oxetyl, pyridine, phenyl is optionally substituted by 1 to 4 selected from halogen, OH, cyano, NH2, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 is substituted by a carbocyclic or 4- to 6-membered heterocyclic substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;
[0062] In some embodiments, R k1 With R k1 、R k2 With R k2 、R k1 With R k2 Direct connection to form C 3-6 A carbocyclic ring or a 4- to 7-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, =O, OH, cyano, C 1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6Substituted by a cycloalkyl substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;
[0063] In some embodiments, R k1 With R k1 、R k2 With R k2 、R k1 With R k2 Direct connection to form C 3-6 A carbocyclic ring or a 4- to 7-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, =O, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Substituted by a cycloalkyl substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;
[0064] In some embodiments, Q1 and Q2 are each independently selected from O, S, N (R q )、C(=O)、C(=O)N(R q )、N(R q )C(=O), C(=O)O, OC(=O), S(=O), S(=O)2, S(=O)2N(R q )、N(R q )S(=O)2、N(R q )C(=O)N(R q )、N(R q )C(=O)N(R q );
[0065] In some embodiments, Q1 and Q2 are each independently selected from O, S, N (R q )、C(=O)、C(=O)N(R q )、N(R q )C(=O), S(=O)2;
[0066] In some embodiments, R q Each independently selected from H, C 1-6 Alkyl or C 3-6 Cycloalkyl, wherein the alkyl or cycloalkyl is optionally substituted by 1 to 4 groups selected from halogen, CF3, OH, cyano, NH2, C 1-6 Alkyl or C 1-6 substituted by an alkoxy substituent;
[0067] In some embodiments, R q Each independently selected from H, C 1-4Alkyl, wherein the alkyl group is optionally substituted by 1 to 4 groups selected from halogen, CF3, OH, cyano, NH2, C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent;
[0068] In some embodiments, R q Each is independently selected from H, methyl, ethyl;
[0069] In some embodiments, R q With R k1 or R k2 Directly connected to form a 4- to 7-membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, =O, OH, cyano, C 1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Substituted by a cycloalkyl substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;
[0070] In some embodiments, R q With R k1 、R q With R k2 Directly connected to form a 4- to 7-membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, =O, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Substituted by a cycloalkyl substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;
[0071] In some embodiments, R q With R k1 、R q With R k2 Directly connected to form a 4- to 7-membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, =O, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Substituted by a cycloalkyl substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;
[0072] In some embodiments, q is each independently selected from 0, 1, 2, 3, or 4;
[0073] In some embodiments, a is selected from 0, 1, 2, 3, or 4;
[0074] In some embodiments, b is selected from 0, 1, 2, 3, or 4;
[0075] In some embodiments, x is selected from 0, 1, 2, 3, or 4;
[0076] In some embodiments, b is selected from 0, 1, 2, 3;
[0077] In some embodiments, x is selected from 1, 2;
[0078] Optionally, 1 to 10 H are replaced by D in the compound represented by general formula (A).
[0079] As a first embodiment of the present invention, the compound represented by the following general formula (A) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,
[0080] W is selected from a bond, C(=O);
[0081] Ring B is selected from is a single bond or a double bond;
[0082] Z is selected from N, C or CH;
[0083] Y is selected from a bond, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)2N(R y )-、-N(R y )-、C 1-4 Alkylene, -OC 1-3 Alkylene-, -C 1-3 Alkylene O-, -C 1-2 Alkylene OC 1-2 Alkylene, -C 1-3 Alkylene S-, -C 1-3 Alkylene S(=O)-, -C 1-3 Alkylene S(=O)2-, -N(R y )C 1-3 Alkylene-, -C 1-3 Alkylene N(R y )-、-C 1-2 Alkylene N(R y )-C 1-2 Alkylene, wherein the alkylene is optionally substituted by 1 to 4 groups selected from halogen, =O, =S, OH, cyano, C 1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 substituted by a cycloalkyl substituent;
[0084] R y Each independently selected from H, C1-6 Alkyl or C 3-6 Cycloalkyl, wherein the alkyl or cycloalkyl is optionally substituted by 1 to 4 groups selected from deuterium, halogen, CF3, OH, cyano, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, 3 to 8 membered heterocyclic group or C 3-6 The heterocyclic group is substituted by a cycloalkyl substituent, wherein the heterocyclic group contains 1 to 3 heteroatoms selected from O, S, and N;
[0085] R b Each independently selected from H, halogen, cyano, OH, =O, C 1-6 Alkyl, C 1-6 Alkoxy, -(CH2) q -C 3-6 Cycloalkyl, wherein the -CH2-, alkyl, alkoxy or cycloalkyl is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, NH2, C 1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy or C 3-6 substituted by a cycloalkyl substituent;
[0086] Ring A is selected from C 6-10 Aromatic ring, 5-10 membered heteroaromatic ring or 5-10 membered heterocyclic ring, wherein the heteroaromatic ring or heterocyclic ring contains 1 to 5 heteroatoms selected from O, S and N;
[0087] Ring X is selected from C 6-10 Aromatic ring, 5-10 membered heteroaromatic ring, C 3-10 A carbocyclic ring or a 5-10 membered heterocyclic ring, wherein the heteroaromatic ring or heterocyclic ring contains 1 to 5 heteroatoms selected from O, S, and N;
[0088] R x 、R a Each independently selected from H, halogen, cyano, OH, =O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, -SO2-C 1-6 Alkyl, -C(=O)C 1-6 Alkyl, -(CH2) q -C 3-10 Carbocyclic ring or -(CH2) q -3 to 12 membered heterocyclic ring, wherein said -CH2-, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, =O, NH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 substituted by a cycloalkyl group or a 3- to 10-membered heterocyclic ring containing 1 to 3 heteroatoms selected from O, S, and N;
[0089] L is selected from -Q1-Ak1-Q2-Ak2-, and the right side is connected to ring B;
[0090] Ak1 and Ak2 are each independently selected from C 1-4 Alkylene, C 2-4 Alkenylene, C 2-4 Alkyne group, wherein Ak1 is optionally substituted by 0 to 4 R k1 The Ak2 is optionally substituted with 0 to 4 R k2 replace;
[0091] R k1 、R k2 Each independently selected from halogen, cyano, OH, =O, NH2, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -OC 3-6 Carbon ring, C 3-6 Carbocyclic or 4 to 7 membered heterocyclic rings, wherein the alkyl, alkenyl, alkynyl, alkoxy, carbocyclic or heterocyclic rings are optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, -OC 3-8 Carbon ring, C 3-8 substituted by a carbocyclic or 4- to 10-membered heterocyclic substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;
[0092] Alternatively, R k1 With R k1 、R k2 With R k2 、R k1 With R k2 Direct connection to form C 3-6 A carbocyclic ring or a 4- to 7-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, =O, OH, cyano, C 1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, C3-6 Substituted by a cycloalkyl substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;
[0093] Q1, Q2 are each independently selected from O, S, N (R q )、C(=O)、C(=O)N(R q )、N(R q )C(=O), C(=O)O, OC(=O), S(=O), S(=O)2, S(=O)2N(R q )、N(R q )S(=O)2、N(R q )C(=O)N(R q )、N(R q )C(=O)N(R q );
[0094] R q Each independently selected from H, C 1-6 Alkyl or C 3-6 Cycloalkyl, wherein the alkyl or cycloalkyl is optionally substituted by 1 to 4 groups selected from halogen, CF3, OH, cyano, NH2, C 1-6 Alkyl or C 1-6 substituted by an alkoxy substituent;
[0095] Alternatively, R q With R k1 or R k2 Directly connected to form a 4- to 7-membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, =O, OH, cyano, C 1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Substituted by a cycloalkyl substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;
[0096] q is each independently selected from 0, 1, 2, 3 or 4;
[0097] a is selected from 0, 1, 2, 3 or 4;
[0098] b is selected from 0, 1, 2, 3 or 4;
[0099] x is selected from 0, 1, 2, 3 or 4;
[0100] Optionally, 1 to 10 H are replaced by D in the compound represented by general formula (A).
[0101] As a second embodiment of the present invention, the compound represented by the above general formula (A) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,
[0102] The compound of general formula (A) is selected from the compounds represented by general formula (I)
[0103] The definitions of the respective groups are the same as those in the first embodiment.
[0104] As a third embodiment of the present invention, the compound represented by the following general formula (II) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,
[0105] Ring X is selected from a 5-6 membered heteroaromatic ring or a 5-6 membered heterocyclic ring, wherein the heteroaromatic ring or heterocyclic ring contains 1 to 5 heteroatoms selected from O, S, and N;
[0106] Or ring X is selected from an 8-10 membered cyclic heteroaromatic ring or an 8-10 membered cyclic heterocyclic ring, wherein the heteroaromatic ring or heterocyclic ring contains 1 to 5 heteroatoms selected from O, S, and N;
[0107] R a1 、R a2 Each independently selected from H, halogen, cyano, OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, -SO2-C 1-6 Alkyl, -C(=O)C 1-6 Alkyl, -(CH2) q -C 3-10 Carbocyclic ring or -(CH2) q -3 to 12 membered heterocyclic ring, wherein said -CH2-, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, =O, C 1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 substituted by a cycloalkyl group or a 3- to 10-membered heterocyclic ring containing 1 to 3 heteroatoms selected from O, S, and N;
[0108] The definitions of the remaining groups are the same as those of the second embodiment of the present invention.
[0109] As a fourth embodiment of the present invention, the compound represented by the above general formula (II) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,
[0110] Y is selected from a bond, -O-, -N(R y )-、C 1-3Alkylene, -OC 1-2 Alkylene-, -C 1-2 Alkylene O-, -C 1-2 Alkylene OC 1-2 Alkylene, -C 1-2 Alkylene S-, -C 1-2 Alkylene S(=O)2-, -N(R y )C 1-2 Alkylene-, -C 1-2 Alkylene N(R y )-、-C 1-2 Alkylene N(R y )-C 1-2 Alkylene, wherein the alkylene is optionally substituted by 1 to 4 groups selected from halogen, =O, =S, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a cycloalkyl substituent;
[0111] R y Each independently selected from H, C 1-4 Alkyl or C 3-6 Cycloalkyl, wherein the alkyl or cycloalkyl is optionally substituted by 1 to 4 groups selected from deuterium, halogen, CF3, OH, cyano, NH2, C 1-4 Alkyl, C 1-4 Alkoxy, 3 to 8 membered heterocyclic group or C 3-6 The heterocyclic group is substituted by a cycloalkyl substituent, wherein the heterocyclic group contains 1 to 3 heteroatoms selected from O, S, and N;
[0112] R x 、R a1 、R a2 Each independently selected from H, halogen, cyano, OH, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 1-4 Alkylthio, -SO2-C 1-4 Alkyl, -C(=O)C 1-4 Alkyl, -(CH2) q -C 3-6 Carbocyclic ring or -(CH2) q -3 to 6 membered heterocyclic ring, wherein said -CH2-, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, =O, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6substituted by a cycloalkyl group or a 3- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms selected from O, S, and N;
[0113] R b Each independently selected from H, halogen, cyano, OH, =O, C 1-4 Alkyl, C 1-4 Alkoxy, -(CH2) q -C 3-6 Cycloalkyl, wherein the -CH2-, alkyl, alkoxy or cycloalkyl is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, NH2, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 substituted by a cycloalkyl substituent;
[0114] Ak1 and Ak2 are each independently selected from C 1-3 Alkylene, C 2-3 Alkenylene, C 2-3 Alkyne group, wherein Ak1 is optionally substituted by 0 to 4 R k1 The Ak2 is optionally substituted with 0 to 4 R k2 replace;
[0115] R k1 、R k2 Each independently selected from halogen, cyano, OH, =O, NH2, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Carbocyclic or 4 to 7 membered heterocyclic rings, wherein the alkyl, alkoxy, carbocyclic or heterocyclic rings are optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, NH2, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 is substituted by a carbocyclic or 4- to 6-membered heterocyclic substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;
[0116] Alternatively, R k1 With R k1 、R k2 With R k2 、R k1 With R k2 Direct connection to form C 3-6 A carbocyclic ring or a 4- to 7-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, =O, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C1-4 Alkoxy, C 3-6 Substituted by a cycloalkyl substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;
[0117] Q1, Q2 are each independently selected from O, S, N (R q )、C(=O)、C(=O)N(R q )、N(R q )C(=O), S(=O)2;
[0118] R q Each independently selected from H, C 1-4 Alkyl, wherein the alkyl group is optionally substituted by 1 to 4 groups selected from halogen, CF3, OH, cyano, NH2, C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent;
[0119] Alternatively, R q With R k1 、R q With R k2 Directly connected to form a 4- to 7-membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, =O, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Substituted by a cycloalkyl substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;
[0120] The remaining groups are defined the same as in the second or third embodiment of the present invention.
[0121] As a fifth embodiment of the present invention, the compound represented by the above general formula (II) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,
[0122] Ring X is selected from a pyridine ring, a pyrimidine ring, a pyrazine ring, a pyridazine ring, a thiophene ring, a thiazole ring, a furan ring, an oxazole ring, a pyrrole ring, a pyrazole ring or an imidazole ring;
[0123] Or ring X is selected from triazine ring, benzothiazole ring, pyridothiazole ring, pyrimidothiazole ring, pyridazinothiazole ring, pyrazinothiazole ring, benzoxazole ring, pyridotoxazole ring, pyrimidotoxazole ring, pyridazinotoxazole ring, pyrazinotoxazole ring, pyridopyrrole ring, pyridopyrazole ring, pyrimidothiphene ring, pyrimidopyrazole ring, pyrimidopyrrole ring, pyrimidoimidazole ring, pyrimidotriazole ring, pyrimidofuran ring, pyrimidopyrrole ring, Quinoline ring, isoquinoline ring, pyrimidopyridine ring, triazole ring, triazolopyridine ring, triazolothiazole ring, triazolooxazole ring, triazoloimidazole ring, triazolopyrazole ring,
[0124] R x 、R a1 、R a2 Each independently selected from H, F, Cl, Br, I, cyano, OH, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, -SCH3, -SCH2CH3, -SO2CH3, -S O2CH2CH3, -C(=O)CH3, -C(=O)CH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl, phenyl, pyridyl, thiazolyl, thienyl, oxazolyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, the methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, -SCH3, -SCH2CH3, -SO2CH3, -SO2CH2CH3, -C(=O)CH3, -C(=O)CH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl, phenyl, pyridyl, thiazolyl, thienyl, oxazolyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, the methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, -SCH3, -SCH2CH3, -SO2CH3, -SO2CH2CH3, -C(=O)CH3, -C(=O)CH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl, phenyl, pyridyl, thiazolyl, thienyl, oxazolyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a cycloalkyl substituent;
[0125] R b Each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl or isopropyl, wherein the methyl, ethyl, propyl or isopropyl is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, NH2, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 substituted by a cycloalkyl substituent;
[0126] Y is selected from a bond, -O-, -N(R y )-、-N(R y )C(=O)-、-C(=O)N(R y)-, -CH2-, -CH2CH2-, -CH2CH2CH2-, -OCH2-, -OCH2CH2-, -CH2O-, -CH2CH2O-, -CH2OCH2-, -CH2S-, -CH2CH2S-, -CH2S(=O)2-, -CH2CH2S(=O)2-, -N(R y )CH2-、-N(R y )CH2CH2-、-CH2N(R y )-、-CH2CH2N(R y )-、-N(R y )C(=O)CH2-、-CH2C(=O)N(R y )-, wherein CH2 is optionally substituted by 0 to 2 groups selected from H, =O, =S, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a cycloalkyl substituent;
[0127] R y Each independently selected from H, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, wherein the methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl is optionally substituted by 1 to 4 groups selected from deuterium, halogen, CF3, OH, cyano, NH2, C 1-4 Alkyl, C 1-4 Alkoxy, 3 to 8 membered heterocyclic group or C 3-6 The heterocyclic group is substituted by a cycloalkyl substituent, wherein the heterocyclic group contains 1 to 3 heteroatoms selected from O, S, and N;
[0128] Ak1 and Ak2 are each independently selected from methylene, ethylene, propylene, vinylene, propenylene, ethynylene, and propynylene, wherein Ak1 is optionally replaced by 0 to 4 R k1 The Ak2 is optionally substituted with 0 to 4 R k2 replace;
[0129] R k1 、R k2Each independently selected from F, Cl, Br, I, cyano, OH, =O, NH2, NH(CH3), N(CH3)2, methyl, ethyl, propyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, azetyl, azetyl, oxetyl, oxetyl, pyridine, phenyl, the methyl, ethyl, propyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, azetyl, azetyl, oxetyl, oxetyl, pyridine, phenyl is optionally substituted by 1 to 4 selected from halogen, OH, cyano, NH2, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 is substituted by a carbocyclic or 4- to 6-membered heterocyclic substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;
[0130] Alternatively, R k1 With R k1 、R k2 With R k2 、R k1 With R k2 Direct connection to form C 3-6 A carbocyclic ring or a 4- to 7-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, =O, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Substituted by a cycloalkyl substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;
[0131] Q1, Q2 are each independently selected from O, S, N (R q )、C(=O)、C(=O)N(R q )、N(R q )C(=O), S(=O)2;
[0132] R q Each is independently selected from H, methyl, ethyl;
[0133] Alternatively, R q With R k1 、R q With R k2 Directly connected to form a 4- to 7-membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, =O, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6Substituted by a cycloalkyl substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;
[0134] The remaining groups are defined the same as in any one of the third or fourth embodiments of the present invention.
[0135] As a sixth embodiment of the present invention, the compound represented by the aforementioned general formula (II) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,
[0136] L is selected from -N(R q )-Ak1-O-Ak2-, -O-Ak1-O-Ak2-, -O-Ak1-N(R q )-Ak2-、-N(R q )-Ak1-N(R q )-Ak2-, the left side is directly connected to the pyridazinone ring;
[0137] Y is selected from a bond, -O-, -NHC(=O)-, -C(=O)NH-, -CH2-, -CH2CH2-, -CH2CH2CH2-, -OCH2-, -OCH2CH2-, -CH2O-, -CH2CH2O-, -NHCH2-, -NHCH2CH2-, -CH2NH-, -CH2CH2NH-, -NHC(=O)CH2-, -CH2C(=O)NH-, -N(CH3)C(=O)-, -C( =O)N(CH3)-, -CH2C(=O)NH-, -CH2C(=O)N(CH3)-, -N(CH2CH3)C(=O)-, -N(CH(CH3)2)C(=O)-, -N(CH2CH( CH3)2)C(=O)-, -N(cyclopropyl)C(=O)-, -N(CH2-cyclopropyl)C(=O)-, -C(=O)N(CH2CH3)-, -C(=O)N(CH(CH3)2)-, -C(=O )N(CH2CH(CH3)2)-, -C(=O)N(cyclopropyl)-, -C(=O)N(CH2-cyclopropyl)-, -C(=O)N(CD3)-, -C(=O)N(CH2-oxetanyl)-, -C(=O)N(CH2-oxolanyl)-, -C(=O)N(CH2-azetidinyl)-, -C(=O)N(CH2-pyrrolidinyl)-, -C(=O)N(CH2-cyclopentyl)-, -C(=O)N(CH2 CH2CH3)-, -C(=O)N(CH2CH(CH2CH3)2)-, -C(=O)N(CH2CH2CH2CH3)-, -C(=O)N(CH2CH2CH(CH3)2)-, -C(= O)N(CH2CH(CH3)CH2CH3)-, -C(=O)N(n-octyl)-, -C(=S)N(CH3)-, -C(=S)N(CH2CH3)-, -C(=S)N(CH2-cyclopropyl)-, -CH2S(=O)2-;
[0138] The definitions of the remaining groups are the same as those in any one of the third, fourth or fifth embodiments of the present invention.
[0139] As a seventh embodiment of the present invention, the compound represented by the aforementioned general formula (II) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,
[0140] L is selected from The left side is directly connected to the pyridazinone ring;
[0141] R xEach independently selected from H, F, Cl, Br, I, cyano, OH, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, -SCH3, -SCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl, phenyl, pyridyl, thiazolyl, thienyl, oxazolyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, the methyl alkyl, ethyl, propyl, isopropyl, vinyl, ethynyl, methoxy, ethoxy, -SCH3, -SCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl, phenyl, pyridyl, thiazolyl, thienyl, oxazolyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, optionally substituted with 1 to 4 substituents selected from F, OH, cyano, methyl, ethyl, methoxy or ethoxy;
[0142] R a1 is selected from H, F, Cl, Br, I, cyano, CF3, CHF2, CH2F, methyl, ethyl, propyl, isopropyl, ethynyl, methoxy, ethoxy, -SCH3, -SCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
[0143] Selected from
[0144] R b Each is independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl or isopropyl;
[0145] The definitions of the remaining groups are the same as those in any one of the third, fourth, fifth or sixth embodiments of the present invention.
[0146] As an eighth embodiment of the present invention, the compound represented by the above general formula (II) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,
[0147] L is selected from The left side is directly connected to the pyridazinone ring;
[0148] R a1 is selected from F, Cl, Br, CF3, CHF2, CH2F, methyl, cyano, cyclopropyl, isopropyl;
[0149] R x Each is independently selected from H, F, Cl, Br, cyano, isopropyl, CD3, CF3, CHF2, CH2F, cyclopropyl, cyclobutyl;
[0150] b is selected from 0, 1, 2, 3;
[0151] x is selected from 1 and 2;
[0152] The remaining groups are defined the same as in any one of the third, fourth, fifth, sixth or seventh embodiments of the present invention.
[0153] As a ninth embodiment of the present invention, the compound represented by the above general formula (A) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,
[0154] W is selected from C(═O);
[0155] Ring X is selected from C 3-10 Cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl, 5- to 6-membered heteroaromatic ring, 5- to 6-membered heterocycle, 8- to 10-membered paracyclic heteroaromatic ring, or 8- to 10-membered paracyclic heterocycle, wherein the heterocycloalkyl, heteroaromatic ring, or heterocycle contains 1 to 5 heteroatoms selected from O, S, and N;
[0156] Preferably, ring X is selected from C 3-6 Monocyclic cycloalkyl, C 5-10 Cycloalkyl, C 5-11 Spirocyclic cycloalkyl, C 5-11 Bridged cycloalkyl, 4-7 membered monocyclic heterocycloalkyl, 5-10 membered cyclic heterocycloalkyl, 5-11 membered spirocyclic heterocycloalkyl, 5-11 membered bridged heterocycloalkyl, phenyl, 5-6 membered heteroaromatic ring, 8-10 membered cyclic heteroaromatic ring, wherein the heterocycloalkyl, heteroaromatic ring or heterocycle contains 1 to 5 heteroatoms selected from O, S and N;
[0157] Preferably, ring X is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclobutylspirocyclobutyl, cyclobutylspirocyclopentyl, cyclobutylspirocyclohexyl, cyclopentylspirocyclopentyl, cyclopentylspirocyclohexyl, cyclohexylspirocyclohexyl, cyclobutylspiroazetidinyl, cyclobutylspiroazacyclopentyl, cyclobutylspiroazacyclohexyl, cyclopentylspiroazacyclopentyl, cyclopentylspiroazacyclohexyl, cyclohexylazaspirocyclohexyl, azetidinylspiroazacyclohexyl, azacyclopentylspiroazacyclopentyl, azacyclopentylspiroazacyclohexyl, azacyclohexylazaspirocyclohexyl, cyclobutyl and cyclobutyl ... Cyclopentyl, cyclobutylcyclohexyl, cyclopentylcyclopentyl, cyclopentylcyclohexyl, cyclohexylcyclohexyl, cyclobutylazetidinyl, cyclobutylazetidinyl, cyclobutylazetidinyl, cyclopentylazetidinyl, cyclopentylazetidinyl, cyclopentylazetidinyl, cyclohexylazetidinyl, azetidinylazetidinyl, azetidinylazetidinyl, azetidinyl, oxetyl, or ring X is as described in claim 5;
[0158] The remaining groups are defined the same as in any one of the second, third, fourth, fifth, sixth, seventh or eighth embodiments of the present invention.
[0159] As a tenth embodiment of the present invention, the compound represented by the above general formula (A) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,
[0160] Selected from
[0161] The remaining groups are defined the same as in any one of the ninth embodiment of the present invention.
[0162] The present invention relates to the compound shown below or its stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein the compound is selected from one of the structures shown in Table E-1.
[0163] Table E-1
[0164] The present invention relates to a pharmaceutical composition comprising any of the above compounds or their stereoisomers, deuterated substances, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals, and a pharmaceutically acceptable carrier.
[0165] The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of the above-mentioned compound of the present invention or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, and a pharmaceutically acceptable carrier.
[0166] In some embodiments, the pharmaceutical composition of the present invention may be in the form of a unit preparation (the amount of the main drug in the unit preparation is also referred to as the "preparation strength").
[0167] As used herein, an "effective amount" or "therapeutically effective amount" refers to a sufficient amount of a compound disclosed herein to be administered to alleviate to some extent one or more symptoms of the disease or condition being treated (e.g., a PARP7-related disease such as prostate cancer). In some embodiments, the result is a reduction and / or alleviation of the signs, symptoms, or causes of the disease, or any other desired change in a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition comprising a compound disclosed herein required to provide a clinically significant reduction in disease symptoms.Examples of therapeutically effective amounts include, but are not limited to, 1-1500 mg, 1-1200 mg, 1-1000 mg, 1-900 mg, 1-800 mg, 1-700 mg, 1-600 mg, 2-600 mg, 3-600 mg, 4-600 mg, 5-600 mg, 6-600 mg, 10-600 mg, 20-600 mg, 25-600 mg, 30-600 mg, 40-600 mg, 50-600 mg, 60-600 mg, 70-600 mg, 75-600 mg, 80-600 mg, 90-600 mg, 100-600 mg, 200-600 mg, 1-500 mg, 2-500mg, 3-500mg, 4-500mg, 5-500mg, 6-500mg, 10-500mg, 20-500mg, 25-500mg, 30-500mg, 40-500mg, 50-500mg, 60-500mg, 70-500mg, 75-500mg , 80-500mg, 90-500mg, 100-500mg, 125-500mg, 150-500mg, 200-500mg, 250-500mg, 300-500mg, 400-500mg, 5-400mg, 10-400mg, 20-400mg, 25-40 0mg, 30-400mg, 40-400mg, 50-400mg, 60-400mg, 70-400mg, 75-400mg, 80-400mg, 90-400mg, 100-400mg, 125-400mg, 150-400mg, 200-400mg, 250- 400mg, 300-400mg, 1-300mg, 2-300mg, 5-300mg, 10-300mg, 20-300mg, 25-300mg, 30-300mg, 40-300mg, 50-300mg, 60-300mg, 70-300mg, 75-300mg , 80-300mg, 90-300mg, 100-300mg, 125-300mg, 150-300mg, 200-300mg, 250-300mg, 1-200mg, 2-200mg, 5-200mg, 10-200mg, 20-200mg, 25-200mg, 30-200mg, 40-200mg, 50-200mg, 60-200mg, 70-200mg, 75-200mg, 80-200mg, 90-200mg, 100-200mg, 125-200mg, 150-200mg, 80-1000mg, 80-800mg.
[0168] In some embodiments, the pharmaceutical composition includes but is not limited to 1-1000 mg, 20-800 mg, 40-800 mg, 40-400 mg, 25-200 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg , 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 300 mg, 320 mg, 400 mg, 480 mg, 500 mg, 600 mg, 640 mg, 840 mg of a compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof.
[0169] A method for treating a disease in a mammal, comprising administering to a subject a therapeutically effective amount of a compound of the present invention or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, wherein the therapeutically effective amount is preferably 1-1500 mg, and the disease is preferably a disease associated with the inhibition or degradation of AR or AR splicing mutants (such as prostate cancer).
[0170] A method for treating a disease in a mammal, comprising administering to a subject a compound of the present invention or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or cocrystal thereof at a daily dose of 1-1000 mg / day. The daily dose may be a single dose or divided doses. In some embodiments, the daily dose includes but is not limited to 10-1500 mg / day, 10-1000 mg / day, 10-800 mg / day, 25-800 mg / day, 50-800 mg / day, 100-800 mg / day, 200-800 mg / day. , 25-400 mg / day, 50-400 mg / day, 100-400 mg / day, 200-400 mg / day, in some embodiments, daily doses include but are not limited to 10 mg / day, 20 mg / day, 25 mg / day, 50 mg / day, 80 mg / day, 100 mg / day, 125 mg / day, 150 mg / day, 160 mg / day, 200 mg / day, 300 mg / day, 320 mg / day, 400 mg / day, 480 mg / day, 600 mg / day, 640 mg / day, 800 mg / day, 1000 mg / day.
[0171] The present invention relates to a kit, which may include a composition in single-dose or multi-dose form, wherein the kit contains a compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, and the amount of the compound of the present invention or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal is the same as the amount in the above-mentioned pharmaceutical composition.
[0172] The present invention relates to the use of any of the above-mentioned compounds or their stereoisomers, deuterated compounds, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals for preparing drugs for treating diseases related to PARP7 activity or expression, preferably, the diseases are selected from tumors.
[0173] The present invention relates to the use of the above-mentioned pharmaceutical composition in the preparation of a drug for treating a disease associated with PARP7 activity or expression. Preferably, the disease is selected from tumors.
[0174] The amount of the compound of the invention or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof is in each case calculated as the free base.
[0175] Synthesis method
[0176] In order to achieve the purpose of the present invention, the compound of the present invention can be prepared by the following scheme:
[0177] Scheme 1: Synthesis method when the compound of formula (II) is selected from the compound of formula (M-13)
[0178] PG, PG1 or PG2 are each independently selected from amino protecting groups, preferably Boc (tert-butyloxycarbonyl), Cbz (benzyloxycarbonyl), PMB (p-methoxybenzyl);
[0179] R is selected from C 1-4 Alkyl, preferably methyl or ethyl;
[0180] X is selected from leaving groups, preferably halogen, OMs, OTs or OTf,
[0181] The remaining groups are defined in the same manner as those in the aforementioned compound of formula (II);
[0182] The compound of formula (M-1) reacts with an amino protecting agent to obtain a compound of formula (M-2);
[0183] The compound of formula (M-2) reacts with X2 through a nucleophilic substitution reaction to obtain a compound of formula (M-3);
[0184] The compound of formula (M-3) and A compound of formula (M-4) is obtained by a nucleophilic substitution reaction in the presence of an alkaline reagent (such as NaH);
[0185] The compound of formula (M-4) is subjected to a deamino protecting group reaction to obtain a compound of formula (M-5);
[0186] The compound of formula (M-5) is reacted under alkaline conditions (such as triethylamine, DIPEA) to obtain the compound of formula (M-6);
[0187] The compound of formula (M-6) is subjected to a deamino protecting group reaction to obtain a compound of formula (M-7);
[0188] The compound of formula (M-7) reacts with the compound of formula (A-1) under alkaline conditions (such as potassium carbonate, cesium carbonate) to obtain the compound of formula (M-8);
[0189] Alternatively, the compound of formula (M-7) and the compound of formula (A-1) are subjected to a coupling reaction in the presence of a metal catalyst to obtain the compound of formula (M-8);
[0190] The compound of formula (M-8) is reacted with a reducing agent (such as NaBH4, LiAlH4) to obtain the compound of formula (M-9);
[0191] The compound of the general formula (M-9) and the compound of the general formula (A-2) undergo a nucleophilic substitution reaction to obtain the compound of the general formula (M-10);
[0192] The compound of the general formula (M-10) is subjected to a deamino protecting group reaction to obtain a compound of the general formula (M-11);
[0193] The compound of formula (M-11) reacts with the compound of formula (A-3) under alkaline conditions (such as triethylamine, DIPEA) to obtain the compound of formula (M-12);
[0194] The compound of the general formula (M-12) is subjected to a deamino protecting group reaction to obtain a compound of the general formula (M-13).
[0195] Scheme 2: Synthesis of intermediate M-9
[0196] The intermediate (M-6) compound is subjected to a reduction reaction under a reducing agent (such as NaBH4, LiAlH4) to obtain a compound of the general formula (N-1);
[0197] The compound of general formula (N-1) is subjected to a deamination protection reaction to obtain a compound of general formula (N-2);
[0198] The compound of formula (N-2) reacts with the compound of formula (A-1) under alkaline conditions (such as potassium carbonate, cesium carbonate) to obtain the compound of formula (M-9);
[0199] Alternatively, the compound of formula (N-2) and the compound of formula (A-1) are subjected to a coupling reaction in the presence of a metal catalyst to obtain the compound of formula (M-9);
[0200] The compound of general formula (M-9) is obtained through scheme 1 to obtain the compound of general formula (M-13).
[0201] Scheme 3: Synthesis of general formula IB and general formula IC
[0202] The specific synthesis conditions refer to the synthesis of compound 11.
[0203] 1c" reacts with M-14B, and referring to the synthesis of compound 11, a compound of formula IC can be obtained.
[0204] The definitions of the various groups are the same as in any of the previous schemes.
[0205] Unless stated otherwise, the terms used in the specification and claims have the following meanings.
[0206] The carbon, hydrogen, oxygen, sulfur, nitrogen or F, Cl, Br, I involved in the groups and compounds of the present invention include their isotopes, and the carbon, hydrogen, oxygen, sulfur or nitrogen involved in the groups and compounds of the present invention are optionally replaced by one or more of their corresponding isotopes, wherein the isotopes of carbon include 12 C. 13 C and 14 C, hydrogen isotopes include protium (H), deuterium (D, also called heavy hydrogen), tritium (T, also called super tritium), oxygen isotopes include 16 O. 17 O and 18 O, sulfur isotopes include 32 S. 33 S. 34 S and 36 S, nitrogen isotopes include 14 N and 15 N, fluorine isotopes include 17 F and 19 F, chlorine isotopes include 35 Cl and 37 Isotopes of Cl, bromine include 79 Br and 81 Br.
[0207] "Halogen" refers to F, Cl, Br or I.
[0208] "Halogen-substituted" refers to substitution with F, Cl, Br or I, including but not limited to substitution with 1 to 10 substituents selected from F, Cl, Br or I, substitution with 1 to 6 substituents selected from F, Cl, Br or I, and substitution with 1 to 4 substituents selected from F, Cl, Br or I. "Halogen-substituted" is abbreviated as "halo".
[0209] "Alkyl" refers to a substituted or unsubstituted straight-chain or branched saturated aliphatic hydrocarbon group, including but not limited to alkyl groups of 1 to 20 carbon atoms, alkyl groups of 1 to 8 carbon atoms, alkyl groups of 1 to 6 carbon atoms, and alkyl groups of 1 to 4 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, neobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, and various branched chain isomers thereof; alkyl groups appearing herein have the same definition as this one. Alkyl groups can be monovalent, divalent, trivalent, or tetravalent.
[0210] "Heteroalkyl" refers to a substituted or unsubstituted alkyl group in which one or more (including but not limited to 2, 3, 4, 5 or 6) carbon atoms are replaced by heteroatoms (including but not limited to N, O or S). Non-limiting examples include -X(CH2)vX(CH2)vX(CH2)vH (v is an integer from 1 to 5, each X is independently selected from a bond or a heteroatom, including but not limited to N, O or S, and at least one X is selected from a heteroatom, and the N or S in the heteroatom can be oxidized to various oxidation states). The heteroalkyl group can be monovalent, divalent, trivalent or tetravalent.
[0211] "Alkylene" refers to substituted or unsubstituted straight-chain and branched divalent saturated hydrocarbon groups, including -(CH2) v -(v is an integer from 1 to 10), examples of alkylene include but are not limited to methylene, ethylene, propylene and butylene.
[0212] "Heteroalkylene" refers to a substituted or unsubstituted alkylene group in which one or more (including but not limited to 2, 3, 4, 5 or 6) carbon atoms are replaced by heteroatoms (including but not limited to N, O or S). Non-limiting examples include -X(CH2)vX(CH2)vX(CH2)v-, where v is an integer from 1 to 5, each X is independently selected from a bond, N, O or S, and at least one X is selected from N, O or S.
[0213] "Cycloalkyl" refers to a substituted or unsubstituted saturated carbocyclic hydrocarbon radical, typically having 3 to 10 carbon atoms, non-limiting examples of which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. Cycloalkyl groups as used herein are as defined above. Cycloalkyl groups can be monovalent, divalent, trivalent, or tetravalent.
[0214] "Heterocycloalkyl" refers to a substituted or unsubstituted saturated cyclic hydrocarbon group containing heteroatoms, including but not limited to 3 to 10 atoms, 3 to 8 atoms, including 1 to 3 heteroatoms selected from N, O or S. The N and S optionally substituted in the ring of the heterocycloalkyl can be oxidized to various oxidation states. The heterocycloalkyl group can be connected to a heteroatom or a carbon atom, the heterocycloalkyl group can be connected to an aromatic ring or a non-aromatic ring, and the heterocycloalkyl group can be connected to a bridged ring or a spiro ring. Non-limiting examples include oxirane, aziridine, oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, dioxolane, dioxane, pyrrolidinyl, piperidinyl, imidazolidinyl, oxazolidinyl, oxazinyl, morpholinyl, hexahydropyrimidinyl, piperazinyl. The heterocycloalkyl group can be monovalent, divalent, trivalent or tetravalent.
[0215] "Alkenyl" refers to substituted or unsubstituted straight and branched unsaturated hydrocarbon groups having at least one, typically one, two or three carbon-carbon double bonds, with a backbone of 2 to 10, 2 to 6 or 2 to 4 carbon atoms. Examples of alkenyl groups include, but are not limited to, vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 2- Methyl-3-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 1-octenyl, 3-octenyl, 1-nonenyl, 3-nonenyl, 1-decenyl, 4-decenyl, 1,3-butadiene, 1,3-pentadiene, 1,4-pentadiene, and 1,4-hexadiene; alkenyl groups appearing herein have the same definition as this one. Alkenyl groups may be monovalent, divalent, trivalent, or tetravalent.
[0216] "Alkynyl" refers to substituted or unsubstituted straight and branched unsaturated hydrocarbon groups having at least one, typically one, two or three carbon-carbon triple bonds, including but not limited to 2 to 10 carbon atoms, 2 to 6 carbon atoms, 2 to 4 carbon atoms in the backbone chain. Examples of alkynyl groups include but are not limited to ethynyl, propargyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1- Alkynyl groups include methyl-1-butynyl, 2-methyl-1-butynyl, 2-methyl-3-butynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-1-pentynyl, 2-methyl-1-pentynyl, 1-heptynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 1-octynyl, 3-octynyl, 1-nonynyl, 3-nonynyl, 1-decynyl, and 4-decynyl. Alkynyl groups may be monovalent, divalent, trivalent, or tetravalent.
[0217] "Alkoxy" refers to a substituted or unsubstituted -O-alkyl group. Non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexoxy, cyclopropyloxy, and cyclobutyloxy.
[0218] "Carbocyclyl" or "carbocycle" refers to a substituted or unsubstituted saturated or unsaturated aromatic or non-aromatic ring, which can be a 3-8 membered monocyclic ring, a 4-12 membered bicyclic ring, or a 10-15 membered tricyclic ring system. The carbocyclyl can be attached to the aromatic or non-aromatic ring, which can be optionally a monocyclic, bridged, or spirocyclic ring. Non-limiting examples include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, 1-cyclopentyl-1-alkenyl, 1-cyclopentyl-2-alkenyl, 1-cyclopentyl-3-alkenyl, cyclohexyl, 1-cyclohexyl-2-alkenyl, 1-cyclohexyl-3-alkenyl, cyclohexenyl, a benzene ring, a naphthalene ring, "Carbocyclyl" or "carbocycle" can be monovalent, divalent, trivalent, or tetravalent.
[0219] "Heterocyclyl" or "heterocycle" refers to a substituted or unsubstituted saturated or unsaturated aromatic or non-aromatic ring, which can be a 3-8 membered monocyclic ring, a 4-12 membered bicyclic ring or a 10-15 membered tricyclic ring system, and contains one or more (including but not limited to 2, 3, 4 or 5) heteroatoms selected from N, O or S. The N and S optionally substituted in the heterocyclyl ring can be oxidized to various oxidation states. The heterocyclic group can be connected to a heteroatom or a carbon atom, the heterocyclic group can be connected to an aromatic ring or a non-aromatic ring, and the heterocyclic group can be connected to a bridged ring or a spiro ring. Non-limiting examples include oxirane, aziridine, oxetanyl, azetidinyl, 1,3-dioxolanyl, 1,4-dioxolanyl, 1,3-dioxhexacyclyl, azepanyl, pyridyl, furyl, thienyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, piperidinyl, morpholinyl, thiomorpholinyl, 1,3-dithianyl, dihydrofuranyl, dihydropyranyl, dithiolanyl, tetrahydrofuranyl, py ... furanyl, tetrahydropyrrolyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydropyranyl, benzimidazolyl, benzopyridinyl, pyrrolopyridinyl, benzodihydrofuranyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, pyrazinyl, indazolyl, benzothiophenyl, benzofuranyl, benzopyrrolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzopyridinyl, benzopyrimidinyl, benzopyrazinyl, piperazinyl, azabicyclo[3.2.1]octyl, azabicyclo[5.2.0]nonyl, oxatricyclo[5.3.1.1]dodecyl, azaadamantyl, oxaspiro[3.3]heptanyl, "Heterocyclyl" or "heterocycle" can be monovalent, divalent, trivalent or tetravalent.
[0220] "Spirocycle" or "spirocyclyl" refers to a polycyclic group in which substituted or unsubstituted monocyclic rings share one atom (called a spiro atom), and the number of ring atoms in the spirocycle system includes but is not limited to 5 to 20, 6 to 14, 6 to 12, 6 to 10, wherein one or more rings may contain 0 or more (including but not limited to 1, 2, 3 or 4) double bonds, and optionally may contain 0 to 5 atoms selected from N, O or S (=O) n Non-limiting examples include: "Spirocycle" or "spirocyclyl" can be monovalent, divalent, trivalent or tetravalent.
[0221] "Parallel ring" or "parallel ring group" refers to a polycyclic group in which each ring in the system shares a pair of adjacent atoms with other rings in the system, wherein one or more rings may contain 0 or more (including but not limited to 1, 2, 3 or 4) double bonds and may be substituted or unsubstituted, and each ring in the parallel ring system may contain 0 to 5 heteroatoms or groups containing heteroatoms (including but not limited to N, S(=O)n or O, n is 0, 1 or 2). The number of ring atoms in the cyclic system includes, but is not limited to, 5 to 20, 5 to 14, 5 to 12, and 5 to 10. Non-limiting examples include:
[0222] "Bicyclic" or "bicyclic group" can be monovalent, divalent, trivalent or tetravalent.
[0223] "Bridged ring" or "bridged ring group" refers to a substituted or unsubstituted polycyclic group containing any two atoms that are not directly connected, which may contain zero or more double bonds, and any ring in the ring system may contain zero to five heteroatoms or groups containing heteroatoms (including but not limited to N, S (=O) n or O, wherein n is 0, 1, 2). The number of ring atoms includes, but is not limited to, 5 to 20, 5 to 14, 5 to 12, or 5 to 10. Non-limiting examples include "Bridged ring" or "bridged ring group" may be monovalent, divalent, trivalent or tetravalent.
[0224] "Carbospirocycle," "spirocarbocyclyl," "spirocarbocyclyl," or "carbospirocyclyl" refers to a "spirocycle" whose ring system consists solely of carbon atoms. As used herein, "carbospirocycle," "spirocarbocyclyl," "spirocarbocyclyl," or "carbospirocyclyl" have the same definition as for spirocycle.
[0225] "Carbocyclyl," "carbocyclyl," "carbocyclyl," or "carbocyclyl" refers to a "carbocyclyl" ring system consisting solely of carbon atoms. As used herein, "carbocyclyl," "carbocyclyl," "carbocyclyl," or "carbocyclyl" has the same definition as for cyclyl.
[0226] "Carbon bridged ring," "bridged ring carbocyclic group," "bridged carbocyclic group," or "carbon bridged cyclic group" refers to a "bridged ring" in which the ring system consists only of carbon atoms. As used herein, "carbon bridged ring," "bridged ring carbocyclic group," "bridged carbocyclic group," or "carbon bridged cyclic group" has the same definition as for a bridged ring.
[0227] "Heteromonocycle", "monocyclic heterocyclyl" or "heteromonocyclyl" refers to a "heterocyclyl" or "heterocycle" of a monocyclic ring system. The heterocyclyl, "monocyclic heterocyclyl" or "heteromonocyclyl" appearing in this document has the same definition as heterocycle.
[0228] "Heterocyclic ring", "heterocyclic ring group", "heterocyclic ring heterocyclyl" or "heterocyclic ring group" refers to a "cyclic ring" containing a heteroatom. The heterocyclic ring, "heterocyclic ring group", "heterocyclic ring heterocyclyl" or "heterocyclic ring group" appearing in this article have the same definition as the cyclic ring.
[0229] "Heterospirocycle", "heterospirocyclyl", "spiroheterocyclyl" or "heterospirocyclyl" refers to a "spirocycle" containing a heteroatom. Heterospirocycle, "heterospirocyclyl", "spiroheterocyclyl" or "heterospirocyclyl" appearing herein have the same definition as spirocycle.
[0230] "Heterobridged ring", "heterobridged cyclic group", "bridged heterocyclic group" or "heterobridged cyclic group" refers to a "bridged ring" containing a heteroatom. The heterobridged ring, "heterobridged cyclic group", "bridged heterocyclic group" or "heterobridged cyclic group" appearing herein have the same definition as that of the bridged ring.
[0231] "Aryl" or "aromatic ring" refers to a substituted or unsubstituted aromatic hydrocarbon group having a single ring or a fused ring, wherein the number of ring atoms in the aromatic ring includes, but is not limited to, 6 to 18, 6 to 12, or 6 to 10 carbon atoms. The aryl ring may be fused to a saturated or unsaturated carbocyclic or heterocyclic ring, wherein the ring connected to the parent structure is the aryl ring, non-limiting examples of which include benzene ring, naphthalene ring, "Aryl" or "aromatic ring" can be monovalent, divalent, trivalent or tetravalent. When divalent, trivalent or tetravalent, the point of attachment is on the aryl ring.
[0232] "Heteroaryl" or "heteroaromatic ring" refers to a substituted or unsubstituted aromatic hydrocarbon group containing 1 to 5 heteroatoms or groups containing heteroatoms (including but not limited to N, O or S(=O)n, n is 0, 1, 2), and the number of ring atoms in the heteroaromatic ring is but not limited to 5 to 15, 5 to 10 or 5 to 6. Non-limiting examples of heteroaryl include but are not limited to pyridyl, furyl, thienyl, pyridyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, benzopyrazole, benzimidazole, benzopyridine, pyrrolopyridine, etc. The heteroaryl ring can be fused to a saturated or unsaturated carbocyclic ring or heterocyclic ring, wherein the ring connected to the parent structure is a heteroaryl ring, and non-limiting examples include
[0233] When heteroaryl appears in this document, its definition is consistent with this definition. Heteroaryl can be monovalent, divalent, trivalent or tetravalent. When it is divalent, trivalent or tetravalent, the attachment point is located on the heteroaryl ring.
[0234] "5-membered ring and 5-membered heteroaromatic ring" refers to a 5-membered fused heteroaromatic ring, at least one of the two fused rings contains one or more heteroatoms (including but not limited to O, S or N), and the entire group is aromatic. Non-limiting examples include pyrrolopyrrole ring, pyrazolopyrrole ring, pyrazolopyrazole ring, pyrrolofuran ring, pyrazolofuran ring, pyrrolothiophene ring, and pyrazolothiophene ring.
[0235] "5-membered and 6-membered heteroaromatic ring" refers to a 5-membered and 6-membered fused heteroaromatic ring, at least one of the two fused rings contains one or more heteroatoms (including but not limited to O, S or N), and the entire group is aromatic. Non-limiting examples include benzo 5-membered heteroaromatic group, 6-membered heteroaromatic ring and 5-membered heteroaromatic ring.
[0236] "Substituted" or "substituted" refers to substitution by one or more (including but not limited to 2, 3, 4 or 5) substituents, including but not limited to H, F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxyl, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclic, bridged, spiro, cycloalkyl, hydroxyalkyl, =O, carbonyl, aldehyde, carboxylic acid, formate, -(CH2), m -C(=O)-R a 、-O-(CH2) m -C(=O)-R a 、-(CH2) m -C(=O)-NR b R c 、-(CH2) m S(=O) n R a 、-(CH2) m -alkenyl-R a , OR d or -(CH2) m -alkynyl-R a (wherein m and n are 0, 1 or 2), arylthio, thiocarbonyl, silyl or -NR b R c etc., where R b With R c R is independently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, b With R c Can form a five- or six-membered cycloalkyl or heterocyclic group, R a With R d Each is independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged ring, spiro ring or paracyclic group.
[0237] “Containing 1 to 5 heteroatoms selected from O, S, and N” means containing 1, 2, 3, 4, or 5 heteroatoms selected from O, S, and N.
[0238] "Replaced by 0 to X substituents" means substituted by 0, 1, 2, 3, ..., X substituents, where X is selected from any integer between 1 and 10. For example, "replaced by 0 to 4 substituents" means substituted by 0, 1, 2, 3, or 4 substituents. For example, "replaced by 0 to 5 substituents" means substituted by 0, 1, 2, 3, 4, or 5 substituents. For example, "a heterobridged ring is optionally substituted by 0 to 4 substituents selected from H or F" means that the heterobridged ring is optionally substituted by 0, 1, 2, 3, or 4 substituents selected from H or F.
[0239] XY-membered rings (where X is selected from an integer less than Y and greater than or equal to 3, and Y is selected from any integer between 4 and 12) include rings with X, X+1, X+2, X+3, X+4, and so on. Rings include heterocyclic rings, carbocyclic rings, aromatic rings, aryl groups, heteroaryl groups, cycloalkyl groups, heteromonocyclic rings, heteroparallel rings, heterospirocyclic rings, and heterobridged rings. For example, "4-7-membered heteromonocyclic ring" refers to a 4-, 5-, 6-, or 7-membered heteromonocyclic ring, and "5-10-membered heteroparallel ring" refers to a 5-, 6-, 7-, 8-, 9-, or 10-membered heteroparallel ring.
[0240] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs and instances where it does not. For example, "alkyl optionally substituted with F" means that the alkyl group may but need not be substituted with F, and the description includes instances where the alkyl group is substituted with F and instances where the alkyl group is not substituted with F.
[0241] "Pharmaceutically acceptable salt" or "pharmaceutically acceptable salt thereof" refers to a salt of the compound of the present invention that retains the biological effectiveness and properties of the free acid or free base, and the free acid is obtained by reacting with a non-toxic inorganic base or organic base, or the free base is obtained by reacting with a non-toxic inorganic acid or organic acid.
[0242] "Pharmaceutical composition" refers to a mixture of one or more compounds of the present invention, or stereoisomers, tautomers, deuterated forms, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals thereof, and other chemical components, wherein "other chemical components" refers to pharmaceutically acceptable carriers, excipients and / or one or more other therapeutic agents.
[0243] "Carrier" refers to a material that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
[0244] "Prescription strength" refers to the weight of the active ingredient per vial, tablet, or other unit of preparation. "Prodrug" refers to a compound of the present invention that can be metabolized in vivo to possess biological activity. Prodrugs of the present invention are prepared by modifying amino or carboxyl groups within a compound of the present invention. These modifications can be removed by conventional manipulation or in vivo to yield the parent compound. When the prodrug of the present invention is administered to a mammalian subject, it is cleaved to form free amino or carboxyl groups.
[0245] A "cocrystal" is a crystal formed by the active pharmaceutical ingredient (API) and cocrystal former (CCF) bound together by hydrogen bonds or other non-covalent bonds. Both the API and CCF are solid in their pure form at room temperature, and the components exist in a fixed stoichiometric ratio. A cocrystal is a multi-component crystal, encompassing both binary cocrystals formed between two neutral solids and multi-component cocrystals formed between a neutral solid and a salt or solvate.
[0246] "Animal" is meant to include mammals, such as humans, companion animals, zoo animals, and livestock, preferably humans, horses, or dogs.
[0247] "Stereoisomers" refer to isomers resulting from different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers, and conformational isomers.
[0248] "Tautomers" refer to functional group isomers produced by the rapid movement of an atom in a molecule between two positions, such as keto-enol isomers and amide-imino alcohol isomers.
[0249] “IC 50 "It is the concentration of a drug or inhibitor required to inhibit a specified biological process (or a component of the process such as an enzyme, receptor, cell, etc.) by half. Description of the drawings:
[0250] Figure 1: 1H-1H COSY (400 MHz, CD3COOD) of 39b;
[0251] Figure 2: 1H-1H NOESY of 39b (400 MHz, CD3COOD). DETAILED DESCRIPTION
[0252] The technical solutions of the present invention are described in detail below in conjunction with the embodiments, but the protection scope of the present invention includes but is not limited to them.
[0253] The structures of the compounds were determined by nuclear magnetic resonance (NMR) or / and mass spectrometry (MS). -6The unit of ppm is given. NMR measurements were performed using a Bruker Avance III 400 and Bruker Avance 300 NMR spectrometer. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD), and deuterated acetic acid (CD3COOD). The internal standard was tetramethylsilane (TMS).
[0254] MS was determined using (Agilent 6120B (ESI) and Agilent 6120B (APCI));
[0255] HPLC determination was performed using an Agilent 1260DAD high-pressure liquid chromatograph (Zorbax SB-C18 100 × 4.6 mm, 3.5 μM);
[0256] Thin layer chromatography silica gel plates used were Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates. The specifications of the silica gel plates used for thin layer chromatography (TLC) were 0.15 mm to 0.20 mm, and the specifications used for thin layer chromatography separation and purification products were 0.4 mm to 0.5 mm.
[0257] Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier;
[0258] In order to accomplish the purpose of the present invention, the compounds used in the reactions described herein are prepared according to organic synthesis techniques known to those skilled in the art, starting from commercially available chemicals and / or compounds described in the chemical literature. "Commercially available chemicals" are obtained from standard commercial sources, including Shanghai Aladdin Biochemical Technology Co., Ltd., Shanghai McLean Biochemical Technology Co., Ltd., Sigma-Aldrich, Alfa Aesar (China) Chemical Co., Ltd., TCI (Shanghai) Chemical Industry Development Co., Ltd., Anage Chemical, Shanghai Titan Technology Co., Ltd., Kelon Chemical, Bailingwei Technology Co., Ltd., etc.
[0259] In the synthesis experiments, the temperature was room temperature unless otherwise specified.
[0260] THF: tetrahydrofuran; DMF: N,N-dimethylformamide; DIPEA: N,N-diisopropylethylamine; HATU: CAS 148893-10-1
[0261] 5-Chloro-2-[(4-methoxybenzyl)methyl]-4-(trifluoromethyl)-2,3-dihydropyridazin-3-one is intermediate 1:
[0262] Example 1: Preparation of Compound 1
[0263] Step 1: Preparation of 1b'
[0264] Under ice-water bath, 1a' (5.00 g, 19.36 mmol) was added to tetrahydrofuran (40 mL). After nitrogen purge, lithium aluminum hydride (0.74 g, 19.43 mmol) was added and stirred in an ice-water bath for 2 h. Sodium sulfate decahydrate was added until gas evolution ceased, and the mixture was stirred at room temperature for 10 min. The mixture was filtered through a pad of Celite, and the filter cake was rinsed with tetrahydrofuran (40 mL x 3). The filtrate was concentrated under reduced pressure to yield 1b' (4.00 g, 90%).
[0265] LCMS m / z=231.1[M+1] + .
[0266] Step 2: Preparation of 1b"
[0267] Triethylamine (53.93 g, 532.72 mmol) was added to a toluene (500 mL) solution of (2S)-2-aminopropan-1-ol (1a") (10.00 g, 133.18 mmol) and phthalic anhydride (19.73 g, 133.18 mmol), and the mixture was refluxed at 145°C to separate the water and react for 7 h. After cooling to room temperature, silica gel was added, and the mixture was concentrated under reduced pressure and purified by column chromatography (dichloromethane: methanol (v / v) = 100:3) to obtain 1b" (20.00 g, 73%).
[0268] LCMS m / z=206.1[M+1] +
[0269] Step 3: Preparation of 1c
[0270] To a solution of 1b" (2 g, 11.41 mmol) in dichloromethane (40 mL) were added 1,8-diazabicyclo[5.4.0]undec-7-ene (1.48 g, 9.74 mmol) and trichloroacetonitrile (3.52 g, 24.35 mmol), and the mixture was reacted at room temperature for 2 h. Silica gel was added, and the mixture was concentrated under reduced pressure and purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 5:1) to obtain 1c" (1.74 g) crude product.
[0271] 1 H NMR (400MHz, DMSO-d6) δ9.41(s,1H),7.89-7.79(m,4H),4.74-4.62(m,2H),4.53-4.42(m,1H),1.45(d,3H).
[0272] Step 4: Preparation of 1b
[0273] L-serine (10.50 g, 99.88 mmol) and potassium bromide (40.41 g, 339.59 mmol) were dissolved in water (80 mL). The atmosphere was purged with nitrogen, and hydrobromic acid (33.67 g, 199.76 mmol, 48%) was slowly added dropwise. The temperature was lowered to -15°C, and a solution of sodium nitrite (8.68 g, 125.82 mmol) in water (25 mL) was slowly added dropwise. The mixture was allowed to react at room temperature for 6 h. Nitrogen was purged for 0.5 h, and the mixture was extracted with ethyl acetate (100 mL x 6). The organic phases were combined, washed once with saturated brine (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain crude product 1b (14.76 g).
[0274] LCMS m / z=166.9[M-1] - .
[0275] Step 5: Preparation of 1c
[0276] 1b (14.70 g, 87.03 mmol) and imidazole (23.70 g, 348.12 mmol) were dissolved in DMF (50 mL). tert-Butyldiphenylsilyl chloride (29.90 g, 108.79 mmol) was slowly added dropwise. The mixture was allowed to react at room temperature overnight. The mixture was poured into water (500 mL) and extracted with ethyl acetate (200 mL x 2). The organic phases were combined, washed with saturated brine (100 mL x 2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product, which was then purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 9:1, 1‰ glacial acetic acid) to afford 1c (20.90 g, 51%, yield over two steps).
[0277] LCMS m / z=405.0[M-1] - .
[0278] Step 6: Preparation of 1d
[0279] Dissolve 1c (2.52 g, 6.19 mmol) in oxalyl chloride (25 mL), add 0.1 mL of DMF, and react at 50°C for 2 h. Concentrate under reduced pressure, dissolve in dichloromethane (20 mL), and then concentrate under reduced pressure. Under an ice-water bath, slowly add the residue in dichloromethane (10 mL) dropwise to a solution of 1b' (1.43 g, 6.20 mmol) and DIPEA (2.40 g, 18.60 mmol) in dichloromethane (20 mL). Allow to react at room temperature for 1 h. Add silica gel, concentrate under reduced pressure, and purify by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 4:1) to afford 1d (3.39 g, 88%).
[0280] LCMS m / z=541.2[M-77] + .
[0281] Step 7: Preparation of 1e
[0282] 1d (2.39 g, 3.85 mmol) was dissolved in tetrahydrofuran (10 mL). After nitrogen substitution, sodium hydroxide (231 mg, 5.78 mmol, 60%) was added portionwise at 0°C and allowed to react for 1 h. The reaction was quenched by the addition of saturated ammonium chloride solution (30 mL). The reaction was extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed once with saturated brine (20 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product, which was then purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 4:1) to afford 1e (1.22 g, 59%).
[0283] LCMS m / z=461.3[M-77] + .
[0284] Step 8: Preparation of trifluoroacetate salt of 1f
[0285] Dissolve 1e (1.62 g, 3.01 mmol) in dichloromethane (20 mL), add trifluoroacetic acid (20 mL), and react at room temperature for 2 h. Concentrate under reduced pressure, dissolve in dichloromethane (20 mL x 2), and then concentrate under reduced pressure to obtain the crude trifluoroacetate salt of 1f.
[0286] LCMS m / z=439.3[M+1] + .
[0287] Step 9: Preparation of 1g
[0288] The crude trifluoroacetate salt of 1f, 2-chloro-5-(trifluoromethyl)pyrimidine (690 mg, 3.78 mmol), and potassium carbonate (1.56 g, 11.25 mmol) were added sequentially to N-methylpyrrolidone (2 mL) and reacted at 90°C for 2 h. The mixture was poured into water (30 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated brine (20 mL x 5), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated and purified by column chromatography (100% tetrahydrofuran) to obtain 1g (546 mg, 52%, yield over two steps).
[0289] LCMS m / z=347.0[M+1] + .
[0290] Step 10: Preparation of compound 1h
[0291] 1g (50 mg, 0.14 mmol) and 1c" (98 mg, 0.28 mmol) were dissolved in toluene (10 mL). After nitrogen replacement, boron tribromide etherate complex (0.5 mL) was added at 0°C and reacted at 23°C for 16 h. Saturated sodium bicarbonate solution (10 mL) was slowly added dropwise at 0°C to quench the reaction. Extraction was performed with ethyl acetate (50 mL x 3), and the organic phases were combined, washed once with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a residue. The residue was separated and purified by column chromatography (petroleum ether: tetrahydrofuran (v / v) = 3:2) to obtain 1h (16 mg, 21%).
[0292] LCMS m / z=534.3[M+1] + .
[0293] Step 11: Preparation of 1i
[0294] Dissolve 1h (80 mg, 0.15 mmol) in ethanol (2 mL) and add hydrazine hydrate (47 mg, 0.75 mmol, 80%). Allow to react at room temperature for 2 h. Concentrate under reduced pressure, and the crude product is purified on a preparative plate (dichloromethane:methanol (v / v) = 10:1) to afford 1i (27 mg, 45%).
[0295] LCMS m / z=404.2[M+1] + .
[0296] Step 12: Preparation of 1j
[0297] 1i (27 mg, 0.7 mmol) was dissolved in acetonitrile (2 mL), and triethylamine (14 mg, 0.13 mmol) was added. The mixture was allowed to react at room temperature for 16 h. The mixture was concentrated under reduced pressure, and the crude product was purified by Prep-TLC (petroleum ether:ethyl acetate (v / v) = 1:2) to afford 1j (45 mg, 98%).
[0298] LCMS m / z=686.2[M+1] + .
[0299] Step 13: Preparation of Compound 1
[0300] 1j (45 mg, 0.07 mmol) was dissolved in trifluoroacetic acid (2 mL), trifluoromethanesulfonic acid (0.2 mL) was added, and the mixture was allowed to react at room temperature for 1 h. The mixture was concentrated under reduced pressure, and the crude product was dissolved in methanol. DIPEA was added dropwise to adjust the pH to 8-9. After concentration under reduced pressure, the residue was purified by Pre-HPLC (Instrument and preparative column: Waters 2767 preparative liquid phase, preparative column model is XBridge@Prep C 18, inner diameter x length = 19 mm x 250 mm). Preparation: The crude product was dissolved in DMF and filtered through a 0.45 μm filter to prepare a sample solution. Mobile phase: acetonitrile / water (containing 0.05% ammonia). Gradient elution: Acetonitrile was used in a gradient elution from 10% to 55% (flow rate: 12 mL / min; elution time: 17 min) to afford compound 1 (15 mg, 40%).
[0301] LCMS m / z=566.1[M+1] + .
[0302] 1 H NMR (400MHz, DMSO-d6) δ12.42(s,1H),8.74(s,2H),7.91(s,1H),6.31-6.20(m,1H),4.44-4.36(m,1H),4.35-4.26(m,2H),4.20-4.09(m,1H),4. 08-4.01(m,2H),3.89-3.80(m,1H),3.77-3.67(m,4H),3.63-3.56(m,1H ),3.55-3.46(m,3H),1.83-1.70(m,1H),1.68-1.60(m,1H),1.16(d,3H).
[0303] Example 2: Preparation of Compound 2-1 and Compound 2-2
[0304] Compound 1 was purified by SFC on ID column (instrument and preparative column: Waters 150SFC, preparative column model: Chiralcel OJ-Column (250*30mm, ID 30mm, 10um particle size). Preparation method: Compound 3 was dissolved in methanol and filtered with a 0.45μm filter membrane to prepare a sample solution. Mobile phase system: A for CO2 and B for MeOH (0.1% NH3·H2O). Gradient elution method: 30% B isocratic elution (flow rate: 100mL / min; elution time 1.6min), and after lyophilization, compounds 2-1 and compound 2-2 were obtained.
[0305] Analytical methods (Instrument and preparative column: HPLC-normal phase chromatography, preparative column model: Chiralcel OJ-3 50×4.6mm ID, 3μm; mobile phase system: A for CO2 and B for MeOH (0.05% DEA), 3.0ml / min).
[0306] The compound with retention time T=1.325 min is compound 2-A (compound 2-A is one of the structures of compound 2-1 and compound 2-2).
[0307] LCMS m / z=566.2[M+1] +
[0308] 1 H NMR(400MHz,CD3OD)δ8.59(s,2H),7.96(s,1H),4.53-4.44(m,1H),4.35-4.27(m,2H),4.20 -4.06(m,3H),4.01-3.93(m,1H),3.89-3.78(m,4H),3.72-3.61(m,3H),3.56-3.50(m,1H), 1.97-1.84(m,1H),1.75-1.66(m,1H),1.27(d,3H).
[0309] The compound with retention time T=1.666 min is compound 2-B (compound 2-B is one of the structures of compound 2-1 and compound 2-2).
[0310] LCMS m / z=566.2[M+1] +
[0311] 1 H NMR(400MHz,CD3OD)δ8.60(s,2H),7.95(s,1H),4.56-4.47(m,1H),4.36-4.27(m,2H),4.21-4.07(m,3H),3.99-3.93 (m,1H),3.90-3.76(m,4H),3.72-3.58(m,3H),3.54-3.49(m,1H),1.95-1.83(m,1H),1.74-1.65(m,1H),1.27(d,3H).
[0312] Example 3: Preparation of Compound 3
[0313] Step 1: Preparation of 3c
[0314] Under ice-water bath, oxalyl chloride (8.29 g, 65.31 mmol) was slowly added dropwise to a solution of 1c (3.80 g, 9.33 mmol) in DCM (30 mL) and DMF (0.05 mL), and the mixture was reacted at 50°C for 2 h. The mixture was concentrated under reduced pressure to obtain the crude acyl chloride.
[0315] Under an ice-water bath, a dichloromethane solution (10 mL) of the prepared acid chloride was slowly added dropwise to a solution of tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate (1.93 g, 8.92 mmol) and DIPEA (4.61 g, 35.68 mmol) in DCM (20 mL). The mixture was allowed to react at room temperature for 1 h. Silica gel was added, the mixture was concentrated under reduced pressure, and then purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 5:1, detection at 210 nm) to afford 3c (3.60 g, 64%).
[0316] LCMS m / z=527.0[M-77] +
[0317] Step 2: Preparation of compound 3d
[0318] Under an ice-water bath, sodium hydroxide (0.36 g, 9.03 mmol, content: 60%) was added portionwise to a solution of 3c (3.60 g, 5.94 mmol) in THF (30 mL). The reaction was allowed to react in an ice-water bath for 1 h and then at room temperature for 1 h. The reaction was quenched with saturated ammonium chloride solution (2 mL). Extraction was performed with dichloromethane (30 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was then purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 5:1, detection at 210 nm) to afford 3d (1.50 g, 48%).
[0319] LCMS m / z=447.2[M-77] +
[0320] Step 3: Preparation of trifluoroacetate salt of 3e
[0321] Trifluoroacetic acid (4 mL) was added to a solution of 3d (1.25 g, 2.38 mmol) in DCM (4 mL), and the mixture was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure to give the crude trifluoroacetic acid salt of 3e (1.2 g).
[0322] LCMS m / z=425.3[M+1] +
[0323] Step 4: Preparation of 3f
[0324] Potassium carbonate (1.23 g, 8.92 mmol) was added to a solution of the trifluoroacetate salt of 3e (1.2 g) and 2-chloro-5-(trifluoromethyl)pyrimidine (0.45 g, 2.45 mmol) in DMSO (4 mL) and the reaction was allowed to proceed at 95°C for 3 h. The mixture was cooled to room temperature, diluted with 50 mL of ethyl acetate, and washed with saturated sodium chloride solution (20 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was then purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 5:2) to afford 3f (600 mg, 76% yield over two steps).
[0325] LCMS m / z=333.1[M+1] +
[0326] Step 5: Preparation of 3g
[0327] 3f (400 mg, 1.20 mmol), 1c (839 mg, 2.4 mmol) were dissolved in toluene (80 mL). After nitrogen replacement, boron trifluoride etherate (4 mL) was added at 0°C and reacted at 23°C for 16 h. Saturated sodium bicarbonate solution (20 mL) was slowly added dropwise at 0°C to quench the reaction. The mixture was extracted with ethyl acetate (50 mL x 3). The organic phases were combined and concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether: tetrahydrofuran (v:v) = 3:2) to obtain 3g (110 mg, 18%).
[0328] LCMS m / z=520.1[M+1] +
[0329] Step 6: Preparation of 3h
[0330] Hydrazine hydrate (0.15 mL) was added to a solution of 3 g (164 mg, 0.32 mmol) in ethanol (4 mL), and the mixture was allowed to react at room temperature for 16 h. The mixture was concentrated under reduced pressure and purified by Prep-TLC (dichloromethane:methanol (v:v) = 10:1) to afford 3h (75 mg, 61%).
[0331] LCMS m / z=390.2[M+1] +
[0332] Step 7: Preparation of 3j
[0333] Intermediate 1 (73 mg, 0.23 mmol) was added to a solution of 3h (75 mg, 0.19 mmol) and triethylamine (58 mg, 0.57 mmol) in acetonitrile (2 mL) and allowed to react at room temperature for 16 h. The product was concentrated under reduced pressure and purified by column chromatography (petroleum ether:ethyl acetate (v:v) = 1:2) to afford 3j (40 mg, 31%).
[0334] LCMS m / z=672.1[M+1] +
[0335] Step 8: Preparation of compound 3
[0336] Trifluoromethanesulfonic acid (32 mg, 0.21 mmol) was added to a TFA (2 mL) solution of 3j (40 mg, 0.06 mmol) and the mixture was allowed to react at room temperature for 1 h. The mixture was concentrated under reduced pressure and quenched with water (4 mL). The pH was adjusted to 8 with aqueous ammonia. The aqueous solution was purified by C 18 The product was separated and purified by column chromatography (mobile phase system: acetonitrile / water (containing 0.1% ammonia water); gradient elution method: acetonitrile from 5% to 40%) to obtain compound 3 (12 mg, 37%).
[0337] LCMS m / z=552.2[M+1] +
[0338] 1 H NMR (400MHz, DMSO-d6) δ12.41(s,1H),8.73(s,2H),7.91(s,1H),6.32-6.20(m,1H),4.72-4.63(m,2H),4.45-4.35(m,1H),4.23( d,1H),4.15(s,1H),3.95-3.81(m,3H),3.79-3.70(m,1H),3.58-3.46(m,3H),3.04-2.88(m,2H),2.85-2.74(m,1H),1.14(d,3H).
[0339] Example 4:
[0340] Compound 3 was purified by SFC on ID column (instrument and preparative column: Waters 150SFC, preparative column model: Chiralcel Column (250*30mm, ID 30mm, 10um particle size). Preparation method: Compound 3 was dissolved in methanol and filtered with a 0.45μm filter membrane to prepare a sample solution. Mobile phase system: A for CO2 and B for MeOH (0.1% NH3.H2O). Gradient elution method: 20% B isocratic elution (flow rate: 110mL / min; elution time 2.5min), and after freeze-drying, compounds 4-1 and compound 4-2 were obtained.
[0341] Analytical methods (Instrument and preparative column: High performance liquid chromatography – normal phase chromatography, preparative column model: Chiralcel OD-3 50×4.6mm ID, 3μm; mobile phase system: A for CO2 and B for MeOH (0.05% DEA), 3.0ml / min).
[0342] The compound with retention time T=1.435 min is compound 4-A (compound 4-A is one of the structures of compound 4-1 and compound 4-2).
[0343] LCMS m / z=552.1[M+1] +
[0344] 1 H NMR(400MHz,CD3OD)δ8.59(s,2H),7.94(s,1H),4.91-4.84(m,1H),4.80-4.76(m,1H),4.58-4.51(m,1H),4.30-4.25(m,1H),4.20-4.10(m,1H),4 .05-3.95(m,3H),3.88-3.82(m,1H),3.68-3.62(m,1H),3.60-3.50(m,2H ),3.17-3.07(m,1H),3.05-2.96(m,1H),2.92-2.81(m,1H),1.24(d,3H).
[0345] The compound with retention time T=1.720 min is compound 4-B (compound 4-B is one of the structures of compound 4-1 and compound 4-2).
[0346] LCMS m / z=552.1[M+1] +
[0347] 1H NMR(400MHz,CD3OD)δ8.61(s,2H),7.95(s,1H),4.88-4.84(m,1H),4.82-4.79(m,1H),4.60-4.54(m,1H),4.31-4.27(m,1H),4 .21-4.15(m,1H),4.07-3.95(m,3H),3.87-3.81(m,1H),3.65-3.54(m,3H),3.12-2.99(m,2H),2.92-2.84(m,1H),1.27(d,3H).
[0348] Example 5: Preparation of Compound 5
[0349] Step 1: Preparation of 5b
[0350] D-serine (10.00 g, 95.13 mmol) and potassium bromide (40.41 g, 339.59 mmol) were dissolved in water (80 mL). The atmosphere was replaced with nitrogen, and hydrobromic acid (33.47 g, 190.26 mmol, 48%) was slowly added dropwise. A solution of sodium nitrite (7.88 g, 114.16 mmol) in water (25 mL) was slowly added dropwise at -15°C. The mixture was allowed to react at room temperature for 6 h. Nitrogen was blown for 0.5 h, and the mixture was extracted with ethyl acetate (100 mL x 6). The organic phases were combined, washed once with saturated brine (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain crude product 5b (13.00 g).
[0351] LCMS m / z=166.9[M-1] - .
[0352] Step 2: Preparation of 5c
[0353] 5b (13.00 g) and imidazole (20.95 g, 307.76 mmol) were dissolved in DMF (50 mL). tert-Butyldiphenylsilyl chloride (25.38 g, 92.33 mmol) was slowly added dropwise and allowed to react at room temperature overnight. The reaction solution was poured into water (500 mL) and extracted with ethyl acetate (200 mL x 2). The organic phases were combined, washed with saturated brine (100 mL x 2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product, which was then separated and purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 9:1, 1‰ glacial acetic acid) to afford 5c (12.00 g, 31%, yield over two steps).
[0354] LCMS m / z=405.1[M-1] - .
[0355] Step 3: Preparation of 5d
[0356] Oxalyl chloride (8.29 g, 65.31 mmol) was added to a solution of 5c (3.80 g, 9.33 mmol) and 0.1 mL of DMF in dichloromethane (20 mL) and allowed to react at 50°C for 2 h. The mixture was concentrated under reduced pressure, dissolved in dichloromethane (20 mL), and then concentrated under reduced pressure to obtain a residue. Under an ice-water bath, the dichloromethane solution of the residue (10 mL) was slowly added dropwise to a solution of 1b' (2.15 g, 9.33 mmol) and DIPEA (2.40 g, 18.60 mmol) in dichloromethane (20 mL) and allowed to react at room temperature for 1 h. Silica gel was added, the mixture was concentrated under reduced pressure, and then purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 4:1) to obtain 5d (1.80 g, 31%).
[0357] Step 4: Preparation of 5e
[0358] 5d (1.80 g, 2.90 mmol) was dissolved in tetrahydrofuran (15 mL). After nitrogen substitution, sodium hydroxide (231 mg, 5.78 mmol, 60%) was added portionwise at 0°C and allowed to react for 1 h. The reaction was quenched by the addition of saturated ammonium chloride solution (30 mL). The mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed once with saturated brine (20 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product, which was then purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 4:1) to afford 5e (900 mg, 58%).
[0359] Step 5: Preparation of trifluoroacetate salt of 5f
[0360] Compound 5e (900 mg, 3.01 mmol) was dissolved in dichloromethane (4 mL) and trifluoroacetic acid (4 mL) was added. The mixture was reacted at room temperature for 2 h and concentrated under reduced pressure. The crude trifluoroacetate of compound 5f was obtained by dissolving the mixture in dichloromethane (20 mL x 2) and concentrating under reduced pressure.
[0361] LCMS m / z=439.2[M+1] + .
[0362] Step 6: Preparation of 5g
[0363] The crude trifluoroacetate salt of 5f, 2-chloro-5-(trifluoromethyl)pyrimidine (309 mg, 1.69 mmol), and potassium carbonate (851 g, 6.16 mmol) were added sequentially to dimethyl sulfoxide (4 mL) and reacted at 95°C for 1 h. The mixture was poured into water (30 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated brine (20 mL x 5), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was then purified by column chromatography (100% tetrahydrofuran) to afford 5 g (400 mg, 69%, yield over two steps).
[0364] LCMS m / z=347.1[M+1] + .
[0365] Step 7: 5h preparation
[0366] 5g (400mg, 1.16mmol), 1c" (811mg, 2.32mmol) were dissolved in toluene (80mL). After nitrogen replacement, the temperature was lowered to 0°C, and boron tribromide etherate complex (4mL) was added. The reaction was allowed to react at 23°C for 16h. The temperature was lowered to 0°C, and a saturated sodium bicarbonate solution (80mL) was slowly added dropwise to quench the reaction. The product was extracted with ethyl acetate (50mL x 3), and the organic phases were combined and concentrated under reduced pressure to obtain a residue. The residue was separated and purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 3:2) to obtain 5h (150mg, 24%).
[0367] LCMS m / z=534.3[M+1] + .
[0368] Step 8: Preparation of 5j
[0369] Dissolve 5h (150 mg, 0.28 mmol) in ethanol (2 mL) and add hydrazine hydrate (172 mg, 0.15 mL, 80%). Allow to react at room temperature for 16 h. After concentration under reduced pressure, the product was purified by Prep-TLC (dichloromethane:methanol (v / v) = 10:1) to afford 5j (70 mg, 62%).
[0370] LCMS m / z=404.2[M+1] + .
[0371] Step 9: Preparation of 5k
[0372] 5-Chloro-2-[(4-methoxyphenyl)methyl]-4-(trifluoromethyl)-2,3-dihydropyrazin-3-one (60 mg, 0.19 mmol) and 5j (70 mg, 0.17 mmol) were dissolved in acetonitrile (2 mL), and triethylamine (34.4 mg, 0.34 mmol) was added. The mixture was reacted at room temperature for 16 h. The mixture was concentrated under reduced pressure and purified by Prep-TLC (petroleum ether:ethyl acetate (v / v) = 1:2) to afford 5k (40 mg, 34%).
[0373] LCMS m / z=686.2[M+1] + .
[0374] Step 10: Preparation of compound 5
[0375] 5k (40 mg, 0.06 mmol) was dissolved in trifluoroacetic acid (2 mL) and trifluoromethanesulfonic acid (0.2 mL) was added. The mixture was reacted at room temperature for 1 h. After concentration under reduced pressure, the mixture was dissolved in methanol and DIPEA was added dropwise to adjust the pH to 8-9. After concentration under reduced pressure, the residue was purified by C 18Purification (preparation method: the crude product was dissolved in DMF and filtered through a 0.45 μm filter membrane to prepare a sample solution. Mobile phase system: acetonitrile / water (containing 0.1% ammonia). Gradient elution method: acetonitrile was gradient eluted from 10% to 55% (flow rate: 60 mL / min; elution time 20 min) to obtain compound 5 (17 mg, 52%).
[0376] LCMS m / z=566.2[M+1] + .
[0377] 1 H NMR (400MHz, DMSO-d6) δ12.42(s,1H),8.74(s,2H),7.91(s,1H),6.31-6.19(m,1H),4.45-4.37(m,1H),4.36-4.26(m,2H),4.21-4.10( m,1H),4.09-3.98(m,2H),3.88-3.80(m,1H),3.78-3.66(m,4H),3.63-3.46(m,4H),1.83-1.70(m,1H),1.68-1.59(m,1H),1.16(d,3H).
[0378] Example 6:
[0379] Compound 5 was purified by SFC on OJ column (instrument and preparative column: Waters 150SFC, preparative column model: Chiralcel OJ Column (250*30mm, ID 30mm, 10um particle size). Preparation method: Compound 5 was dissolved in methanol and filtered with a 0.45μm filter membrane to prepare a sample solution. Mobile phase system: A for CO2 and B for MeOH (0.1% NH3.H2O). Gradient elution method: 25% B isocratic elution (flow rate: 100mL / min; elution time 2min), and after freeze-drying, compounds 6-1 and compound 6-2 were obtained.
[0380] Analytical methods (Instrument and preparative column: HPLC-normal phase chromatography, preparative column model: Chiralcel OJ-3 50×4.6mm ID, 3μm; mobile phase system: A for CO2 and B for MeOH (0.05% diethylamine), 3mL / min).
[0381] The compound with retention time T=1.326 min is compound 6-A (compound 6-A is one of the structures of compound 6-1 and compound 6-2).
[0382] LCMS m / z=566.2[M+1] +
[0383] 1 H NMR(400MHz,CD3OD)δ8.60(s,2H),7.96(s,1H),4.51-4.45(m,1H),4.36-4.28(m,2H),4.21-4.07(m,3H),4.01-3.94 (m,1H),3.90-3.78(m,4H),3.73-3.62(m,3H),3.57-3.51(m,1H),1.96-1.84(m,1H),1.75-1.67(m,1H),1.27(d,3H).
[0384] The compound with retention time T=1.665 min is compound 6-B (compound 6-B is one of the structures of compound 6-1 and compound 6-2).
[0385] LCMS m / z=566.2[M+1] +
[0386] 1 H NMR(400MHz,CD3OD)δ8.60(s,2H),7.95(s,1H),4.54-4.46(m,1H),4.35-4.28(m,2H),4.18-4.08(m,3H),3.99-3.92 (m,1H),3.89-3.76(m,4H),3.72-3.59(m,3H),3.55-3.49(m,1H),1.96-1.84(m,1H),1.74-1.66(m,1H),1.27(d,3H).
[0387] Example 7:
[0388] Step 1: Preparation of 7a
[0389] 1b' (4.00 g, 17.37 mmol) was dissolved in tetrahydrofuran (50 mL) and water (25 mL). Sodium bicarbonate (13.02 g, 154.94 mmol) was added, followed by benzyl chloroformate (3.56 g, 20.84 mmol) at 0°C. The mixture was allowed to react at room temperature for 16 h. 20 mL of water was then added, and the mixture was extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine (30 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 77:23) to afford 7a (5.00 g, 79%).
[0390] LCMS m / z=309.1[M-55] +
[0391] Step 2: Preparation of 7b
[0392] Dissolve triphenylphosphine (7.20 g, 27.44 mmol) and imidazole (1.87 g, 27.44 mmol) in anhydrous dichloromethane (30 mL). Slowly add iodine (6.96 g, 27.44 mmol) at 0°C. Allow to react at room temperature for 10 minutes. Then slowly add 7a (5.00 g, 13.72 mmol) at 0°C. Allow to react at room temperature for 16 hours. Add silica gel, concentrate under reduced pressure, and purify by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 85:15) to obtain 7b (5.00 g, 77%).
[0393] LCMS m / z=375.0[M-99] +
[0394] Step 3: Preparation of 7c
[0395] Diethyl malonate (8.44 g, 52.70 mmol) was dissolved in anhydrous tetrahydrofuran (60 mL). After nitrogen purge, sodium hydride (2.11 g, 52.70 mmol, 60% w / t) was added portionwise at 0°C. After stirring at 0°C for 20 minutes, 7b (5.00 g, 10.54 mmol) was slowly added and allowed to react at room temperature for 16 hours. The reaction was quenched by the addition of saturated aqueous ammonium chloride at 0°C, washed with saturated brine (40 mL), and extracted with ethyl acetate (40 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 85:15) to afford 7c (5.50 g, crude product).
[0396] LCMS m / z=407.3[M-99] +
[0397] Step 4: Preparation of 7d
[0398] Dissolve 7c (2.50 g) in methanol (30 mL), add ammonia (0.7 mL) and palladium carbon (600 mg), replace the atmosphere with hydrogen three times, and react at room temperature for 16 h. Filter through a pad of celite, and concentrate the filtrate under reduced pressure to obtain 7d (1.84 g, crude product).
[0399] LCMS m / z=373.2[M+1] +
[0400] Step 5: Preparation of compound 7e
[0401] 7d (1.84 g, crude product) and ethanol (30 mL) were added to a sealed glass tube, and triethylamine (2.50 g, 24.7 mmol) was added, and the mixture was sealed at 90°C for 16 h. The mixture was concentrated under reduced pressure to obtain 7e (1.61 g, crude product).
[0402] LCMS m / z=327.2[M+1] +
[0403] Step 6: Preparation of the hydrochloride salt of 7f
[0404] 7e (1.61 g, crude) was dissolved in hydrogen chloride-1,4-dioxane solution (4.0 M, 20 mL, 80 mmol) and reacted at room temperature for 2 h. The mixture was concentrated under reduced pressure to give the crude hydrochloride salt of 7f (1.48 g).
[0405] LCMS m / z=227.2[M+1] +
[0406] Step 7: Preparation of 7g
[0407] The hydrochloride salt of 7f (1.48 g, crude) and 2-chloro-5-trifluoromethylpyrimidine (0.99 g, 5.42 mmol) were dissolved in N-methylpyrrolidone (25 mL), potassium carbonate (2.04 g, 14.74 mmol) was added, and the mixture was reacted at 90°C for 16 h. Saturated brine (30 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (30 mL x 2). The organic phases were combined, washed with saturated brine (30 mL x 2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by preparative column chromatography (petroleum ether:ethyl acetate (v / v) = 11:9) to yield 7f (1.65 g).
[0408] LCMS m / z=373.2[M+1] +
[0409] Step 8: 7h preparation
[0410] Dissolve 7g (1.20g, 3.22mmol) in a mixture of tetrahydrofuran (50mL) and anhydrous ethanol (50mL), add sodium borohydride (122mg, 3.22mmol), and stir at room temperature for 1h. Calcium chloride (208mg, 1.61mmol) is added portionwise at 0℃, and the mixture is allowed to react at 0℃ for 2h. Saturated aqueous ammonium chloride is slowly added dropwise to quench the reaction, and the mixture is washed with saturated brine (30mL). Extract with ethyl acetate (30mL x 2), and the organic phases are combined, dried over sodium sulfate, and filtered. The filtrate is concentrated under reduced pressure and purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 4:1) to obtain 7h (800mg, 75%).
[0411] LCMS m / z=331.1[M+1] +
[0412] Step 9: Preparation of 7i
[0413] 7h (900 mg, 2.72 mmol) and 1c (1.90 g, 5.44 mmol) were dissolved in toluene (180 mL). After nitrogen substitution, boron trifluoride ether solution (9 mL) was added at 0°C. The reaction was allowed to proceed at 23°C for 16 h. Saturated sodium bicarbonate was added at 0°C to adjust the pH until no bubbles appeared and the solid was completely dissolved. The mixture was extracted with ethyl acetate (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 5:1) to give 7i (250 mg, 18%).
[0414] LCMS m / z=518.2[M+1] +
[0415] Step 10: Preparation of 7j
[0416] Hydrazine hydrate (1 mL, 80%) was added to a solution of 7i (250 mg, 0.48 mmol) in ethanol (4 mL) and allowed to react at room temperature for 16 h. The mixture was concentrated under reduced pressure and purified by Prep-TLC (dichloromethane:methanol (v:v) = 10:1) to afford 7j (150 mg, 80%).
[0417] LCMS m / z=388.2[M+1] +
[0418] Step 11: Preparation of 7k
[0419] 7j (150 mg, 0.39 mmol) and intermediate 1 (137 mg, 0.43 mmol) were dissolved in acetonitrile (5 mL), and triethylamine (79 mg, 0.78 mmol) was added. The mixture was allowed to react at room temperature for 16 h. The product was concentrated under reduced pressure and purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 1:2) to afford 7k (150 mg, 58%).
[0420] LCMS m / z=670.3[M+1] + .
[0421] Step 12: Preparation of Compound 7-1 and Compound 7-2
[0422] Trifluoromethanesulfonic acid (116 mg, 0.77 mmol) was added to a solution of 7k (150 mg, 0.22 mmol) in trifluoroacetic acid (2 mL) and the mixture was allowed to react at room temperature for 1 h. The mixture was concentrated under reduced pressure and quenched with water (4 mL). The pH was adjusted to 7-9 with aqueous ammonia. The aqueous solution was heated to C 18 Column purification yielded 45 mg of crude product, which was then purified by pre-HPLC (instrument and preparative column: WATERS 2767 preparative liquid phase, Xselect C18 preparative column, 5 μm, inner diameter x length = 19 mm x 150 mm). Preparation method: The reaction solution was filtered through a 0.45 μm filter to prepare the sample solution. The mobile phase system was acetonitrile / water (containing 0.05% ammonia). Gradient elution method: Acetonitrile was gradiently eluted from 5% to 50% (elution time 15 min). After lyophilization, compound 7-A (6 mg, 5%) and compound 7-B (8 mg, 7%) were obtained.
[0423] Analytical method (instrument: Shimadzu high-performance liquid chromatograph (instrument model: LC-20AT)-reversed-phase chromatography; preparative column brand and model: Yuexu (Xtimate C18 4.6*50 mm, 3 μm); mobile phase system: mobile phase A is 0.05% TFA solution, mobile phase B is acetonitrile; flow rate: 1.0 mL / min).
[0424] The compound with retention time T=4.224 is compound 7-A (compound 7-A is one of the structures of compound 7-1 and compound 7-2).
[0425] LCMS m / z=550.2[M+1] +
[0426] 1 H NMR(400MHz,DMSO-d6)δ12.41(s,1H),8.72(s,2H),7.93(d,1H),6.35-6.20(m,1H),4.70-4.53(m,2H),4.52-4.42(m,1H),4.26-4.12(m,1H),3. 77-3.55(m,2H),3.54-3.40(m,3H),2.99-2.88(m,1H),2.86-2.76(m,1H ),2.73-2.62(m,1H),2.49-2.45(m,1H),2.04-1.61(m,4H),1.16(d,3H).
[0427] The compound with retention time T=4.284 is compound 7-B (compound 7-B is one of the structures of compound 7-1 and compound 7-2).
[0428] LCMS m / z=550.2[M+1] +
[0429] 1 H NMR(400MHz,DMSO-d6)δ12.34(s,1H),8.73(s,2H),7.89(d,1H),6.32-6.15(m,1H ),4.72-4.58(m,2H),4.52-4.39(m,1H),4.25-4.09(m,1H),3.76-3.57(m,2H),3. 53-3.37(m,3H),3.09-2.95(m,1H),2.86-2.74(m,1H),2.71-2.58(m,1H),2.47-2 .37(m,1H),2.08-1.95(m,1H),1.88-1.77(m,1H),1.63-1.42(m,2H),1.15(d,3H).
[0430] Example 8:
[0431] Compound 7-B (58 mg) was purified by SFC on ID column (instrument and preparative column: Waters 150SFC, preparative column model: Chiralcel OJ-Column (250*30 mm, ID 30 mm, 10 μm particle size). Preparation method: Compound 7-B was dissolved in methanol and filtered with a 0.45 μm filter membrane to prepare a sample solution. Mobile phase system: A for CO2 and B for MeOH (0.1% NH3.H2O). Gradient elution method: 30% B isocratic elution (flow rate: 100 mL / min; elution time 4.5 min), and after lyophilization, compound 8-A (26 mg) and compound 8-B (20 mg) were obtained.
[0432] Analytical method (instrument: Shimadzu LC-30AD sf; preparative column model: Chiralcel OJ-3 50×4.6mm ID, 3μm; mobile phase system: A for CO2 and B for MeOH (0.05% DEA), 3.0ml / min. Retention time T = 1.387min is compound 8-A (compound 8-A is one of the structures of compound 8-1, compound 8-2, compound 8-3, and compound 8-4). Retention time T = 2.009 min is compound 8-B (compound 8-B is one of the structures of compound 8-1, compound 8-2, compound 8-3, and compound 8-4).
[0433] Compound 8-A:
[0434] LCMS m / z=550.6[M+1]+
[0435] 1 H NMR(400MHz,DMSO-d6)δ12.40(s,1H),8.73(s,2H),7.90(s,1H),6.33-6.15(m,1H),4. 72-4.56(m,2H),4.49-4.38(m,1H),4.24-4.09(m,1H),3.73-3.60(m,2H),3.55-3.45( m,1H),3.43-3.34(m,2H),3.09-2.96(m,1H),2.85-2.75(m,1H),2.70-2.57(m,1H),2. 46-2.37(m,1H),2.08-1.95(m,1H),1.88-1.78(m,1H),1.64-1.39(m,2H),1.15(d,3H).
[0436] Compound 8-B:
[0437] LCMS m / z=550.6[M+1] +
[0438] 1 H NMR(400MHz,DMSO-d6)δ12.40(s,1H),8.73(s,2H),7.88(s,1H),6.31-6.17(m,1H),4.71-4 .57(m,2H),4.52-4.42(m,1H),4.23-4.09(m,1H),3.75-3.67(m,1H),3.65-3.57(m,1H),3. 51-3.40(m,2H),3.40-3.32(m,1H),3.09-2.94(m,1H),2.85-2.73(m,1H),2.72-2.59(m,1H ),2.47-2.34(m1H),2.06-1.93(m,1H),1.90-1.77(m,1H),1.60-1.42(m,2H),1.15(d,3H).
[0439] Example 9: Preparation of Compound 9
[0440] Step 1: Preparation of 9b
[0441] 9a (18.28 g, 79.37 mmol) was dissolved in a mixture of tetrahydrofuran (200 mL) and water (100 mL). Sodium bicarbonate (59.48 g, 708 mmol) was added, and a solution of benzyl chloroformate (16.25 g, 95.24 mmol) in tetrahydrofuran was slowly added dropwise at 0°C. The mixture was allowed to react at room temperature for 16 h. 100 mL of water was added, and the mixture was extracted with ethyl acetate (80 mL x 2). The organic phases were combined, washed with saturated brine (80 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 81:19) to afford 9b (15.48 g, 54%).
[0442] LCMS m / z=309.2[M-55] +
[0443] Step 2: Preparation of 9c
[0444] Dissolve triphenylphosphine (22.28 g, 84.96 mmol) and imidazole (5.78 g, 84.96 mmol) in anhydrous dichloromethane (120 mL). Slowly add elemental iodine (21.56 g, 84.96 mmol) at 0°C and react at room temperature for 10 minutes. Slowly add a dichloromethane solution of 9b (15.48 g, 42.48 mmol) dropwise at 0°C and react at room temperature for 16 hours. Saturated sodium thiosulfate solution is slowly added dropwise at 0°C, followed by 100 mL of saturated brine, and extraction with ethyl acetate (80 mL x 2). The combined organic phases are dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure and purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 9:1) to afford 9c (18.00 g, 89%).
[0445] LCMS m / z=375.1[M-99] +
[0446] Step 3: Preparation of 9d
[0447] Diethyl malonate (30.39 g, 189.75 mmol) was dissolved in anhydrous tetrahydrofuran (120 mL). After nitrogen substitution, sodium hydride (7.59 g, 189.75 mmol, 60%) was added portionwise at 0°C. The mixture was stirred at 0°C for 20 minutes, and a solution of 9c (18.00 g, 37.95 mmol) in tetrahydrofuran was slowly added dropwise. The reaction was allowed to react at room temperature for 16 hours. The reaction was quenched by the addition of saturated aqueous ammonium chloride at 0°C. The mixture was washed with saturated brine (80 mL) and extracted with ethyl acetate (80 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 85:15) to afford 9d (17.50 g, 91%).
[0448] LCMS m / z=407.4[M-99] +
[0449] Step 4: Preparation of 9e
[0450] Palladium on carbon (400 mg, 10%) was added to a solution of 9d (2.00 g, 3.95 mmol) in methanol (20 mL) and aqueous ammonia (0.05 mL, 25%-28%). The mixture was reacted at room temperature under a hydrogen atmosphere for 16 h. The filtrate was filtered and concentrated under reduced pressure to afford 9e (1.40 g, crude product).
[0451] LCMS m / z=373.4[M+1] +
[0452] Step 5: Preparation of 9f
[0453] Triethylamine (1.52 g, 15.04 mmol) was added to a solution of 9b (1.40 g, crude) in ethanol (15 mL) and reacted at 90°C for 16 h. After cooling to room temperature, the mixture was concentrated under reduced pressure to obtain 9f (1.20 g, crude).
[0454] LCMS m / z=327.1[M+1] +
[0455] Step 6: Preparation of 9g hydrochloride
[0456] 9f (1.20 g, crude product) was dissolved in 4N hydrochloric acid in dioxane (10 mL), reacted at room temperature for 2 h, and concentrated under reduced pressure to obtain 9 g of hydrochloride (1.00 g, crude product).
[0457] LCMS m / z=227.2[M+1] +
[0458] Step 7: 9h preparation
[0459] Potassium carbonate (2.10 g, 15.24 mmol) was added to a solution of the hydrochloride salt of 9d (1.00 g, crude) and 2,5-dichloropyrimidine (0.68 g, 4.57 mmol) in dimethyl sulfoxide (10 mL). The mixture was allowed to react at 90°C for 2 h. The mixture was cooled to room temperature and quenched with water (20 mL). The mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined. The organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was then purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 5:1) to afford 9h (1.25 g, 93% yield over four steps).
[0460] LCMS m / z=339.1[M+1] +
[0461] Step 8: Preparation of 9j
[0462] Calcium chloride (1.44 g, 13 mmol) and sodium borohydride (0.98 g, 26 mmol) were added sequentially to a mixture of compound 9h (1.10 g, 3.25 mmol) in tetrahydrofuran (12 mL) and methanol (3 mL) under ice-salt bath. The mixture was allowed to react for 0.5 h. The reaction was quenched by the addition of ethyl acetate (30 mL) and saturated sodium carbonate solution (10 mL). The mixture was stirred for 1 h and then filtered. The filtrate was concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (dichloromethane (containing 9% methanol): petroleum ether (containing 16% ethyl acetate) (v:v) = 5:1) to afford compound 9j-1 (180 mg, 19%) and compound 9j-2.
[0463] Compound 9j-1 is compound 9j
[0464] LCMS m / z=297.1[M+1] + .
[0465] 1 H NMR(400MHz,DMSO-d6)δ8.45(s,2H),4.59-4.41(m,4H),3.73-3.52(m,2H),3.45-3.34(m,1H),2.97-2.8 5(m,1H),2.76-2.57(m,2H),2.35-2.23(m,1H),2.10-2.00(m,1H),1.93-1.84(m,1H),1.65-1.42(m,2H).
[0466] Compound 9j-2
[0467] LCMS m / z=297.1[M+1] + .
[0468] 1 H NMR(400MHz,DMSO-d6)δ8.44(s,2H),4.69-4.63(m,1H),4.56-4.42(m,3H),3.69-3.53(m,2H),3.47-3.38(m,1H), 2.93-2.83(m,1H),2.82-2.73(m,1H),2.69-2.59(m,1H),2.40-2.30(m,1H),1.93-1.81(m,2H),1.80-1.62(m,2H).
[0469] Step 9: Preparation of 9k
[0470] 9j (120 mg, 0.40 mmol) and 1c (280 mg, 0.80 mmol) were dissolved in toluene (10 mL) at 0°C. After nitrogen substitution, boron trifluoride etherate (1 mL) was slowly added at 0°C and reacted at 23°C for 16 h. The pH was adjusted to 7-8 with saturated sodium carbonate solution at 0°C. Extraction was performed with ethyl acetate (100 mL x 3). The organic phases were combined and concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 10:3) to obtain 9k (70 mg, 36%).
[0471] LCMS m / z=484.2[M+1] +
[0472] Step 10: Preparation of compound 9m
[0473] Hydrazine hydrate (0.1 mL, 80% content) was added to a solution of compound 9k (135 mg, 0.28 mmol) in ethanol (4 mL) and allowed to react at room temperature for 16 h. The solution was concentrated under reduced pressure, slurried with ethyl acetate, filtered, and the filter cake washed with ethyl acetate (10 mL x 3). The filtrate was concentrated under reduced pressure to yield compound 9m (100 mg, crude product).
[0474] LCMS m / z=354.2[M+1] +
[0475] Step 11: Preparation of compound 9n
[0476] Intermediate 1 (116 mg, 0.36 mmol) was added to a solution of compound 9m (100 mg, crude) and triethylamine (113 mg, 1.12 mmol) in acetonitrile (5 mL) and allowed to react at room temperature for 6 h. Silica gel was added, the mixture was concentrated under reduced pressure, and then purified by column chromatography (dichloromethane:tetrahydrofuran (v:v) = 5:1) to afford compound 9n (100 mg, 56% yield over two steps).
[0477] LCMS m / z=636.3[M+1] +
[0478] Step 12: Preparation of compound 9
[0479] Trifluoromethanesulfonic acid (105 mg, 0.70 mmol) was added to a solution of compound 9n (100 mg, 0.16 mmol) in trifluoroacetic acid (2 mL) and allowed to react at room temperature for 1 h. The mixture was concentrated under reduced pressure, and the crude product was diluted with ethyl acetate (20 mL). The pH of the mixture was adjusted to 8-9 with saturated sodium carbonate solution. Extraction was performed with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 5:2) to obtain compound 9 (45 mg, 55%).
[0480] Compound 9 is one of the structures of Compound 9-1 and Compound 9-2.
[0481] LCMS m / z=516.2[M+1] +
[0482] 1 H NMR(400MHz,DMSO-d6)δ12.40(s,1H),8.45(s,2H),7.88(s,1H),6.30-6.17(m,1H ),4.57-4.40(m,3H),4.22-4.11(m,1H),3.74-3.68(m,1H),3.64-3.58(m,1H),3. 49-3.40(m,2H),3.37-3.31(m,1H),2.95-2.86(m,1H),2.73-2.57(m,2H),2.46-2 .37(m,1H),2.05-1.95m,1H),1.86-1.77(m,1H),1.58-1.41(m,2H),1.15(d,3H).
[0483] Example 10: Preparation of Compound 10p and Its Stereoisomers (Compound 10-a, Compound 10-b, Compound 10-c, Compound 10-d)
[0484] Step 1: Preparation of 10b
[0485] A solution of benzyl chloroformate (17.35 g, 101.73 mmol) in dichloromethane (50 mL) was slowly added dropwise to a mixture of 10a (20.00 g, 92.48 mmol) in dichloromethane (300 mL) and saturated sodium bicarbonate solution (300 mL) at 0°C. The mixture was allowed to react at room temperature for 16 h. The mixture was extracted with dichloromethane (300 mL x 2). Silica gel was added to the organic phase, and the mixture was concentrated under reduced pressure and purified by column chromatography (petroleum ether:tetrahydrofuran ester (v:v: = 20:3)) to afford 10b (32.00 g, 99%).
[0486] LCMS m / z=251.0[M-99] +
[0487] Step 2: Preparation of 10c
[0488] 10b (33.00 g, 94.18 mmol) was dissolved in dichloromethane (600 mL). Dess-Martin periodinane (41.94 g, 98.89 mmol) was added at 0°C and allowed to react for 2 h. The reaction was quenched by slowly adding saturated aqueous sodium bicarbonate (200 mL). The phases were allowed to separate to obtain an organic phase. The phase was concentrated under reduced pressure. The crude product was slurried with a mixture of water (500 mL) and ethyl acetate (500 mL) and filtered. The filtrate was extracted with ethyl acetate (500 mL x 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 5:1) to obtain 10c (24.00 g, 73%).
[0489] LCMS m / z=293.2[M-55] +
[0490] Step 3: Preparation of 10d
[0491] Diethyl malonate (5.75 g, 35.88 mmol) was added to a toluene (100 mL) solution of 10c (10.00 g, 28.70 mmol), benzoic acid (1.05 g, 8.61 mmol), and hexahydropyridine (0.73 g, 8.61 mmol). The mixture was reacted at 135°C for 8 h. After cooling to room temperature, silica gel was added, and the mixture was concentrated under reduced pressure and purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 10:1) to afford 10d (5.20 g, 33%).
[0492] LCMS m / z=435.1[M-55] +
[0493] Step 4: Preparation of 10e
[0494] Palladium on carbon (0.50 g, 10%) was added to a solution of compound 10d (5.20 g, 10.60 mmol) in methanol (50 mL) and aqueous ammonia (0.05 mL, 25%-28%). The mixture was reacted at room temperature under a hydrogen atmosphere for 16 h. The mixture was filtered through a pad of Celite, and the filtrate was concentrated under reduced pressure to afford compound 10e (3.50 g, crude product).
[0495] LCMS m / z=359.3[M+1] +
[0496] Step 5: Preparation of 10f
[0497] Triethylamine (3.20 g, 29.28 mmol) was added to a sealed tube containing 10e (3.50 g, 9.76 mmol) in ethanol (30 mL). The mixture was reacted at 90°C for 2 h. The reaction was cooled to room temperature, silica gel was added, and the mixture was concentrated under reduced pressure and purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 5:1) to afford 10f (1.50 g, 49%).
[0498] LCMS m / z=257.3[M-55] +
[0499] Step 6: Preparation of 10g
[0500] Trifluoroacetic acid (10 ml) was added to a solution of 10f (1.50 g, 4.80 mmol) in dichloromethane (20 mL), and the mixture was reacted at room temperature for 3 h. The mixture was concentrated under reduced pressure to obtain 10 g of the trifluoroacetic acid salt (1.50 g, crude product).
[0501] LCMS m / z=213.1[M+1] +
[0502] Step 7: Preparation of 10n
[0503] Potassium carbonate (2.54 g, 18.4 mmol) was added to a solution of 10 g of trifluoroacetate (1.50 g, crude) and 2-chloro-5-(trifluoromethyl)pyrimidine (0.92 g, 5.06 mmol) in dimethyl sulfoxide (10 mL) and allowed to react at 95°C for 3 h. After cooling to room temperature, the reaction was quenched with water (20 mL) and extracted with ethyl acetate (50 mL x 3). The organic phases were combined. The organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography (petroleum ether:ethyl acetate (v:v) = 4:1) to afford 10n (1.20 g, two-step yield: 69%).
[0504] LCMS m / z=359.1[M+1] +
[0505] Step 8: Preparation of 10j
[0506] Calcium chloride (1.36 g, 12.25 mmol) and sodium borohydride (0.93 g, 24.59 mmol) were added sequentially to a mixture of 10n (1.10 g, 3.07 mmol) in tetrahydrofuran (12 mL) and ethanol (3 mL) under ice-salt bath. The mixture was allowed to react for 0.5 h. The reaction was quenched with saturated sodium carbonate solution (10 mL) and ethyl acetate (100 mL) and stirred for 0.5 h. The filtrate was filtered, concentrated under reduced pressure, and purified by column chromatography (dichloromethane:methanol (v:v) = 10:1) to afford 10j (930 mg, 96%).
[0507] LCMS m / z=317.1[M+1] +
[0508] Step 9: Preparation of 10k
[0509] 10j (1.00 g, 3.16 mmol) and 1c (2.21 g, 6.32 mmol) were dissolved in toluene (50 mL) at 0°C. After nitrogen substitution, boron trifluoride etherate (3 mL) was slowly added dropwise and reacted at 23°C for 16 h. Saturated sodium carbonate solution was added at 0°C to adjust the pH to 8-9. The mixture was extracted with ethyl acetate (100 mL x 3). The combined organic phases were concentrated under reduced pressure and purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 10:3) to give 10k (0.80 g, 50%).
[0510] LCMS m / z=504.2[M+1] +
[0511] Step 10: Preparation of 10m
[0512] Hydrazine hydrate (0.5 ml, 80%) was added to a solution of 10k (800 mg, 1.59 mmol) in ethanol (10 mL) and allowed to react at room temperature for 16 h. The mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was slurried in ethyl acetate (50 mL), filtered again, and the filtrate was concentrated under reduced pressure to obtain the crude product 10m (600 mg).
[0513] LCMS m / z=374.2[M+1] +
[0514] Step 11: 10h preparation
[0515] Intermediate 1 (667 mg, 2.09 mmol) was added to a solution of 10m (600 mg, crude) and triethylamine (0.65 g, 6.44 mmol) in acetonitrile (20 mL) and allowed to react at room temperature for 16 h. Silica gel was added, the mixture was concentrated under reduced pressure, and then purified by column chromatography (dichloromethane:ethyl acetate (v:v) = 2:1) to afford 10h (740 mg, two-step yield: 71%).
[0516] LCMS m / z=656.8[M+1] +
[0517] Step 12: Preparation of 10p
[0518] Trifluoromethanesulfonic acid (594 mg, 3.95 mmol) was added to a solution of 10h (740 mg, 1.13 mmol) in trifluoroacetic acid (10 mL) at 0°C for 1 h. The reaction was concentrated under reduced pressure, and the crude product was dissolved in ethyl acetate (20 mL) and water (10 mL). The pH was adjusted to 8-9 by adding saturated sodium carbonate solution, and the product was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, concentrated under reduced pressure, and purified by column chromatography (dichloromethane:ethyl acetate (v:v) = 5:4) to afford 10p (440 mg, 73%).
[0519] LCMS m / z=536.1[M+1] +
[0520] Step 13: Preparation of Compound 10-a, Compound 10-b, Compound 10-c, and Compound 10-d
[0521] Compound 10p was purified by SFC on AD column (instrument and preparative column: Waters 150SFC, preparative column model: Chiralpak AD Column (250*30mm, ID 30mm, 10um particle size). Preparation method: Compound 10p was dissolved in methanol and filtered through a 0.45μm filter membrane to prepare a sample solution. Mobile phase system: A for CO2 and B for etoh. Gradient elution method: 35% B isocratic elution (flow rate: 100ml / min; elution time: 4.5min; column temperature: 25°C; column pressure: 100bar, absorption wavelength: 220nm) to obtain compounds 10-P1, compound 10-P2 and compound 10-P3, among which compound 10-P3 was a mixture of two configurations.
[0522] Analytical method (instrument: Shimadzu LC-30AD sf; preparative column model: Chiralpak AD-3 50×4.6mm ID, 3μm; mobile phase system: A for CO2 and B for etoh (0.05% DEA). Retention time T = 1.635min for compound 10-P1 (compound 10-P1 is one of the structures of compound 10-a, compound 10-b, compound 10-c, and compound 10-d); retention time T = 1.886min for compound 10-P2 (compound 10-P2 is one of the structures of compound 10-a, compound 10-b, compound 10-c, and compound 10-d); retention time T = 2.288min for compound 10-P3 (compound 10-P3 is a mixture of two structures of compound 10-a, compound 10-b, compound 10-c, and compound 10-d).
[0523] Compound 10-P1
[0524] LCMS m / z=536.1[M+1] +
[0525] 1 H NMR (400MHz, DMSO-d6) δ12.37(s,1H),8.73(d,2H),7.87(s,1H),6.27-6.13(m,1H),4.84-4.69(m,2H),4.20-4.07(m,1H),3.95-3.87(m,1H),3. 68-3.62(m,1H),3.54-3.38(m,4H),2.94-2.84(m,1H),2.82-2.71(m,2H ),2.70-2.62(m,1H),2.05-1.95(m,1H),1.86-1.75(m,1H),1.13(d,3H).
[0526] Compound 10-P2
[0527] LCMS m / z=536.1[M+1] +
[0528] 1 H NMR (400MHz, DMSO-d6) δ12.42(s,1H),8.73(d,2H),7.93(s,1H),6.34-6.16(m,1H),4.94-4.82(m,1H),4.81-4.72(m,1H),4.28-4.15(m,1H),3. 92-3.82(m,1H),3.69-3.56(m,2H),3.54-3.42(m,3H),2.91-2.71(m,2H ),2.69-2.56(m,2H),2.28-2.16(m,1H),1.55-1.44(m,1H),1.16(d,3H).
[0529] Compound 10-P3 was purified by SFC on an OJ column (instrument and preparative column: Waters 150SFC, preparative column model: Chiralcel OJ-Column (250*30mm, ID 30mm, 10um particle size)). Preparation method: Compound 10-P3 was dissolved in methanol and filtered through a 0.45μm filter membrane to prepare a sample solution. Mobile phase system: A for CO2 and B for EtOH (0.1% NH3·H2O). Gradient elution method: 30% B isocratic elution (flow rate: 120ml / min; elution time: 2.0min; column temperature: 25℃; column pressure: 100bar, absorption wavelength: 220nm) to obtain compounds 10-P3-1 and compound 10-P3-2.
[0530] Analytical method (instrument: Shimadzu LC-30AD SFC; preparative column model: Chiralcel OJ-3 50×4.6mm ID, 3μm; mobile phase system: A for CO2, B for 0.05% DEA in EtOH. Retention time T = 1.124min is compound 10-P3-1 (compound 10-P3-P1 is one of the structures of compound 10-a, compound 10-b, compound 10-c, and compound 10-d); retention time T = 1.886min is compound 10-P3-2 (compound 10-P3-P2 is one of the structures of compound 10-a, compound 10-b, compound 10-c, and compound 10-d).
[0531] Compound 10-P3-1
[0532] LCMS m / z=536.1[M+1] +
[0533] 1 H NMR (400MHz, DMSO-d6) δ12.38(s,1H),8.73(s,2H),7.89(s,1H),6.25-6.10(m,1H),4.88-4.67(m,2H),4.25-4.10(m,1H),3.95-3.84(m,1H),3. 64-3.53(m,2H),3.52-3.37(m,3H),2.94-2.83(m,1H),2.82-2.70(m,2H ),2.69-2.61(m,1H),2.08-1.98(m,1H),1.86-1.75(m,1H),1.12(d,3H).
[0534] Compound 10-P3-2
[0535] LCMS m / z=536.1[M+1] +
[0536] 1 H NMR (400MHz, DMSO-d6) δ12.42(s,1H),8.74(s,2H),7.92(s,1H),6.41-6.28(m,1H),4.90-4.73(m,2H),4.29-4.11(m,1H),3.95-3.82( m,1H),3.73-3.62(m,1H),3.57-3.41(m,4H),2.88-2.72(m,2H),2.69-2.52(m,2H),2.28-2.17(m,1H),1.53-1.41(m,1H),1.15(d,3H).
[0537] Example 11: Preparation of Compound 11
[0538] Step 1: Preparation of 11b
[0539] Potassium carbonate (2.19 g, 15.84 mmol) was added to a solution of 9 g of the hydrochloride salt (1.04 g, crude product) and 2-chloro, 5-cyclopropylpyrimidine (730 mg, 4.75 mmol) in dimethyl sulfoxide (10 ml). The mixture was allowed to react at 90°C for 16 h. The mixture was cooled to room temperature and quenched with water (20 mL). The mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined. The organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 5:1) to obtain compound 11b (1.00 g, 73%).
[0540] LCMS m / z=345.3[M+1] +
[0541] Step 2: Preparation of compound 11c
[0542] Calcium chloride (1.03 g, 9.28 mmol) was added to a solution of compound 11b (800 mg, 2.32 mmol) in tetrahydrofuran (10 ml) and methanol (2 ml). Sodium borohydride (352 mg, 9.28 mmol) was added portionwise at -60°C. The mixture was allowed to react for 0.5 h at -5°C. The reaction was quenched by the addition of ethyl acetate (30 mL) and saturated ammonium chloride solution (10 mL) at -5°C. After stirring for 1 h, the mixture was filtered and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated and purified by column chromatography (dichloromethane (containing 9% methanol): petroleum ether (containing 16% ethyl acetate) (v:v) = 5:1) to obtain compound 11c-1 (200 mg, 29%) and compound 11c-2.
[0543] Compound 11c-1 is compound 11c.
[0544] LCMS m / z=303.4[M+1] +
[0545] 1 H NMR(400MHz,CD3OD)δ8.15(s,2H),4.70-4.52(m,3H),3.87-3.72(m,2H),3.53-3.40(m,1H),3.01-2.89(m,1H),2.80-2.64(m,2H),2 .49-2.38(m,1H),2.19-2.08(m,1H),2.02-1.92(m,1H),1.82-1.66(m,2H),1.66-1.54(m,1H),0.97-0.88(m,2H),0.66-0.59(m,2H).
[0546] Compound 11c-2
[0547] LCMS m / z=303.4[M+1] +
[0548] 1 H NMR(400MHz,CD3OD)δ8.16(s,2H),4.65-4.52(m,3H),3.86-3.74(m,2H),3.56-3.44(m,1H),2.99-2.88(m,1H),2 .85-2.70(m,2H),2.56-2.46(m,1H),2.06-1.94(m,2H),1.91-1.72(m,3H),0.97-0.89(m,2H),0.66-0.59(m,2H).
[0549] Step 3: Preparation of compound 11d
[0550] Compound 11c (235 mg, 0.78 mmol) and compound 1c" (545 mg, 1.56 mmol) were dissolved in toluene (10 mL) at 0°C. After nitrogen substitution, boron trifluoride etherate (1 mL) was slowly added dropwise to the system and reacted at 23°C for 16 h. The pH was adjusted to 7-8 with saturated sodium carbonate solution at 0°C. Extraction was performed with ethyl acetate (100 mL x 3). The organic phases were combined and concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 10:3) to obtain compound 11d (190 mg, 50%).
[0551] LCMS m / z=490.2[M+1] +
[0552] Step 4: Preparation of compound 11e
[0553] Hydrazine hydrate (0.1 mL, 80% content) was added to a solution of compound 11d (217 mg, 0.44 mmol) in ethanol (4 mL) and allowed to react at room temperature for 16 h. The mixture was concentrated under reduced pressure, and the crude product was slurried with acetonitrile, filtered, and the filtrate was concentrated under reduced pressure to obtain compound 11e (150 mg, crude product).
[0554] LCMS m / z=360.6[M+1] +
[0555] Step 5: Preparation of compound 11f
[0556] Intermediate 1 (174 mg, 0.55 mmol) was added to a solution of compound 11e (150 mg, crude) and triethylamine (170 mg, 1.68 mmol) in acetonitrile (5 mL). The mixture was allowed to react at room temperature for 16 h. Silica gel was added, the mixture was concentrated under reduced pressure, and then purified by column chromatography (dichloromethane:tetrahydrofuran (v:v) = 5:1) to afford compound 11f (150 mg, 53% yield over two steps).
[0557] LCMS m / z=642.4[M+1] +
[0558] Step 6: Preparation of compound 11
[0559] Trifluoromethanesulfonic acid (116 mg, 0.77 mmol) was added to a solution of compound 11f (140 mg, 0.22 mmol) in trifluoroacetic acid (4 mL) at 0°C for 1 h. The mixture was concentrated under reduced pressure, and the crude product was diluted with ethyl acetate (20 mL) and the pH was adjusted to 8-9 with saturated sodium carbonate solution. The product was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated and purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 5:2) to obtain compound 11 (72 mg, 63%).
[0560] Compound 11 is one of the structures of compound 11-1 and compound 11-2.
[0561] LCMS m / z=522.5[M+1] +
[0562] 1 H NMR(400MHz,DMSO-d6)δ12.40(s,1H),8.19(s,2H),7.88(s,1H),6.30-6.17(m,1H),4.60-4.49( m,2H),4.49-4.41(m,1H),4.22-4.10(m,1H),3.74-3.66(m,1H),3.65-3.58(m,1H),3.50-3.40( m,2H),3.34-3.25(m,1H),2.87-2.74(m,1H),2.65-2.53(m,2H),2.46-2.36(m,1H),2.04-1.95( m,1H),1.87-1.72(m,2H),1.59-1.41(m,2H),1.15(d,3H),0.92-0.84(m,2H),0.68-0.59(m,2H).
[0563] Example 12: Preparation of Compound 12 and Its Stereoisomers
[0564] Step 1: Preparation of 12b
[0565] Methyl 2-(dimethoxyphosphoryl)acetate (26.19 g, 143.79 mmol) was dissolved in tetrahydrofuran (50 mL), the atmosphere was replaced with nitrogen, and the mixture was cooled to -78°C and potassium bis(trimethylsilyl)amide (143.79 mL, 1 M) was added dropwise. After reacting at -78°C for 1 h, a solution of 12a (synthesized according to patent WO2015013835) (16.7 g, 47.93 mmol) in tetrahydrofuran (50 mL) was added dropwise. The reaction was allowed to react at -78°C for 2 h. The reaction was quenched by the dropwise addition of saturated ammonium chloride solution, and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phases were combined, washed with saturated brine (50 mL x 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a residue. The residue was separated and purified by silica gel column chromatography (petroleum ether:tetrahydrofuran (v / v) = 9:1) to give 12b (14 g, 72%).
[0566] LCMS m / z=349.1[M-55] +
[0567] Step 2: Preparation of 12c
[0568] 12b (12.5 g, 30.91 mmol) was dissolved in tetrahydrofuran (150 mL). Lithium borohydride (6.73 g, 309.1 mmol) was added portionwise at 0°C and allowed to react at room temperature for 18 h. Dilute hydrochloric acid (1 M) was slowly added dropwise to adjust the pH to 8-9. Ethyl acetate (150 mL x 3) was added for extraction. The organic phases were combined, washed with saturated brine (150 mL x 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (petroleum ether:tetrahydrofuran (v / v) = 4:1) to obtain 12c (7 g, 60%).
[0569] LCMS m / z=279.2[M-99] +
[0570] Step 3: Preparation of 12d
[0571] Triphenylphosphine (9.45 g, 36.96 mmol) and imidazole (2.52 g, 36.96 mmol) were dissolved in anhydrous dichloromethane (210 mL). Elemental iodine (9.38 g, 36.96 mmol) was slowly added at 0°C under nitrogen. After reacting at room temperature for 10 minutes, 12c (7.00 g, 18.48 mmol) was slowly added dropwise at 0°C and reacted at room temperature for 16 hours. Silica gel was added, the mixture was concentrated under reduced pressure, and then purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 12:1) to obtain 12d (7.00 g, 77%).
[0572] LCMS m / z=389.0[M-99] +
[0573] Step 4: Preparation of 12e
[0574] Diethyl malonate (9.19 g, 57.35 mmol) was dissolved in anhydrous tetrahydrofuran (100 mL). After nitrogen substitution, sodium hydride (2.29 g, 57.35 mmol, 60% wt) was added portionwise at 0°C. The reaction was allowed to proceed at 0°C for 20 minutes. A solution of 12d (5.60 g, 11.47 mmol) in anhydrous tetrahydrofuran (50 mL) was slowly added dropwise, and the mixture was allowed to react at room temperature for 16 hours. The reaction was quenched by the slow dropwise addition of saturated aqueous ammonium chloride at 0°C. The mixture was washed with saturated brine (50 mL) and extracted with ethyl acetate (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 8:1) to afford 12e (4.50 g, 75%).
[0575] LCMS m / z=421.3[M-99] +
[0576] Step 5: Preparation of 12f
[0577] 12e (4.50 g, 8.64 mmol) was dissolved in ethanol (50 mL), and water (8.64 mL) and sodium hydroxide (0.35 g, 8.64 mmol) were added. The reaction was allowed to react at room temperature for 16 h. The mixture was concentrated under reduced pressure, and the pH was adjusted to 5-6 by adding dilute hydrochloric acid (2N) at 0°C. The mixture was extracted with ethyl acetate (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (methanol:dichloromethane (v / v) = 5:95) to obtain 12f (4.20 g, 98%).
[0578] LCMS m / z=393.2[M-99] +
[0579] Step 6: Preparation of 12g
[0580] 12f (5.10 g, 10.35 mmol) was dissolved in methanol (100 mL). Ammonia (0.3 mL, 25%-28%) and palladium on carbon (510 mg, 10%) were added, respectively. The atmosphere was replaced with hydrogen three times and the mixture was allowed to react at room temperature for 16 h. The mixture was filtered through a pad of celite, and the filtrate was concentrated under reduced pressure to yield 12g (3.71 g, crude product).
[0581] LCMS m / z=359.2[M+1] +
[0582] Step 7: 12h preparation
[0583] Dissolve 12g (3.71g, crude product) in DMF (30mL), add DIPEA (4.01g, 31.05mmol) and HATU (3.94g, 10.35mmol), and react at room temperature overnight. Add water (50mL) and extract with ethyl acetate (50mL x 3). The organic phases are combined, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain the crude product. The crude product is separated and purified by column chromatography (tetrahydrofuran:petroleum ether (v / v) = 1:10) to obtain 12h (3.52g, crude product).
[0584] LCMS m / z=341.2[M+1] +
[0585] Step 8: Preparation of 12i hydrochloride
[0586] 12h (3.52 g, crude) was dissolved in a 4.0 M hydrogen chloride-1,4-dioxane solution (20 mL, 80 mmol), reacted at room temperature for 2 h, and concentrated under reduced pressure to obtain the hydrochloride salt of 12i (2.86 g, crude).
[0587] LCMS m / z=241.2[M+1] +
[0588] Step 9: Preparation of 12j
[0589] The hydrochloride salt of 12i (2.86 g, crude) and 2-chloro-5-trifluoromethylpyrimidine (1.89 g, 10.33 mmol) were dissolved in dimethyl sulfoxide (50 mL). Potassium carbonate (4.28 g, 30.99 mmol) was added and the mixture was reacted at 90°C for 16 h. After cooling to room temperature, saturated brine (50 mL) was added and extracted with ethyl acetate (50 mL x 2). The organic phases were combined, washed with saturated brine (50 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative column chromatography (petroleum ether:ethyl acetate (v / v) = 5:1) to obtain 12j (2 g, 64%).
[0590] LCMS m / z=387.7[M+1] +
[0591] Step 10: Preparation of 12k
[0592] 12j (0.90 g, 2.33 mmol) was dissolved in a mixture of tetrahydrofuran (39 mL) and anhydrous ethanol (39 mL). Sodium borohydride (88.14 mg, 2.33 mmol) was added and the mixture was allowed to react at room temperature for 1 h. Calcium chloride (150.28 mg, 1.17 mmol) was added portionwise at 0°C and allowed to react for 2 h. The reaction was quenched by the slow dropwise addition of saturated aqueous ammonium chloride. The mixture was washed with saturated brine (30 mL) and extracted with ethyl acetate (30 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 5:3) to afford 12k (750 mg, 93%).
[0593] LCMS m / z=345.4[M+1] +
[0594] Step 11: Preparation of 12L
[0595] 12k (700 mg, 2.03 mmol) and 1c (1.38 g, 3.95 mmol) were dissolved in toluene (70 mL). After nitrogen substitution, the temperature was lowered to 0°C, and a solution of boron trifluoride in ether (7 mL) was added. The reaction was allowed to react at 23°C for 16 h. The pH was adjusted by adding saturated sodium bicarbonate at 0°C until no bubbles appeared and the solid was completely dissolved. The mixture was extracted with ethyl acetate (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was separated and purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 5:1) to obtain 12l (380 mg, 35%).
[0596] LCMS m / z=532.2[M+1] +
[0597] Step 12: Preparation of 12m
[0598] Hydrazine hydrate (0.22 mL, 80% content) was added to a solution of 12l (380 mg, 0.71 mmol) in ethanol (15 mL) and allowed to react at room temperature for 16 h. The mixture was concentrated under reduced pressure to afford a crude product, which was then purified on a preparative plate (dichloromethane:methanol (v:v) = 10:1) to afford 12m (190 mg, 66%).
[0599] LCMS m / z=402.2[M+1] +
[0600] Step 13: Preparation of 12n
[0601] 12m (190 mg, 0.47 mmol) and intermediate 1 (150 mg, 0.47 mmol) were dissolved in acetonitrile (6 mL), and triethylamine (190 mg, 1.88 mmol) was added. The mixture was allowed to react at room temperature for 16 h. The product was concentrated under reduced pressure and purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 1:2) to afford 12n (220 mg, 68%).
[0602] LCMS m / z=684.2[M+1] + .
[0603] Step 14: Preparation of compound 12 and its stereoisomers
[0604] Trifluoromethanesulfonic acid (340 mg, 2.27 mmol) was added to a solution of compound 12n (220 mg, 0.32 mmol) in trifluoroacetic acid (2 mL) and allowed to react at room temperature for 1 h. The mixture was concentrated under reduced pressure, quenched with water (4 mL), and the pH adjusted to 7-9 with aqueous ammonia. The mixture was concentrated under reduced pressure and purified by Pre-HPLC (apparatus and preparative column: SHIMADZU LC-20AP preparative HPLC, Phenomenex C18, 5 μm, inner diameter x length = 19 mm x 150 mm). Preparation method: The crude product was dissolved in acetonitrile and water, filtered through a 0.45 μm filter, and the sample solution was prepared. The mobile phase system was acetonitrile / water (containing 10 mM ammonium carbonate). Gradient elution was performed: 32% acetonitrile to 62% acetonitrile (elution time 15 min). Freeze-drying gave compound 12.
[0605] Compound 12 was purified by SFC on AD column (instrument and preparative column: Waters 150SFC, preparative column model is Chiralpak IG Column (250*30mm, ID 30mm, 10um particle size). Preparation method: Compound 12 was dissolved in acetonitrile and filtered with a 0.45μm filter membrane to prepare a sample solution. Mobile phase system: A for CO2 and B for EtOH+ACN (0.1% NH3·H2O). Gradient elution method: 50% phase B (flow rate: 100mL / min; elution time 2.8min) to obtain compound 12-Peak-1 and compound 12-Peak-2.
[0606] Analytical methods (Instrument and preparative column: SHIMADZU LC-30AD sf, preparative column model: Chiralpak AD-3 50×4.6mm ID, 3μm) Mobile phase system: A for CO2 and B for MeOH (0.05% DEA). Retention time T = 0.971 for compound 12-Peak-1 (81 mg) (compound 12-Peak-1 is one of the structures of compounds 12-P1, 12-P2, 12-P3, and 12-P4); retention time T = 1.845 for compound 12-Peak-2 (77 mg) (compound 12-Peak-1 is one of the structures of compounds 12-P1, 12-P2, 12-P3, and 12-P4).
[0607] Compound 12-Peak-1
[0608] LCMS m / z=564.7[M+1] +
[0609] 1 H NMR(400MHz,DMSO-d6)δ12.41(s,1H),8.72(s,2H),7.90(s,1H),6.31-6. 18(m,1H),4.25-3.98(m,4H),3.95-3.86(m,1H),3.72-3.56(m,4H),3.56- 3.49(m,1H),3.45-3.37(m,1H),3.28-3.23(m,1H),2.85-2.75(m,1H),1. 77-1.65(m,2H),1.65-1.47(m,2H),1.45-1.32(m,1H),1.18-1.03(m,4H).
[0610] Compound 12-Peak-2
[0611] LCMS m / z=564.6[M+1] +
[0612] 1H NMR(400MHz,DMSO-d6)δ12.41(s,1H),8.71(s,2H),7.91(s,1H),6.28-6. 18(m,1H),4.23-4.05(m,3H),4.04-3.97(m,1H),3.96-3.87(m,1H),3.72- 3.55(m,4H),3.49-3.45(m,2H),3.33-3.29(m,1H),2.87-2.77(m,1H),1. 81-1.66(m,2H),1.66-1.51(m,2H),1.45-1.32(m,1H),1.19-1.05(m,4H).
[0613] Example 13: Preparation of Compound 13
[0614] Compound 13 was obtained using 12c as the starting material by referring to the synthetic method of compound 1.
[0615] LCMS m / z=580.3[M+1] + .
[0616] 1 H NMR(400MHz,DMSO-d6)δ12.44(s,1H),8.72(s,2H),7.94-7.88(m,1H),6.30-6.19( m,1H),4.80-4.70(m,1H),4.68-4.46(m,3H),4.24-4.07(m,2H),3.91-3.82(m,1H), 3.74-3.57(m,3H),3.56-3.46(m,2H),3.43-3.35(m,1H),3.15-3.02(m,1H),2.89- 2.77(m,1H),1.88-1.63(m,2H),1.55-1.43(m,1H),1.28-1.19(m,1H),1.16(d,3H).
[0617] Example 14: Preparation of Compound 14
[0618] Compound 14 was obtained using 14a as the starting material by referring to the synthetic method of compound 9. Compound 14 is one of the structures of compound 14-1 and compound 14-2.
[0619] LCMS m / z=550.2[M+1] +
[0620] 1H NMR(400MHz,DMSO-d6)δ12.40(s,1H),9.24(s,1H),7.88(s,1H),7.73-7.63(m,2H),7.63-7.57( m,1H),6.30-6.18(m,1H),4.81-4.68(m,2H),4.56-4.46(m,1H),4.23–4.08(m,1H),3.76-3.67( m,1H),3.66-3.58(m,1H),3.50-3.42(m,2H),3.42-3.33(m,1H),3.02-2.90(m,1H),2.77-2.62( m,2H),2.47-2.38(m,1H),2.12-1.99(m,1H),1.91-1.77(m,1H),1.61-1.45(m,2H),1.15(d,3H).
[0621] Example 15: Preparation of Compound 15
[0622] Step 1: Preparation of 15b
[0623] 15a (3.00 g, 15.48 mmol), 2-fluorophenylboronic acid (2.17 g, 15.48 mmol), cesium carbonate (10.09 g, 30.96 mmol), 1,4-dioxane (40 mL), and water (4 mL) were added sequentially to a single-necked flask. After nitrogen displacement, tetrakis(triphenylphosphine)palladium (1.79 g, 1.55 mmol) was added and the mixture was allowed to react at 90°C for 16 h. The mixture was concentrated under reduced pressure and quenched by the addition of water (50 mL). The reaction was extracted with ethyl acetate (40 mL x 2). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product, which was then separated and purified by column chromatography (petroleum ether:dichloromethane (v / v) = 7:3) to obtain 15b (2.60 g, 80%).
[0624] LCMS m / z=209.0[M+1] +
[0625] Compound 15 was obtained using 15b as a substrate by referring to the synthesis method of compound 9. Compound 15 is one of the structures of compound 15-1 and compound 15-2.
[0626] LCMS m / z=576.3[M+1] +
[0627] 1H NMR(400MHz,DMSO-d6)δ12.41(s,1H),8.61(d,2H),7.89(s,1H),7.60-7.55(m,1H),7.45-7.38(m,1H ),7.36-7.28(m,2H),6.30-6.19(m,1H),4.72-4.61(m,2H),4.53-4.45(m,1H),4.23-4.10(m,1H),3. 75-3.68(m,1H),3.66-3.59(m,1H),3.49-3.41(m,2H),3.41-3.32(m,1H),2.99-2.89(m,1H),2.76-2 .60m,2H),2.47-2.38(m,1H),2.07-1.97(m,1H),1.89-1.78(m,1H),1.60-1.44(m,2H),1.15(d,3H).
[0628] Example 16: Preparation of trifluoroacetate salt of compound 16
[0629] Step 1: Preparation of 16a
[0630] Sodium borohydride (58 mg, 1.53 mmol) and calcium chloride (85 mg, 0.77 mmol) were added sequentially to a mixture of 9f (500 mg, 1.53 mmol) in tetrahydrofuran (5 mL) and ethanol (5 mL) at 0°C for 1 h. The reaction was quenched by the addition of ethyl acetate (30 mL) and saturated ammonium chloride solution (10 mL). The layers were separated, and the organic phase was concentrated under reduced pressure to afford 16a (438 mg, crude product).
[0631] LCMS m / z=285.4[M+1] + .
[0632] Step 2: Preparation of 16b hydrochloride
[0633] 16a (438 mg, crude) was dissolved in 4N hydrochloric acid in dioxane (10 mL), reacted at room temperature for 2 h, and concentrated under reduced pressure to obtain the hydrochloride salt of 16b (339 mg, crude).
[0634] LCMS m / z=185.2[M+1] +
[0635] The trifluoroacetate of compound 16 was obtained using the hydrochloride of 16b as a substrate by referring to the synthesis method of compound 9. Compound 16 is one of the structures of compound 16-1 and compound 16-2.
[0636] LCMS m / z=538.2[M+1]+
[0637] 1 H NMR(400MHz,CD3OD)δ8.81(s,1H),7.91(s,1H),7.26-7.18(m,2H),4.80-4.70(m, 2H),4.64-4.56(m,1H),4.23-4.11(m,1H),4.02-3.92(m,1H),3.64-3.53(m,2H),3 .52-3.36(m,2H),3.15-3.03(m,1H),2.93-2.83(m,1H),2.82-2.74(m,1H),2.55-2 .45(m,1H),2.17-2.07(m,1H),1.95-1.85(m,1H),1.75-1.52(m,2H),1.25(d,3H).
[0638] Example 17: Preparation of Compound 17
[0639] Compound 17 was obtained using 17a as a substrate by referring to the synthetic method of compound 9. Compound 17 is one of the structures of compound 17-1 and compound 17-2.
[0640] LCMS m / z=522.3[M+1] +
[0641] 1 H NMR (400MHz, DMSO-d6) δ12.39(s,1H),8.19(s,1H),7.88(s,1H),6.27-6.20(m,1H),4. 62-4.53(m,2H),4.50-4.42(m,1H),4.21-4.10(m,1H),3.74-3.66(m,1H),3.64-3.58( m,1H),3.49-3.40(m,2H),3.36-3.33(m,1H),2.82-2.72(m,5H),2.62-2.53(m,2H),2. 45-2.37(m,1H),2.04-1.95(m,3H),1.86-1.78(m,1H),1.58-1.40(m,2H),1.15(d,3H).
[0642] Example 18: Preparation of Compound 18
[0643] Compound 18 was obtained by using 18a as substrate and referring to the synthesis method of compound 9. Compound 18 is one of the structures of compound 18-1 and compound 18-2.
[0644] LCMS m / z=536.7[M+1] +
[0645] 1 H NMR(400MHz,DMSO-d6)δ12.36(s,1H),9.14(s,1H),7.92(s,1H),7.88(s,1H),6.32-6.1 6(m,1H),4.70-4.57(m,2H),4.54-4.43(m,1H),4.22-4.11(m,1H),4.07(s,3H),3.76-3. 67(m,1H),3.66-3.58(m,1H),3.53-3.41(m,3H),2.91-2.80(m,1H),2.70-2.58(m,2H),2 .47-2.37(m,1H),2.09-1.97(m,1H),1.88-1.79(m,1H),1.62-1.42(m,2H),1.15(d,3H).
[0646] Example 19: Preparation of Compound 19
[0647] Compound 19 was obtained using 19a as a substrate by referring to the synthesis method of compound 9. Compound 19 is one of the structures of compound 19-1 and compound 19-2.
[0648] LCMS m / z=538.1[M+1] +
[0649] 1 H NMR(400MHz,DMSO-d6)δ12.40(s,1H),9.09(s,1H),8.28(d,1H),7.88(s,1H),7.28(d,1H),6 .32-6.16(m,1H),4.75-4.58(m,2H),4.55-4.43(m,1H),4.25-4.08(m,1H),3.76-3.68(m,1H) ,3.66-3.58(m,1H),3.50-3.41(m,2H),3.40-3.33(m,1H),2.96-2.82(m,1H),2.73-2.58(m,2 H),2.48-2.37(m,1H),2.11-1.97(m,1H),1.90-1.76(m,1H),1.60-1.43(m,2H),1.15(d,3H).
[0650] Example 20: Preparation of Compound 20
[0651] Step 1: Preparation of 20b
[0652] 20a (3.00 g, 17.75 mmol) was dissolved in acetonitrile (150 mL), and sodium nitrite (2.45 g, 35.50 mmol) and aqueous hydrobromic acid (6 mL, 48% content) were added sequentially. The mixture was allowed to react at room temperature for 16 h. The mixture was concentrated under reduced pressure to obtain a crude product, which was then purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 75:25) to obtain 20b (3.00 g, 73%).
[0653] LCMS m / z=232.0[M+1] +
[0654] Step 2: Preparation of 20c
[0655] 20b (2.67 g, 11.49 mmol) was dissolved in 1,4-dioxane (30 mL). Then, 9 g (2.60 g, crude product), potassium carbonate (3.18 g, 22.98 mmol), tris(dibenzylideneacetone)palladium (526.08 mg, 0.57 mmol), and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (664.83 mg, 1.15 mmol) were added sequentially. The atmosphere was purged with nitrogen three times and the reaction was carried out at 100°C for 16 h. The mixture was cooled to room temperature, and water (50 mL) was added. The mixture was then extracted with ethyl acetate (50 mL x 2). The organic phases were combined, washed with saturated brine (60 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was then purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 25:75) to obtain 20c (850 mg, 20%).
[0656] LCMS m / z=378.1[M+1] +
[0657] Compound 20 was obtained using 20c as a substrate by referring to the synthetic method of compound 9. Compound 20 is one of the structures of compound 20-1 and compound 20-2.
[0658] LCMS m / z=555.2[M+1] +
[0659] 1H NMR(400MHz,DMSO-d6)δ12.41(s,1H),8.70(d,1H),7.88(s,1H),7.67(d,1H),7.04( dd,1H),6.33-6.15(m,1H),4.58-4.46(m,1H),4.23-4.03(m,3H),3.75-3.66(m,1H) ,3.65-3.57(m,1H),3.51-3.40(m,3H),2.92-2.80(m,1H),2.75-2.60(m,2H),2.45- 2.36(m,1H),2.08-1.95(m,1H),1.89-1.76(m,1H),1.59-1.39(m,2H),1.15(d,3H).
[0660] Example 21: Preparation of Compound 21
[0661] Compound 21 was obtained by using 21a as substrate and referring to the synthesis method of compound 9. Compound 21 is one of the structures of compound 21-1 and compound 21-2.
[0662] LCMS m / z=507.2[M+1] +
[0663] 1 H NMR (400MHz, DMSO-d6) δ12.40(s,1H),8.79(s,2H),7.87(s,1H),6.32-6.17(m,1H),4. 70-4.57(m,2H),4.52-4.40(m,1H),4.22-4.08(m,1H),3.76-3.68(m,1H),3.64-3.57( m,1H),3.48-3.42(m,3H),3.09-2.98(m,1H),2.87-2.76(m,1H),2.70-2.60(m,1H),2. 45-2.38(m,1H),2.05-1.95(m,1H),1.87-1.77(m,1H),1.60-1.41(m,2H),1.14(d,3H).
[0664] Example 22: Preparation of Compound 22
[0665] Step 1: Preparation of 22-b
[0666] N-Bromosuccinimide (2.81 g, 15.82 mmol) was added portionwise to a solution of 22a (2.15 g, 13.18 mmol) in acetonitrile (20 mL), and the mixture was reacted at room temperature for 16 h. The mixture was concentrated under reduced pressure to afford 22b (3.10 g, crude product).
[0667] LCMS m / z=241.9[M+1] +
[0668] Step 2: Preparation of 22c
[0669] Potassium thiocyanate (1.49 g, 15.37 mmol) was added to a solution of 22b (3.10 g, crude) in acetic acid (30 mL) and the reaction was allowed to proceed at 140°C for 3 h. The mixture was concentrated under reduced pressure to afford the crude product, which was slurried with water (20 mL) and filtered. The filter cake was dried to afford 22c (1.90 g, 65% yield over two steps).
[0670] LCMS m / z=221.1[M+1] +
[0671] Step 3: Preparation of 22d
[0672] 22c (1.80 g, 8.18 mmol) was dissolved in acetonitrile (20 mL), and tert-butyl nitrite (1.69 g, 16.36 mmol) and copper bromide (3.65 g, 16.36 mmol) were added sequentially. The mixture was reacted at 60°C under a nitrogen atmosphere for 3 h. After cooling to room temperature, 100 mL of saturated sodium chloride solution was added, and extraction was performed with ethyl acetate (100 mL x 3). The organic phases were combined, washed with saturated brine (80 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was then purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 83:17) to afford 22d (1.00 g, 43%).
[0673] 1 H NMR (400MHz, DMSO-d6) δ9.68 (s, 1H).
[0674] Compound 22 was obtained by using 22d as a substrate and referring to the synthesis method of compound 16. Compound 22 is one of the structures of compound 22-1 and compound 22-2.
[0675] LCMS m / z=607.2[M+1] +
[0676] 1H NMR(400MHz,DMSO-d6)δ12.41(s,1H),8.92(s,1H),7.88(s,1H),6.34-6.18(m,1H ),4.58-4.46(m,1H),4.30-4.00(m,3H),3.79-3.68(m,1H),3.64-3.55(m,1H),3. 54-3.41(m,3H),3.37-3.26(m,1H),3.20-3.07(m,1H),2.86-2.73(m,1H),2.48-2 .39(m,1H),2.12-2.02(m,1H),1.89-1.77(m,1H),1.59-1.42(m,2H),1.15(d,3H).
[0677] Example 23: Preparation of Compound 23
[0678] Step 1: Preparation of 23b
[0679] Bistriphenylphosphine palladium dichloride (1.56 g, 2.23 mmol) was added to a mixture of 23a (7.80 g, 44.57 mmol), 2-fluorophenylboronic acid (6.24 g, 44.57 mmol), potassium carbonate (13.55 g, 98.05 mmol) in dioxane (150 mL), and water (10 mL) under a nitrogen atmosphere and reacted at 95°C for 16 h. The mixture was cooled to room temperature, and saturated sodium chloride solution (200 mL) was added to the reaction mixture, followed by extraction with ethyl acetate (200 mL x 3). The organic phases were combined and concentrated under reduced pressure to obtain a residue, which was then purified by column chromatography (dichloromethane:tetrahydrofuran (v / v) = 83:17) to afford 23b (6.40 g, 76%).
[0680] LCMS m / z=191.1[M+1] + ,
[0681] Step 2: Preparation of 23c
[0682] Tert-butyl nitrite (3.69 g, 35.76 mmol) was added dropwise to a solution of 23b (3.40 g, 17.88 mmol) and cupric chloride (2.68 g, 26.82 mmol) in acetonitrile (50 mL). The mixture was allowed to react at 60°C for 1 h. After cooling to room temperature, saturated sodium chloride solution (50 mL) was added, and the mixture was extracted with ethyl acetate (80 mL x 3). The organic phases were combined and concentrated under reduced pressure to obtain a residue, which was then purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 83:17) to afford 23c (1.40 g, 37%).
[0683] LCMS m / z=210.1[M+1]+
[0684] Compound 23 was obtained using 23c as a substrate by referring to the synthetic method of compound 16. Compound 23 is one of the structures of compound 23-1 and compound 23-2.
[0685] LCMS m / z=577.3[M+1] +
[0686] 1 H NMR(400MHz,DMSO-d6)δ12.36(s,1H),8.71(d,1H),7.95-7.85(m,2H),7.58-7.48(m,1H),7.42-7 .33(m,2H),6.32-6.18(m,1H),4.77-4.60(m,2H),4.57-4.46(m,1H),4.24-4.10(m,1H),3.78-3.6 9(m,1H),3.65-3.58(m,1H),3.50-3.38(m,3H),3.15-3.02(m,1H),2.92-2.82(m,1H),2.79-2.68 (m,1H),2.48-2.41(m,1H),2.12-1.98(m,1H),1.89-1.81(m,1H),1.60-1.46(m,2H),1.15(d,3H).
[0687] Example 24: Preparation of Compound 24
[0688] Compound 24 was obtained using 9 g of hydrochloride and 3-chloro-6-trifluoromethylpyridazine as substrates, referring to the synthesis method of compound 9. Compound 24 is one of the structures of compound 24-1 and compound 24-2.
[0689] LCMS m / z=550.8[M+1] + .
[0690] 1H NMR(400MHz,DMSO-d6)δ12.41(s,1H),7.89(s,1H),7.84(d,1H),7.45(d,1H),6. 31-6.18(m,1H),4.54-4.37(m,3H),4.23-4.12(m,1H),3.79-3.68(m,1H),3.64- 3.57(m,1H),3.50-3.39(m,3H),3.12-3.00(m,1H),2.87-2.71(m,2H),2.48-2.4 0(m,1H),2.06-1.96(m,1H),1.90-1.78(m,1H),1.62-1.42(m,2H),1.15(d,3H).
[0691] Example 25: Preparation of Compound 25
[0692] Compound 25 was obtained using 2-chloro-5-fluoropyrimidine as a substrate by referring to the synthetic method of compound 9. Compound 25 is one of the structures of compound 25-1 and compound 25-2.
[0693] LCMS m / z=500.7[M+1] + .
[0694] 1 H NMR(400MHz,DMSO-d6)δ12.41(s,1H),8.47(s,2H),7.88(s,1H),6.32-6.18( m,1H),4.58-4.40(m,3H),4.23-4.09(m,1H),3.76-3.67(m,1H),3.64-3.57( m,1H),3.51-3.37(m,3H),2.92-2.83(m,1H),2.70-2.57(m,2H),2.46-2.38( m,1H),2.05-1.95(m,1H),1.87-1.76(m,1H),1.59-1.41(m,2H),1.15(d,3H).
[0695] Example 26: Preparation of Compound 26
[0696] Compound 26 was obtained using 2,6-dichlorobenzothiazole as a substrate by referring to the synthetic method of compound 9. Compound 26 is one of the structures of compound 26-1 and compound 26-2.
[0697] LCMS m / z=571.1[M+1] +
[0698] 1 H NMR(400MHz,DMSO-d6)δ12.32(s,1H),7.93(d,1H),7.89(s,1H),7.45(d,1H),7.31(dd,1H),6 .34-6.18(m,1H),4.57-4.46(m,1H),4.23-4.11(m,1H),4.07-3.93(m,2H),3.75-3.68(m,1H), 3.65-3.58(m,1H),3.48-3.43(m,3H),3.18-3.09(m,1H),3.00-2.91(m,1H),2.79-2.69(m,1 H),2.48-2.39(m,1H),2.10-1.99(m,1H),1.88-1.79(m,1H),1.60-1.41(m,2H),1.15(d,3H).
[0699] Example 27: Preparation of Compound 27
[0700] Step 1: Preparation of 27b
[0701] Potassium carbonate (5.08 g, 36.76 mmol) was added to a solution of 9 g of the hydrochloride salt (2.08 g, crude product) and 27a (2.18 g, 11.04 mmol) in dimethyl sulfoxide (15 mL) and allowed to react at room temperature overnight. The mixture was cooled to room temperature, quenched with water (80 mL), and extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine (50 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was then purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 68:32) to afford 27b (2.72 g, 64%).
[0702] LCMS m / z=388.1[M+1] +
[0703] Step 2: Preparation of 27c
[0704] N,N-Dimethylformamide dimethyl acetal (1086 mg, 9.11 mmol) was added to a toluene (20 mL) solution of 27b (2.72 g, 7.01 mmol) and reacted overnight at 120°C. The mixture was cooled to room temperature and concentrated under reduced pressure to afford 27c (3.20 g, crude product).
[0705] LCMS m / z=443.1[M+1] +
[0706] Step 3: Preparation of 27d
[0707] Hydroxylaminesulfonic acid (1084 mg, 9.59 mmol) and pyridine (1083 mg, 13.7 mmol) were added to a solution of 27c (3.03 g, crude) in methanol (30 mL) under an ice-water bath and allowed to react at room temperature for 18 h. Saturated aqueous sodium carbonate was added to adjust the pH to 8-9, and the mixture was concentrated under reduced pressure. Water (100 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 2). The organic phases were combined, washed with saturated brine (50 mL x 2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product, which was then separated and purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 64:36) to afford 27d (2.30 g, 79% yield over two steps).
[0708] LCMS m / z=413.5[M+1] +
[0709] Compound 27 was obtained using 27d as a substrate by referring to the synthetic method of compound 9. Compound 27 is one of the structures of compound 27-1 and compound 27-2.
[0710] Compound 27:
[0711] LCMS m / z=590.3[M+1] +
[0712] 1 H NMR(400MHz,DMSO-d6)δ12.37(s,1H),8.65(s,1H),8.38(s,1H),7.88(s,1H),6.30-6.18(m, 1H),5.13(t,2H),4.57-4.40(m,1H),4.25-4.06(m,1H),3.77-3.66(m,1H),3.65-3.59(m,1H) ,3.58-3.50(m,1H),3.49-3.40(m,2H),3.29-3.24(m,1H),3.15-3.04(m,1H),2.92-2.80(m,1 H),2.47-2.38(m,1H),2.04-1.91(m,1H),1.90-1.75(m,1H),1.60-1.44(m,2H),1.15(d,3H).
[0713] Example 28: Preparation of Compound 28
[0714] Step 1: Preparation of 28b
[0715] DIPEA (2.31 g, 17.85 mmol) was added to a solution of 9 g of the hydrochloride salt (1.62 g, crude product) and 28a (1.00 g, 5.97 mmol) in n-butanol (20 mL). The mixture was microwaved at 120°C for 2 h. The mixture was concentrated under reduced pressure to obtain the crude product, which was then purified by column chromatography (dichloromethane:ethyl acetate (v / v) = 62:38) to afford 28b (1.58 g, 68%).
[0716] LCMS m / z=386.2[M+1] +
[0717] Step 2: Preparation of 28c
[0718] N-Chlorosuccinimide (1.31 g, 9.80 mmol) was added to a solution of 28b (3.15 g, 8.17 mmol) in DMF (30 mL) and allowed to react at room temperature for 16 h. The reaction was quenched by the addition of saturated aqueous sodium bicarbonate (100 mL) and extracted with ethyl acetate (20 mL x 2). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 58:42) to afford 28c (1.76 g, 51%).
[0719] LCMS m / z=420.2[M+1] +
[0720] Compound 28 was obtained using 28c as a substrate by referring to the synthetic method of compound 9. Compound 28 is one of the structures of compound 28-1 and compound 28-2.
[0721] Compound 28:
[0722] LCMS m / z=569.2[M+1] +
[0723] 1H NMR(400MHz,DMSO-d6)δ12.41(s,1H),8.43(s,1H),7.89(s,1H),7.55(s,1H),6.35 -6.17(m,1H),5.23-4.97(m,2H),4.57-4.43(m,1H),4.20(s,3H),4.19-4.10(m,1H) ,3.7-3.56(m,2H),3.51-3.36(m,3H),3.08-2.91(m,1H),2.81-2.63(m,2H),2.47- 2.37(m,1H),2.07-1.93(m,1H),1.89-1.77(m,1H),1.60-1.44(m,2H),1.15(d,3H).
[0724] Example 29: Preparation of Compound 29
[0725] Step 1: Preparation of 29b
[0726] Sodium nitrite (1.64 g, 23.72 mmol) was added to a solution of 29a (2 g, 11.86 mmol) in acetonitrile (100 mL). Aqueous hydrobromic acid (4 mL, 48%) was slowly added dropwise. The mixture was allowed to react at room temperature for 16 h. Silica gel was added, the mixture was concentrated under reduced pressure, and then purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 4:1) to afford 29b (1.92 g, 70%).
[0727] LCMS m / z=232.0[M+1] +
[0728] Step 2: Preparation of 29c
[0729] 29b (0.82 g, 3.53 mmol) was added to a solution of the hydrochloride salt of 16b (0.65 g, crude), DIPEA (1.37 g, 10.56 mmol), and 4-dimethylaminopyridine (43 mg, 0.35 mmol) in ethanol (20 mL). The mixture was microwaved at 120°C for 3 h. Silica gel was added, the mixture was concentrated under reduced pressure, and then purified by column chromatography (dichloromethane (containing 9% methanol): petroleum ether (containing 16% ethyl acetate) (v / v) = 20:80) to afford 29c-1 (0.165 g, 14%) and 29c-2.
[0730] 29c-1 is 29c
[0731] LCMS m / z=336.2[M+1] + .
[0732] 1H NMR(400MHz,DMSO-d6)δ9.05-8.98(m,1H),7.62-7.56(m,1H),7.53-7.49 (m,1H),4.59-4.46(m,2H),4.17-4.05(m,2H),3.73-3.64(m,1H),3.63-3 .53(m,1H),3.52-3.41(m,1H),2.94-2.81(m,1H),2.78-2.60(m,2H),2.3 5-2.23(m,1H),2.14-2.00(m,1H),1.95-1.83(m,1H),1.66-1.42(m,2H).
[0733] 29c-2
[0734] LCMS m / z=336.2[M+1] + .
[0735] 1 H NMR(400MHz,DMSO-d6)δ9.05-8.98(m,1H),7.62-7.55(m,1H),7.54-7.47(m,1H),4.67(t, 1H),4.58-4.46(m,1H),4.14-4.03(m,2H),3.70-3.43(m,3H),2.92-2.75(m,2H ),2.74-2.63(m,1H),2.41-2.30(m,1H),1.94-1.81(m,2H),1.80-1.63(m,2H).
[0736] Compound 29 was obtained using 29c as a substrate by referring to the synthetic method of compound 16. Compound 29 is one of the structures of compound 29-1 and compound 29-2.
[0737] Compound 29:
[0738] LCMS m / z=555.2[M+1] +
[0739] 1H NMR(400MHz,DMSO-d6)δ12.41(s,1H),9.06-8.98(m,1H),7.88(s,1H),7.62-7.56(m,1H) ),7.54-7.49(m,1H),6.29-6.20(m,1H),4.57-4.47(m,1H),4.22-4.03(m,3H),3.74-3.6 6(m,1H),3.65-3.58(m,1H),3.49-3.36(m,3H),2.92-2.81(m,1H),2.73-2.61(m,2H),2 .45-2.38(m,1H),2.07-1.95(m,1H),1.88-1.77(m,1H),1.60-1.41(m,2H),1.15(d,3H).
[0740] Example 30: Preparation of Compound 30
[0741] Step 1: Preparation of 30b
[0742] Ethyl isothiocyanate (14.47 g, 110.36 mmol) was added to a solution of 30a (15.00 g, 91.97 mmol) in 1,4-dioxane (150 mL) and the mixture was allowed to react at 35°C for 72 h. Silica gel was added, the mixture was concentrated under reduced pressure, and then purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 80:20) to afford 30b (7.00 g, 26%).
[0743] LCMS m / z=295.1[M+1] +
[0744] Step 2: Preparation of 30c
[0745] Hydroxylamine hydrochloride (6.61 g, 95.16 mmol) and triethylamine (7.22 g, 71.35 mmol) were added sequentially to a mixture of 30b (7.00 g, 23.79 mmol) in methanol (100 mL) and ethanol (100 mL). The mixture was reacted at room temperature for 2 h and then at 80°C for 4 h. Silica gel was added, the mixture was concentrated under reduced pressure, and then purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 67:33) to afford 30c (3.88 g, 80%).
[0746] LCMS m / z=204.1[M+1] +
[0747] Step 3: 30d preparation
[0748] Sodium nitrite (2.65 g, 38.40 mmol) was added to a solution of 30c (3.90 g, 19.20 mmol) in acetonitrile (100 mL). Concentrated aqueous hydrochloric acid (10 mL) was slowly added dropwise and allowed to react at room temperature for 16 h. Silica gel was added, the mixture was concentrated under reduced pressure, and then purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 80:20) to afford 30d (1.16 g, 27%).
[0749] LCMS m / z=223.1[M+1] +
[0750] Step 4: Preparation of 30e
[0751] 30d (0.79 g, 3.53 mmol) was added to a solution of the hydrochloride salt of 16b (0.65 g, crude), DIPEA (1.82 g, 14.12 mmol), and 4-dimethylaminopyridine (43 mg, 0.35 mmol) in ethanol (20 mL). The mixture was microwaved at 120°C for 3 h. Silica gel was added, the mixture was concentrated under reduced pressure, and then purified by column chromatography (dichloromethane (containing 9% methanol): petroleum ether (containing 16% ethyl acetate) (v / v) = 20:80) to afford 30e-1 (0.36 g, 27%) and 30e-2.
[0752] 30e-1 is 30e
[0753] LCMS m / z=371.4[M+1] + .
[0754] 1 H NMR (400MHz, DMSO-d6) δ9.64(s,1H),8.14(s,1H),4.62-4.49(m,2H),4.23-4.12(m,2H),3.73-3.64(m,1H),3.63-3.55(m,1H),3.54-3.43(m ,1H),3.08-2.95(m,1H),2.90-2.80(m,1H),2.76-2.64(m,1H),2.37- 2.23(m,1H),2.15-2.03(m,1H),1.96-1.85(m,1H),1.67-1.44(m,2H).
[0755] 30e-2
[0756] LCMS m / z=371.4[M+1] + .
[0757] 1H NMR(400MHz,DMSO-d6)δ9.64(s,1H),8.14(s,1H),4.78-4.46(m,2H),4.25-4.06(m,2H),3.74-3.48(m ,3H),3.04-2.86(m,2H),2.76-2.65(m,1H),2.40-2.32(m,1H),1.96-1.82(m,2H),1.81-1.67(m,2H).
[0758] Compound 30 was obtained by using 30e as substrate and referring to the synthesis method of compound 16. Compound 30 is one of the structures of compound 30-1 and compound 30-2.
[0759] Compound 30:
[0760] LCMS m / z=590.8[M+1] +
[0761] 1 H NMR(400MHz,DMSO-d6)δ12.38(s,1H),9.64(s,1H),8.14(s,1H),7.88(s,1H),6.30-6 .18(m,1H),4.60-4.48(m,1H),4.25-4.09(m,3H),3.76-3.67(m,1H),3.65-3.56(m,1 H),3.49-3.36(m,3H),3.07-2.93(m,1H),2.87-2.76(m,1H),2.73-2.62(m,1H),2.47 -2.38(m,1H),2.10-1.97(m,1H),1.89-1.77(m,1H),1.61-1.42(m,2H),1.15(d,3H).
[0762] Example 31: Preparation of Compound 31
[0763] Step 1: Preparation of 31b
[0764] Palladium on carbon (400 mg, 10%) and potassium carbonate (1.60 g, 11.56 mmol) were added to a solution of 31a (2.00 g, 8.89 mmol) in tetrahydrofuran (50 mL). After hydrogen substitution, the reaction was maintained at 30°C in an autoclave (2.5 MPa hydrogen pressure) for 24 h. The mixture was filtered through a pad of Celite, and silica gel was added to the filtrate. The mixture was concentrated under reduced pressure and purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 80:20) to afford 31b (0.80 g, 47%).
[0765] LCMS m / z=191.1[M+1]+
[0766] Step 2: Preparation of 31c
[0767] 31a (0.67 g, 3.53 mmol) was added to a solution of the hydrochloride salt of 16b (0.65 g, crude), DIPEA (1.82 g, 14.12 mmol), and 4-dimethylaminopyridine (43 mg, 0.35 mmol) in ethanol (20 mL). The mixture was microwaved at 120°C for 3 h. Silica gel was added, the mixture was concentrated under reduced pressure, and then purified by column chromatography (dichloromethane (containing 9% methanol): petroleum ether (containing 16% ethyl acetate) (v / v) = 20:80) to afford 31c-1 (0.42 g, 35%) and 31c-2.
[0768] 31c-1 is 31c
[0769] LCMS m / z=339.2[M+1] + .
[0770] 1 H NMR(400MHz,DMSO-d6)δ8.58(s,1H),4.64-4.45(m,4H),3.72-3.64(m,1H),3.63-3.54(m,1H),3.47-3.36(m,1H), 2.99-2.80(m,3H),2.77-2.51(m,4H),2.35-2.24(m,1H),2.14-2.02(m,1H),1.95-1.84(m,1H),1.67-1.43(m,2H).
[0771] 31c-2
[0772] LCMS m / z=339.2[M+1] + .
[0773] 1 H NMR(400MHz,DMSO-d6)δ8.58(s,1H),4.70-4.65(m,1H),4.64-4.43(m,3H),3.72-3.53(m,2H),3.50-3.3 7(m,1H),2.94-2.75(m,4H),2.71-2.52(m,3H),2.42-2.31(m,1H),1.94-1.82(m,2H),1.81-1.65(m,2H).
[0774] Compound 31 was obtained using 31c as a substrate by referring to the synthesis method of compound 16. Compound 31 is one of the structures of compound 31-1 and compound 31-2.
[0775] Compound 31:
[0776] LCMS m / z=558.6[M+1] +
[0777] 1 H NMR(400MHz,DMSO-d6)δ12.40(s,1H),8.59(s,1H),7.88(s,1H),6.35-6.10(m,1H ),4.66-4.52(m,2H),4.51-4.40(m,1H),4.24-4.08(m,1H),3.76-3.57(m,2H),3. 50-3.40(m,2H),3.40-3.31(m,1H),3.00-2.80(m,3H),2.75-2.52(m,4H),2.47-2 .36(m,1H),2.10-1.94(m,1H),1.88-1.78(m,1H),1.63-1.41(m,2H),1.15(d,3H).
[0778] Example 32: Preparation of Compound 32
[0779] Step 1: Preparation of 32b
[0780] Ethyl isothiocyanate (2.67 g, 20.36 mmol) was added to a solution of 32a (3.00 g, 18.51 mmol) in dioxane (30 mL) and reacted at 100°C under nitrogen for 16 h. The mixture was cooled to room temperature and concentrated under reduced pressure to obtain the crude product. The crude product was slurried with a mixed solvent (petroleum ether:tetrahydrofuran (v / v) = 5:1) and filtered. The filter cake yielded 32b (5.00 g, 92%).
[0781] LCMS m / z=294.2[M+1] +
[0782] Step 2: Preparation of 32c
[0783] 32b (4.70 g, 16.03 mmol) was added to a solution of hydroxylamine hydrochloride (4.46 g, 64.12 mmol) and triethylamine (4.87 g, 48.09 mmol) in ethanol (40 mL) under a nitrogen atmosphere and reacted at 100°C for 3 h. The mixture was concentrated under reduced pressure to obtain a residue. The residue was added with ethyl acetate (50 mL) and petroleum ether (50 mL), stirred for 1 h, filtered, and the filtrate was concentrated again to obtain the crude product. The crude product was slurried with a mixed solvent (petroleum ether:ethyl acetate (v / v) = 5:1) and filtered. The filter cake was 32c (2.40 g, 74%).
[0784] LCMS m / z=203.2[M+1] +
[0785] Step 3: Preparation of 32d
[0786] Under an ice-water bath, concentrated hydrochloric acid (1 mL) was added to a solution of 32c (1.10 g, 5.44 mmol) and sodium nitrite (940 mg, 13.60 mmol) in acetonitrile (10 mL). The mixture was slowly warmed to room temperature and allowed to react for 2 h. The reaction solution was diluted with ethyl acetate (100 mL), and the pH was adjusted to 8-9 with saturated sodium carbonate solution. The mixture was extracted with ethyl acetate (100 mL x 2), and the organic phases were combined. The organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 83:17) to afford 32d (1.00 g, 83%).
[0787] LCMS m / z=222.1[M+1] +
[0788] Step 4: Preparation of 32e
[0789] 32d (510 mg, 2.30 mmol) was added to a solution of the trifluoroacetic acid salt of 16b (755 mg, 2.53 mmol) and potassium carbonate (1.59 g, 11.50 mmol) in dimethyl sulfoxide (7 mL) and allowed to react at 100°C for 16 h. The mixture was cooled to room temperature, quenched with water (20 mL), and extracted with ethyl acetate (30 mL x 3). The organic phases were combined. The organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (dichloromethane (containing 9% methanol): petroleum ether (containing 16% ethyl acetate) (v / v) = 75:25) to afford 32e-1 (450 mg, 53%) and its diastereomer 32e-2.
[0790] Compound 32e-1 is compound 32e
[0791] LCMS m / z=370.2[M+1] +
[0792] 1H NMR (400MHz, CD3OD) δ8.72-8.66(m,1H),7.80-7.72(m,1H),7.24-7.17(m,1H),4.73-4.60(m,1H),4.33-4.20(m,2H),3.88-3.74(m,2H) ,3.65-3.54(m,1H),3.11-2.99(m,1H),2.90-2.76(m,2H),2.51-2.41(m,1H),2.23-2.14(m,1H),2.04-1.94(m,1H),1.81-1.55(m,2H).
[0793] Compound 32e-2
[0794] LCMS m / z=370.2[M+1] +
[0795] 1 H NMR(400MHz,CD3OD)δ8.70(d,1H),7.76(s,1H),7.21(dd,1H),4.73-4.64(m,1H),4.31-4.16(m,2H),3.91-3.77(m,2H ),3.71-3.59(m,1H),3.12-2.92(m,2H),2.91-2.80(m,1H),2.60-2.46(m,1H),2.13-1.97(m,2H),1.94-1.80(m,2H).
[0796] Step 5: Preparation of 32f
[0797] Under ice-water bath, boron trifluoride etherate (4.5 mL) was added to a solution of 32e (450 mg, 1.22 mmol) and 1c (853 mg, 2.44 mmol) in toluene (45 mL), and the reaction was carried out at 35 ° C under nitrogen atmosphere for 16 h. Under ice-water bath, the pH was adjusted to 7-8 with saturated sodium carbonate solution, extracted with ethyl acetate (30 mL x 3), and the organic phases were combined. The organic phase was washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 67:33) to give 32f (40 mg, 6%).
[0798] LCMS m / z=557.2[M+1] +
[0799] Step 6: Preparation of 32g
[0800] Hydrazine hydrate (0.5 mL, 80% content) was added to a solution of 32f (220 mg, 0.40 mmol) in ethanol (5 mL) and allowed to react at room temperature for 16 h. The mixture was filtered, and the filter cake was washed with acetonitrile (10 mL x 3). The filtrate was concentrated under reduced pressure, slurried again with acetonitrile (10 mL), filtered, and the filtrate was concentrated under reduced pressure to yield 32f (160 mg, crude product).
[0801] LCMS m / z=427.3[M+1] +
[0802] Step 7: 32h preparation
[0803] To a solution of intermediate 1 (145 mg, 0.46 mmol) and 32g (160 mg, crude product) in acetonitrile (4 mL) was added triethylamine (154 mg, 1.52 mmol) and allowed to react at room temperature for 16 h. Silica gel was added, the mixture was concentrated under reduced pressure, and then purified by column chromatography (petroleum ether (containing 16% ethyl acetate): dichloromethane (containing 9% methanol) (v / v) = 75:25) to afford 32h (160 mg, two-step yield: 57%).
[0804] LCMS m / z=709.3[M+1] +
[0805] Step 8: Preparation of compound 32
[0806] Trifluoromethanesulfonic acid (121 mg, 0.81 mmol) was added to a solution of 32h (160 mg, 0.23 mmol) in trifluoroacetic acid (2 mL) under ice-water bath and the mixture was allowed to react for 2 h. The reaction solution was concentrated under reduced pressure, and the residue was dissolved in ethyl acetate (10 mL). The pH was adjusted to 8-9 with saturated sodium carbonate solution, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined. The organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated and purified by column chromatography (petroleum ether (containing 16% ethyl acetate): dichloromethane (containing 9% methanol) (v / v) = 75:25) to obtain compound 32 (100 mg, 75%).
[0807] Analytical method (instrument and preparative column: high performance liquid chromatography-normal phase chromatography, preparative column model: AD-H (4.6*2.50mm, 5um)) mobile phase system: n-hexane: isopropanol (80:20), column temperature: 35°C, flow rate: 1.0mL / min.
[0808] The retention time T = 27.431min is compound 32, which is one of the structures of compound 32-1 and compound 32-2.
[0809] LCMS m / z=589.7[M+1] +
[0810] 1 H NMR(400MHz,DMSO-d6)δ12.41(s,1H),8.91(d,1H),7.98(s,1H),7.89(s,1H),7.26( dd,1H),6.32-6.16(m,1H),4.61-4.46(m,1H),4.25-4.06(m,3H),3.77-3.67(m,1H) ,3.66-3.58(m,1H),3.51-3.35(m,3H),3.00-2.85(m,1H),2.80-2.61(m,2H),2.47- 2.36(m,1H),2.10-1.96(m,1H),1.90-1.78(m,1H),1.62-1.41(m,2H),1.15(d,3H).
[0811] Example 33: Preparation of Compound 33
[0812] Compound 33 was obtained using 33a as a substrate by referring to the synthetic method of compound 32. Compound 33 is one of the structures of compound 33-1 and compound 33-2.
[0813] LCMS m / z=590.2[M+1] +
[0814] 1 H NMR(400MHz,DMSO-d6)δ12.39(s,1H),9.37(d,1H),7.88(s,1H),7.56(d,1H),6.31-6 .14(m,1H),4.62-4.47(m,1H),4.26-4.06(m,3H),3.78-3.66(m,1H),3.65-3.56(m,1 H),3.51-3.34(m,3H),3.06-2.92(m,1H),2.88-2.75(m,1H),2.73-2.60(m,1H),2.47 -2.38(m,1H),2.10-1.99(m,1H),1.89-1.77(m,1H),1.60-1.43(m,2H),1.15(d,3H).
[0815] Example 34: Preparation of Compound 34
[0816] Step 1: Preparation of 34b
[0817] Ethyl isothiocyanate (4.86 g, 37.02 mmol) was added to a solution of 34a (5.00 g, 30.85 mmol) in 1,4-dioxane (50 mL) and the reaction was carried out at 100°C for 16 h. The mixture was concentrated under reduced pressure to obtain a crude product, which was slurried with a mixed solvent (petroleum ether:ethyl acetate (v:v) = 5:1), filtered, and the filter cake was dried to afford 34b (7 g, 77%).
[0818] LCMS m / z=294.1[M+1] +
[0819] Step 2: Preparation of 34c
[0820] Hydroxylamine hydrochloride (4.74 g, 68.20 mmol) and triethylamine (5.18 g, 51.15 mmol) were added sequentially to a solution of 34b (5.00 g, 17.05 mmol) in ethanol (50 mL). The mixture was stirred at room temperature for 1 h and then reacted at 80°C for 16 h. Silica gel was added, the mixture was concentrated under reduced pressure, and then purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 67:33) to afford 34c (3.20 g, 93%).
[0821] LCMS m / z=203.1[M+1] +
[0822] Step 3: Preparation of 34d
[0823] Sodium nitrite (2.18 g, 31.66 mmol) was added to a solution of 34c (3.20 g, 15.83 mmol) in acetonitrile (50 mL). Concentrated hydrochloric acid (5 mL) was slowly added dropwise and the mixture was allowed to react at room temperature for 16 h. Silica gel was added, the mixture was concentrated under reduced pressure, and then purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 80:20) to afford 34d (2.60 g, 74%).
[0824] LCMS m / z=222.0[M+1] +
[0825] Step 4: Preparation of 34e
[0826] 34d (0.45 g, 2.03 mmol) was added to a solution of the hydrochloride salt of 16b (0.45 g, crude), DIPEA (1.05 g, 8.12 mmol), and 4-dimethylaminopyridine (25 mg, 0.20 mmol) in ethanol (8 mL). The mixture was microwaved at 120°C for 3 h. Silica gel was added, the mixture was concentrated under reduced pressure, and purified by column chromatography (dichloromethane (containing 9% methanol): petroleum ether (containing 16% ethyl acetate) (v / v) = 20:80) to afford compounds 34e-1 (80 mg, 11%) and 34e-2.
[0827] Compound 34e-1 is compound 34e
[0828] LCMS m / z=370.2[M+1] +
[0829] 1 H NMR(400MHz,DMSO-d6)δ9.40-9.27(m,1H),7.83-7.75(m,1H),7.70-7.60 (m,1H),4.63-4.46(m,2H),4.22-4.08(m,2H),3.74-3.64(m,1H),3.63-3 .54(m,1H),3.53-3.43(m,1H),3.02-2.86(m,1H),2.85-2.61(m,2H),2.3 7-2.23(m,1H),2.14–2.03(m,1H),1.96-1.83(m,1H),1.68–1.43(m,2H).
[0830] Compound 34e-2
[0831] LCMS m / z=370.2[M+1] +
[0832] 1 H NMR(400MHz,DMSO-d6)δ9.39-9.25(m,1H),7.84-7.72(m,1H),7.70-7.59(m,1H),4.76-4.62(m,1H),4.60-4.46(m,1H),4.18–4 .04(m,2H),3.71–3.47(m,3H),3.01-2.79(m,2H),2.78-2.64(m,1H),2.44-2.31(m,1H),1.96-1.83(m,2H),1.82–1.65(m,2H).
[0833] Step 5: Preparation of 34f
[0834] 34e (0.19 g, 0.51 mmol) and 1c (0.36 g, 1.02 mmol) were dissolved in toluene (9.5 mL). After nitrogen substitution, boron trifluoride etherate (0.57 mL) was slowly added at 0°C. The mixture was reacted at 35°C for 16 h. The pH was adjusted to 7-8 with saturated sodium carbonate solution at 0°C. The mixture was extracted with ethyl acetate (20 mL x 3), and the organic phases were combined. The organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was separated and purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 70:30) to obtain 34f (100 mg, 35%).
[0835] LCMS m / z=557.2[M+1] +
[0836] Step 6: Preparation of 34g
[0837] Hydrazine hydrate (0.5 mL, 80% content) was added to a solution of 34f (100 mg, 0.18 mmol) in ethanol (5 mL) and allowed to react at room temperature for 16 h. The mixture was filtered, the filter cake was washed with ethyl acetate (10 mL x 3), and the filtrate was concentrated under reduced pressure to yield a residue. The residue was slurried with ethyl acetate (10 mL), filtered, the filter cake was washed with ethyl acetate (10 mL x 3), and the filtrate was concentrated under reduced pressure to yield 34f (110 mg, crude product).
[0838] LCMS m / z=427.4[M+1] +
[0839] Step 7: 34h preparation
[0840] To a solution of intermediate 1 (86 mg, 0.27 mmol) and 34g (110 mg, crude) in acetonitrile (10 mL) was added triethylamine (73 mg, 0.72 mmol) and allowed to react at room temperature for 16 h. Silica gel was added, the mixture was concentrated under reduced pressure, and then purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 50:50) to afford 34h (85 mg, 67% yield over two steps).
[0841] LCMS m / z=709.3[M+1] +
[0842] Step 8: Preparation of compound 34
[0843] Trifluoromethanesulfonic acid (0.2 mL) was added to a solution of 34h (85 mg, 0.12 mmol) in trifluoroacetic acid (2 mL) under an ice-water bath and allowed to react at room temperature for 1 h. The mixture was concentrated under reduced pressure and diluted with ethyl acetate (20 mL). The pH was adjusted to 8-9 with saturated sodium carbonate solution, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined. The organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (dichloromethane (containing 9% methanol): petroleum ether (containing 16% ethyl acetate) (v / v) = 20:80) to afford compound 34 (10 mg, 14%).
[0844] Analytical method (instrument and preparative column: high performance liquid chromatography-normal phase chromatography, preparative column model: AD-H (4.6*2.50mm, 5um)) mobile phase system: n-hexane: isopropanol (80:20), column temperature: 35°C, flow rate: 1.0mL / min.
[0845] The compound with retention time T=26.649 min is compound 34, which is one of the structures of compound 34-1 and compound 34-2.
[0846] LCMS m / z=589.2[M+1] +
[0847] 1 H NMR(400MHz,DMSO-d6)δ12.39(s,1H),9.32(s,1H),7.88(s,1H),7.81-7.76(m,1H),7 .65(d,1H),6.32-6.13(m,1H),4.59–4.45(m,1H),4.23-4.03(m,3H),3.76-3.66(m,1 H),3.65-3.57(m,1H),3.50–3.34(m,3H),2.98–2.87(m,1H),2.80–2.60(m,2H),2.47 -2.38(m,1H),2.08–1.97(m,1H),1.89-1.76(m,1H),1.61-1.42(m,2H),1.15(d,3H).
[0848] Example 35: Preparation of Compound 35
[0849] Step 1: Preparation of 35B
[0850] Benzyl alcohol (9.31 g, 86.07 mmol) and potassium carbonate (16.98 g, 122.90 mmol) were added to a solution of 35A (15.00 g, 81.93 mmol) in N,N-dimethylformamide (150 mL) at 0°C. The mixture was allowed to react at room temperature for 16 h. After completion, the reaction solution was added to water (400 mL) and extracted with n-hexane (100 mL x 2). The organic phases were combined. The organic phases were washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was then separated and purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 99:1) to obtain 35B (14.30 g, yield: 64%).
[0851] 1 H NMR (400MHz, DMSO-d6) δ8.47-8.42(m,1H),8.23(dd,1H),7.57-7.46(m,2H),7.45-7.30(m,3H),5.53(s,2H).
[0852] Step 2: Preparation of 35C
[0853] At -78°C, n-butyllithium (10.02 mL, 25.04 mmol, 2.5 M in hexane) was added dropwise to a solution of 35B (7.00 g, 25.81 mmol) in tetrahydrofuran (70 mL). After reacting at -78°C for 30 min, N,N-dimethylformamide (2.26 g, 30.97 mmol) was added and the reaction continued for 1 h. After completion, the reaction was quenched with saturated aqueous ammonium chloride (50 mL) and extracted with ethyl acetate (50 mL x 2). The organic phases were combined and washed with saturated brine (80 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was then purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 95:5) to afford 35C (6.02 g, 78% yield).
[0854] 1 H NMR (400MHz, DMSO-d6) δ10.32(d,1H),8.56(s,1H),7.55-7.46(m,2H),7.45-7.33(m,3H),5.57(s,2H).
[0855] Step 3: Preparation of 35D
[0856] Hydrazine hydrate (33 mL, 80% content) was added to a mixture of 35C (11.20 g, 37.43 mmol) in ethanol (30 mL) and 1,4-dioxane (150 mL) at room temperature and allowed to react at 95°C for 16 h. After completion, the reaction was concentrated under reduced pressure, and water (100 mL) was added. The mixture was extracted with ethyl acetate (100 mL x 2). The combined organic phases were washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 91:9) to afford 35D (7.38 g, yield: 67%).
[0857] LCMS m / z=294.1[M+H] +
[0858] Step 4: Preparation of 35E
[0859] Sodium hydride (764 mg, 19.1 mmol, 60% content) was added portionwise to a solution of 35D (4.00 g, 13.64 mmol) in tetrahydrofuran (40 mL) at 0°C. After reacting at 0°C for 30 min, iodomethane (2.42 g, 17.05 mmol) was added and the reaction was allowed to react at room temperature for 1 h. After completion, the reaction was quenched by the addition of saturated aqueous ammonium chloride (10 mL). After concentration under reduced pressure, water (100 mL) was added. Extraction was performed with dichloromethane (100 mL x 2). The combined organic phases were washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 88:12) to afford 35E (2.59 g, 62% yield).
[0860] LCMS m / z=308.1[M+H] +
[0861] 1 H NMR (400MHz, DMSO-d6) δ8.60(s,1H),8.08-8.02(m,1H),7.57-7.47(m,2H),7.456-7.31(m,3H),5.61(s,2H),4.24(s,3H).
[0862] Step 5: Preparation of 35F
[0863] Palladium on carbon (519 mg, 10% content) was added to a solution of compound 35E (2.59 g, 8.43 mmol) in methanol (40 mL). The mixture was allowed to react at room temperature under a hydrogen atmosphere for 16 h. After completion, the reaction was filtered through Celite and rinsed with dichloromethane:methanol (v / v) = 10:1 (100 mL). The filtrate was concentrated under reduced pressure to afford 35F (1.88 g, crude product).
[0864] LCMS m / z=218.1[M+H] +
[0865] Step 6: Preparation of 35G
[0866] The hydrochloride of compound 16b (1.31 g, crude), 1H-benzotriazol-1-yloxytripyrrolidino hexafluorophosphate (4.03 g, 7.74 mmol), and 1,8-diazabicyclo[5.4.0]undec-7-ene (3.93 g, 25.80 mmol) were added sequentially to a solution of compound 35F (1.40 g, crude) in N,N-dimethylformamide (15 mL) and reacted at room temperature for 16 h. After completion of the reaction, water (100 mL) was added, and the mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was separated and purified by column chromatography (dichloromethane:dichloromethane (containing 9% methanol) (v:v) = 71 / 29) to give 35G-1 (643 mg, two-step yield: 15%) and 35G-2.
[0867] 35G-1 means 35G.
[0868] LCMS m / z=384.2[M+H] +
[0869] 1 H NMR(400MHz,DMSO-d6)δ8.43(s,1H),7.93-7.88(m,1H),5.53-5.15(m,2H) ,4.64-4.42(m,2H),4.22(s,3H),3.74-3.65(m,1H),3.64-3.55(m,1H),3.5 4-3.44(m,1H),3.24-3.11(m,1H),2.97-2.86(m,1H),2.80-2.69(m,1H),2 .38-2.26(m,1H),2.11-2.02(m,1H),1.97-1.87(m,1H),1.67-1.47(m,2H).
[0870] 35G-2
[0871] LCMS m / z=384.5[M+H] +
[0872] 1H NMR(400MHz,DMSO-d6)δ8.44(s,1H),7.98-7.85(m,1H),5.51-5.16(m,2H),5.06-4.41(m,2H),4.22(s,3H),3.73-3.64(m,1H),3.63-3.57(m ,1H),3.56-3.45(m,1H),3.22-3.07(m,1H),3.03-2.89(m,1H),2.82- 2.69(m,1H),2.44-2.32(m,1H),1.96-1.83(m,2H),1.82-1.66(m,2H).
[0873] Compound 35 was obtained using 35G as a substrate by referring to the synthesis method of compound 16. Compound 35 is one of the structures of compound 35-1 and compound 35-2.
[0874] LCMS m / z=603.7[M+1] +
[0875] 1 H NMR(400MHz,DMSO-d6)δ12.41(s,1H),8.44(s,1H),7.94-7.85(m,2H),6.39-6.12( m,1H),5.50-5.14(m,2H),4.56-4.45(m,1H),4.26-4.09(m,4H),3.75-3.58(m,2H), 3.52-3.37(m,3H),3.24-3.09(m,1H),2.96-2.82(m,1H),2.79-2.69(m,1H),2.48- 2.39(m,1H),2.05-1.94(m,1H),1.90-1.78(m,1H),1.61-1.44(m,2H),1.15(d,3H).
[0876] Example 36: Preparation of Compound 36
[0877] Compound 36 was obtained using 36A as a substrate by referring to the synthetic method of compound 32. Compound 36 is one of the structures of compound 36-1 and compound 36-2.
[0878] LCMS m / z=590.6[M+1] +
[0879] 1H NMR(400MHz,DMSO-d6)δ12.40(s,1H),9.55(s,1H),9.09(s,1H),7.88(s,1H),6.39-6 .14(m,1H),4.63-4.45(m,1H),4.25-4.06(m,3H),3.79-3.67(m,1H),3.65-3.55(m,1 H),3.50-3.37(m,3H),3.06-2.94(m,1H),2.88-2.76(m,1H),2.74-2.60(m,1H),2.47 -2.37(m,1H),2.11-1.97(m,1H),1.90-1.74(m,1H),1.60-1.42(m,2H),1.15(d,3H).
[0880] Example 37: Preparation of Compound 37
[0881] Compound 37 was obtained using compound 34e-2 as the starting material by referring to the synthetic method of compound 34.
[0882] Analytical method (instrument and preparative column: high performance liquid chromatography-normal phase chromatography, preparative column model: AD-H (4.6*2.50mm, 5um)) mobile phase system: n-hexane: isopropanol (80:20), column temperature: 35°C, flow rate: 1.0mL / min.
[0883] The compound with retention time T=39.932 min is compound 37, which is one of the structures of compound 34-1 and compound 34-2.
[0884] LCMS m / z=589.2[M+1] +
[0885] 1 H NMR(400MHz,CD3OD)δ9.00(s,1H),7.98(s,1H),7.75(dd,1H),7.58(d,1H),4.70–4.62(m,1H),4.30-4.12(m,3H),3.93-3.81(m,1H) ),3.76-3.69(m,1H),3.68-3.58(m,2H),3.54-3.44(m,1H),3.04-2.80(m,3H),2.67-2.56(m,1H),2.09-1.78(m,4H),1.28(d,3H).
[0886] Example 38: Preparation of Compound 38
[0887] Compound 38 was obtained using compound 32e-2 as a substrate by referring to the synthetic method of compound 32.
[0888] Analytical method (instrument and preparative column: high performance liquid chromatography-normal phase chromatography, preparative column model: AD-H (4.6*2.50mm, 5um)) mobile phase system: n-hexane: isopropanol (80:20), column temperature: 35°C, flow rate: 1.0mL / min.
[0889] The compound with retention time T=42.395 min is compound 38, which is one of the structures of compound 32-1 and compound 32-2.
[0890] LCMS m / z=589.3[M+1] +
[0891] 1 H NMR(400MHz,CD3OD)δ8.70(d,1H),7.97(s,1H),7.77(s,1H),7.22(dd,1H),4.72-4.62(m,1H),4.30-4.13(m,3H),3.93-3.83(m,1H ),3.77-3.69(m,1H),3.68-3.59(m,2H),3.54–3.45(m,1H),3.04-2.80(m,3H),2.67–2.56(m,1H),2.10-1.79(m,4H),1.28(d,3H).
[0892] Example 39: Synthesis of Compound 8-4:
[0893] Step 1: Synthesis of 39a
[0894] 9 g of the hydrochloride salt (4.61 g, crude product) and 2-chloro-5-trifluoromethylpyrimidine (3.66 g, 20.05 mmol) were dissolved in dimethyl sulfoxide (50 mL). Potassium carbonate (6.39 g, 46.23 mmol) was added and the mixture was reacted at 90°C for 16 hours. After cooling to room temperature, saturated brine (40 mL) was added to the reaction solution, and extraction was performed with ethyl acetate (60 mL x 2). The organic phases were combined, washed with saturated brine (50 mL x 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative column chromatography (petroleum ether:ethyl acetate (v / v) = 7:3) to obtain 39a (5.00 g).
[0895] LCMS m / z=373.2[M+1] +
[0896] Step 2: Synthesis of 39b
[0897] 39a (6.5 g, 17.46 mmol) was dissolved in a mixture of tetrahydrofuran (250 mL) and anhydrous ethanol (250 mL). Sodium borohydride (660 mg, 17.46 mmol) and calcium chloride (970 mg, 8.74 mmol) were added and the mixture was maintained at 0°C for 1 hour. The reaction was quenched by the slow dropwise addition of saturated aqueous ammonium chloride (6 mL) and ethyl acetate (6 mL). The mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (0-25% (MeOH:DCM = 1:10) in (EA:PE = 1:5)) to afford 39b (2.18 g, 38%).
[0898] 39b (diastereomer 1) H at C2 on ring A (δ 2.71–2.53) and H at C4 1 (δ1.72-1.60) has obvious 1 H- 1 H NOESY signal (deuterated solvent is CD3COOD, 1 H- 1 H COSY see Figure 1, 1 H- 1 H NOESY (see Figure 2 ) confirmed that the configuration of 39b is as follows:
[0899] LCMS m / z=331.1[M+1] +
[0900] 1 H NMR(400MHz,CD3COOD)δ8.66(d,2H),4.88-4.73(m,2H),4.70-4.60(m,1H),4.08-3.94(m,1H),3.89-3.79(m,1H),3.66-3.54(m,1H), 3.29-3.13(m,1H),3.00-2.83(m,2H),2.71–2.53(m,1H),2.27-2.14(m,1H),2.03-1.92(m,1H),1.85-1.72(m,1H),1.72-1.60(m,1H).
[0901] Step 3: Synthesis of 39c
[0902] 39b (2.0 g, 6.05 mmol) and 1c (4.10 g, 11.74 mmol) were dissolved in toluene (100 mL). After nitrogen substitution, boron trifluoride etherate (6 mL) was added dropwise at 0°C and the temperature was raised to 25°C for 16 h. The reaction mixture was cooled to 0°C and slowly added dropwise to a saturated sodium bicarbonate solution at 0°C. Extraction was performed with ethyl acetate (50 mL x 3), and the organic phases were combined. The organic phases were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography (petroleum ether:tetrahydrofuran (v:v) = 3:1) to obtain 39c (1.3 g, 41%).
[0903] LCMS m / z=518.1[M+1] +
[0904] Step 4: Synthesis of 39d
[0905] Hydrazine hydrate (3 mL, 80% content) was added to a solution of 39c (2.0 g, 3.86 mmol) in ethanol (100 mL) and allowed to react at room temperature for 16 hours. The mixture was filtered, and the filter cake was washed with ethanol. The filtrate was concentrated under reduced pressure, and ethyl acetate (100 mL) was added, filtered, and the filter cake was washed with ethyl acetate. The filtrate was concentrated to yield 39d (1.5 g, crude product).
[0906] LCMS m / z=388.1[M+1] +
[0907] Step 5: Synthesis of 39e
[0908] 39d (1.5 g, crude) and intermediate 1 (1.6 g, 5.03 mmol) were dissolved in acetonitrile (20 mL), and triethylamine (1.57 g, 15.48 mmol) was added. The mixture was allowed to react at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure to obtain the crude product, which was then purified by column chromatography (petroleum ether:tetrahydrofuran (v / v) = 1:1) to afford 39e (2.138 g, 83% yield over two steps).
[0909] LCMS m / z=670.8[M+1] + .
[0910] Step 6: Synthesis of compound 8-4
[0911] 39e (2.138 g, 3.19 mmol) was dissolved in trifluoroacetic acid (20 mL). Trifluoromethanesulfonic acid (20 mL) was added at 0°C and the mixture was allowed to react at room temperature for 2 hours. The reaction solution was concentrated to dryness under reduced pressure, and ethyl acetate (50 mL) was added. The pH of the system was adjusted to a weakly alkaline state by slowly adding saturated aqueous sodium bicarbonate at 0°C. The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (50 mL x 2). The organic phases were combined. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography (petroleum ether:ethyl acetate (v / v) = 1:9) to afford compound 8-4 (1.1 g, 63%).
[0912] LCMS m / z=550.6[M+1] + .
[0913] 1 H NMR(400MHz,DMSO-d6)δ12.40(s,1H),8.73(s,2H),7.88(s,1H),6.31-6.17(m,1H), 4.71-4.57(m,2H),4.52-4.42(m,1H),4.23-4.09(m,1H),3.75-3.67( m,1H),3.65-3.57(m,1H),3.51-3.40(m,2H),3.40-3.32(m,1H),3.09- 2.94(m,1H),2.85-2.73(m,1H),2.72-2.59(m,1H),2.47-2.34(m1H), 2.06-1.93(m,1H),1.90-1.77(m,1H),1.60-1.42(m,2H),1.15(d,3H).
[0914] Chiral HPLC: Analytical method (instrument: Shimadzu LC-30AD sf; preparative column model: Chiralcel OJ-3 50×4.6 mm ID, 3 μm; mobile phase system: A for CO2 and B for MeOH (0.05% DEA), 3.0 ml / min, retention time T=2.009 min.
[0915] pass 1 H NMR and chiral HPLC confirmed that compound 8-B obtained in Example 8 was compound 8-4.
[0916] Biological test cases
[0917] 1. NCI-H1373 cell proliferation inhibition
[0918] NCI-H1373 cells were purchased from ATCC and cultured in RPMI-1640 + 10% FBS + 1% double-antibody in a 37°C, 5% CO2 incubator. On the first day, exponentially growing NCI-H1373 cells were harvested and plated onto clear-bottomed, white, 96-well plates at a density of 500 cells / well. The plates were incubated overnight at 37°C, 5% CO2, and T0 wells were plated simultaneously. The next day, before drug addition, the culture medium was aspirated and 90 μL of fresh culture medium and 10 μL of various compound concentrations were added to each well, resulting in a final DMSO concentration of 0.1% in each well. After 72 hours of incubation at 37°C, 5% CO2, the culture medium was replaced and fresh compound was added, and the cells were cultured for another 72 hours. The next day, drug addition was performed and the T0 plate was detected using the CellTiter-Glo assay, recorded as RLU0. After the incubation period, 50 μL of detection solution (Cell Viability Assay, Promega, G7573) was added to each well, mixed for 2 minutes, incubated at room temperature for 10 minutes, and the chemiluminescence reading was detected by microplate reader. The results were processed according to formula (1) to calculate the cell viability of each concentration of the compound, and the concentration GI of the compound when the proliferation rate was 50% was calculated using origin9.2 software. 50 Value. RLU compound The readings for the drug-treated groups, RLU control is the average value of the solvent control group. Growth%=(RLU compound -RLU0) / (RLU control -RLU0)×100% Formula (1)
[0919] Table 1 Inhibitory effects of compounds on cell proliferation of NCI-H1373 cells
[0920] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good cell proliferation inhibitory activity against NCI-H1373 cells. The inhibitory activity of some compounds against NCI-H1373 cells is shown in Table 1.
[0921] 2. Pharmacokinetic Testing in Mice
[0922] 2.1 Experimental Animals: Male Balb / c mice, approximately 22 g, 6 to 8 weeks old, 6 mice per compound, purchased from Chengdu Dashuo Experimental Animal Co., Ltd.
[0923] 2.2 Experimental Design: On the day of the experiment, Balb / c mice were randomly divided into groups according to body weight. They were fasted but not watered for 12-14 hours before administration and fed 4 hours after administration.
[0924] Table 2. Dosing Information
[0925] Intravenous administration solvent: 5% DMA + 5% Solutol + 90% Saline; Oral administration solvent: 0.5% MC
[0926] Before and after drug administration, 0.03 ml of blood was collected from the eye sockets under isoflurane anesthesia. The blood was placed in an EDTAK2 centrifuge tube and centrifuged at 5000 rpm at 4°C for 10 minutes to collect plasma. Blood was collected from the intravenous and oral gavage groups at 0, 2, 5, 15, 30 minutes, and 1, 2, 4, and 7 hours. All samples were stored at -80°C until analysis.
[0927] Table 3. Pharmacokinetic parameters of test compounds in mouse plasma -:not applicable.
[0928] Conclusion: The compounds of the present invention, such as the example compounds, have good pharmacokinetic properties. Specifically, compound 8-B, compound 9, compound 31 and compound 34 have higher exposure in mice and good bioavailability.
[0929] 3. Pharmacokinetic Testing in Beagle Dogs
[0930] Experimental purpose: To administer the test substance to beagle dogs by single-dose intravenous and oral gavage, determine the concentration of the test substance in beagle dog plasma, and evaluate the pharmacokinetic characteristics of the test substance in beagle dogs.
[0931] Experimental animals: Male beagle dogs, weighing about 8-11 kg, 6 per compound, purchased from Chengdu Dashuo Experimental Animal Co., Ltd.
[0932] Experimental method: On the day of the experiment, beagle dogs were randomly divided into groups according to body weight. They were fasted but not watered for 12-14 hours before administration and fed 4 hours after administration.
[0933] Table 4. Dosing Information
[0934] Intravenous administration solvent: 5% DMA + 5% Solutol + 90% Saline; Oral administration solvent: 0.5% MC
[0935] Sampling: Before and after administration, 1 ml of blood was collected from the limb vein and placed in an EDTAK2 centrifuge tube. Centrifuge at 5000 rpm, 4°C for 10 min to collect plasma.
[0936] Blood was collected at 0, 5, 15, 30 min, 1, 2, 4, 6, 8, 10, 12, and 24 h. All samples were stored at -80°C prior to analysis. Quantitative analysis was performed using LC-MS / MS.
[0937] Table 5. Pharmacokinetic parameters of test compounds in beagle dog plasma -:not applicable.
[0938] Conclusion: The compounds of the present invention, such as the example compounds, have good pharmacokinetic properties. Specifically, compound 34 has good PK performance in beagle dogs.
[0939] 4.CYP450 enzyme inhibition test
[0940] The purpose of this study was to evaluate the effects of test substances on the activities of five cytochrome P450 (CYP) isoforms (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) in human liver microsomes using an in vitro assay system. Specific probe substrates for each CYP450 isoform were incubated with human liver microsomes and varying concentrations of the test substances. The reaction was initiated by the addition of reduced nicotinamide adenine dinucleotide phosphate (NADPH). After the reaction, the samples were processed and metabolites generated from the specific substrates were quantitatively detected by liquid chromatography-tandem mass spectrometry (LC-MS / MS). Changes in CYP enzyme activity were measured, and IC50 values were calculated to evaluate the inhibitory potential of the test substances against each CYP enzyme isoform.
[0941] Conclusion: The compounds of the present invention, such as the example compounds, have poor inhibitory activity against CYP enzymes. Specifically, the IC50 values of compound 8-B against CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 are all greater than 50 μM.
[0942] 5. hERG potassium channel effect test
[0943] Experimental platform: electrophysiology manual patch clamp system
[0944] Cell line: Chinese hamster ovary (CHO) cell line stably expressing hERG potassium channel
[0945] Experimental Methods: hERG potassium channel currents were recorded using the whole-cell patch-clamp technique at room temperature in CHO (Chinese Hamster Ovary) cells stably expressing the hERG potassium channel. Glass microelectrodes were pulled from glass electrode blanks (BF150-86-10, Sutter) using a puller. After perfusion with electrode solution, the tip resistance was approximately 2-5 MΩ. The microelectrodes were connected to the patch-clamp amplifier by inserting them into the amplifier headstage. Clamping voltage and data recording were controlled and recorded by a computer using pClamp 10 software with a sampling frequency of 10 kHz and a filter frequency of 2 kHz. After whole-cell recordings were obtained, cells were clamped at -80 mV. To elicit hERG potassium currents (I hERG ), a 2-second depolarization step from -80 mV to +20 mV was applied, followed by repolarization to -50 mV, which was maintained for 1 second before returning to -80 mV. This voltage stimulus was applied every 10 seconds, and drug administration was initiated after confirming the stability of the hERG potassium current (at least 1 minute). Compounds were administered for at least 1 minute at each tested concentration, and at least two cells were tested at each concentration (n≥2).
[0946] Data processing: Data analysis was performed using pClamp 10, GraphPad Prism 5, and Excel software. The degree of inhibition of hERG potassium current (peak hERG tail current induced at -50 mV) by different compound concentrations was calculated using the following formula: Inhibition% = [1–(I / Io)] × 100%
[0947] Wherein, Inhibition% represents the inhibition percentage of the compound on hERG potassium current, and I and Io represent the amplitude of hERG potassium current before and after drug addition, respectively.
[0948] Compound IC 50 Calculated using GraphPad Prism 5 software by fitting the following equation: Y = Bottom + (Top-Bottom) / (1 + 10^((LogIC50-X)*HillSlope))
[0949] Where X is the Log value of the test sample concentration, Y is the inhibition percentage at the corresponding concentration, and Bottom and Top are the minimum and maximum inhibition percentages, respectively.
[0950] Table 6: IC values of compounds for inhibition of hERG potassium channel current 50 value
[0951] Conclusion: The compounds of the present invention, such as the example compounds, have poor hERG inhibitory activity. Specifically, the IC values of compounds 31 and 34 for hERG potassium channel current inhibition are 50Greater than 20μM.
[0952] 7. PARP7 enzyme activity test
[0953] PARP7 chemiluminescence detection kit was purchased from BPS Bioscience. The histone solution in the kit was diluted 5 times with 1X PBS, 25 μL of histone dilution was taken to the microplate, and incubated at 4°C overnight. After the incubation, the plate was washed 3 times with PBST (0.05% Tween-20), 100 μL of blocking solution was taken to the microplate, and incubated at 25°C for 90 minutes; after the incubation, the plate was washed 3 times with PBST. 2.5 μL of compounds of different concentrations diluted in the test buffer and 12.5 μL of substrate mixed solution (1.25 μL 10X PARP test buffer; 1.25 μL 10X PARP test mixture; 10 μL double distilled water) were taken to the microplate. The PARP7 enzyme was diluted to 6 ng / μL, 10 μL was taken to the microplate, and the reaction system was incubated at 25°C for 60 minutes;
[0954] After incubation, wash the plate three times with PBST. Dilute Streptavidin-HRP 50-fold with blocking buffer, then transfer 25 μL to the microplate and incubate at 25°C for 30 minutes. After incubation, wash the plate three times with PBST. Mix ELISA ECL substrate A and substrate B at a 1:1 (v / v) ratio, transfer 50 μL to the microplate, and read the chemiluminescence value.
[0955] The inhibition rate was calculated according to Formula 2, where RLU sample Read the compound wells, RLU max Reading value for solvent control well, RLU min The values of the control wells without PARP7 enzyme were read and the IC was calculated using GraphPad Prism software using a four-parameter curve fitting (log (inhibitor) vs. response--Variable slope). 50 Inhibition% = (1-(RLU sample -RLU min ) / (RLU max -RLU min ))×100%(Formula 2)
[0956] Conclusion: The compounds of the present invention, such as the compounds in the examples, have an inhibitory effect on the PARP7 enzyme.
[0957] 8. MARylation test in NCI-H1373 cells
[0958] NCI-H1373 cells were purchased from ATCC and cultured in RPMI-1640 + 10% FBS + 1% double-antibody in a 37°C, 5% CO2 incubator. On the first day, NCI-H1373 cells in the exponential growth phase were collected and plated on a clear-bottom white 6-well culture plate at a density of 2 × 10 5 Cells were cultured overnight in a 37°C, 5% CO2 incubator. The next day, before drug addition, the culture medium was aspirated and 1 mL of fresh culture medium and 1 mL of various compound concentrations were added to each well, resulting in a final DMSO concentration of 0.1%. The cells were incubated at 37°C, 5% CO2 for 48 hours. After incubation, the cells were harvested. 35 μL of cell lysis buffer was added to each tube and lysed on ice for 15 minutes with vortexing. The cells were centrifuged at 4°C, 13,000 rpm, and the supernatant was stored at low temperature. Protein quantification was performed using a BCA assay kit (Biyuntian, P0009) to calculate the protein concentration of the samples. The protein concentration of each sample was diluted to 0.8 mg / mL with 0.1× sample buffer. 4 μL of the dilution and 1 μL of 5× mix were mixed and incubated at 95°C for 5 minutes to denature the protein. Samples were added according to the WES (ProteinSimple) instructions, with a dilution ratio of 1:100 for Poly / Mono-ADP Ribose (E6F6A) Rabbit mAb and 1:400 for β-Actin (8H10D10) Mouse mAb, and assayed. The results were processed according to formula (3), and the MARylation % at each compound concentration was calculated. GraphPad Prism 8 software was used to fit the IC values. 50 Value. Corr.Area compound is the peak area of the drug-treated group, Corr.Area control is the peak area of the solvent control group. compound / Corr.Area control )×100 Formula (3)
[0959] Table 7. Inhibitory activity of compounds in MARylation in NCI-H1373 cells
[0960] Conclusion: The compounds of the present invention, such as the compounds in the examples, have an inhibitory effect on MARylation in NCI-H1373 cells. Specifically, the inhibitory activity of compound 8-B on MARylation in NCI-H1373 cells is better than that of the control RBN-2397.
[0961] 9. Liver microsome stability test
[0962] In this study, human liver microsomes were used as an in vitro model to evaluate the metabolic stability of the test substances.
[0963] At 37°C, 1 μM of the test substance was incubated with microsomal proteins and coenzyme NADPH. The reaction was terminated by adding ice-cold acetonitrile containing an internal standard after a certain time (5, 10, 20, 30, 60 min). The concentration of the test substance in the sample was detected by LC-MS / MS. The T value was calculated based on the ln value of the drug residual rate in the incubation system and the incubation time. 1 / 2 , and further calculated the liver microsomal intrinsic clearance CL int(Liver) .
[0964] Table 8. Human liver microsome stability results
[0965] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good metabolic stability in human liver microsomes.
Claims
1. A compound or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, the compound being selected from the compound represented by general formula (A), wherein W is selected from a bond, C(=O); Ring B is selected from is a single bond or a double bond; Z is selected from N, C or CH; Y is selected from a bond, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)2N(R y )-、-N(R y )-、C 1-4 Alkylene, -OC 1-3 Alkylene-, -C 1-3 Alkylene O-, -C 1-2 Alkylene OC 1-2 Alkylene, -C 1-3 Alkylene S-, -C 1-3 Alkylene S(=O)-, -C 1-3 Alkylene S(=O)2-, -N(R y )C 1-3 Alkylene-, -C 1-3 Alkylene N(R y )-、-C 1-2 Alkylene N(R y )-C 1-2 Alkylene, wherein the alkylene is optionally substituted by 1 to 4 groups selected from halogen, =O, =S, OH, cyano, C 1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 substituted by a cycloalkyl substituent; R y Each independently selected from H, C 1-6 Alkyl or C 3-6 Cycloalkyl, wherein the alkyl or cycloalkyl is optionally substituted by 1 to 4 groups selected from deuterium, halogen, CF3, OH, cyano, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, 3 to 8 membered heterocyclic group or C 3-6 The heterocyclic group is substituted by a cycloalkyl substituent, wherein the heterocyclic group contains 1 to 3 heteroatoms selected from O, S, and N; R b Each independently selected from H, halogen, cyano, OH, =O, C 1-6 Alkyl, C 1-6 Alkoxy, -(CH2) q -C 3-6 Cycloalkyl, wherein the -CH2-, alkyl, alkoxy or cycloalkyl is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, NH2, C 1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy or C 3-6 substituted by a cycloalkyl substituent; Ring A is selected from C 6-10 Aromatic ring, 5-10 membered heteroaromatic ring or 5-10 membered heterocyclic ring, wherein the heteroaromatic ring or heterocyclic ring contains 1 to 5 heteroatoms selected from O, S and N; Ring X is selected from C 6-10 Aromatic ring, 5-10 membered heteroaromatic ring, C 3-10 A carbocyclic ring or a 5-10 membered heterocyclic ring, wherein the heteroaromatic ring or heterocyclic ring contains 1 to 5 heteroatoms selected from O, S, and N; R x 、R a Each independently selected from H, halogen, cyano, OH, =O, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, -SO2-C 1-6 Alkyl, -C(=O)C 1-6 Alkyl, -(CH2) q -C 3-10 Carbocyclic ring or -(CH2) q -3 to 12 membered heterocyclic ring, wherein said -CH2-, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, =O, NH2, NH(C 1-6 alkyl), N(C 1-6 Alkyl)2, C 1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 substituted by a cycloalkyl group or a 3- to 10-membered heterocyclic ring containing 1 to 3 heteroatoms selected from O, S, and N; L is selected from -Q1-Ak1-Q2-Ak2-, and the right side is connected to ring B; Ak1 and Ak2 are each independently selected from C 1-4 Alkylene, C 2-4 Alkenylene, C 2-4 Alkyne group, wherein Ak1 is optionally substituted by 0 to 4 R k1 The Ak2 is optionally substituted with 0 to 4 R k2 replace; R k1 、R k2 Each independently selected from halogen, cyano, OH, =O, NH2, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -OC 3-6 Carbon ring, C 3-6 Carbocyclic or 4 to 7 membered heterocyclic rings, the alkyl, alkene alkyl, alkynyl, alkoxy, carbocyclic or heterocyclic rings are optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, -OC 3-8 Carbon ring, C 3-8 is substituted by a carbocyclic or 4- to 10-membered heterocyclic substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N; Alternatively, R k1 With R k1 、R k2 With R k2 、R k1 With R k2 Direct connection to form C 3-6 A carbocyclic ring or a 4- to 7-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, =O, OH, cyano, C 1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 The heterocyclic ring is substituted by a cycloalkyl substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N; Q1, Q2 are each independently selected from O, S, N (R q )、C(=O)、C(=O)N(R q )、N(R q )C(=O), C(=O)O, OC(=O), S(=O), S(=O)2, S(=O)2N(R q )、N(R q )S(=O)2、N(R q )C(=O)N(R q )、N(R q )C(=O)N(R q ); R q Each independently selected from H, C 1-6 Alkyl or C 3-6 Cycloalkyl, wherein the alkyl or cycloalkyl is optionally substituted by 1 to 4 groups selected from halogen, CF3, OH, cyano, NH2, C 1-6 Alkyl or C 1-6 substituted by an alkoxy substituent; Alternatively, R q With R k1 or R k2 Directly connected to form a 4- to 7-membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, =O, OH, cyano, C 1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 The heterocyclic ring is substituted by a cycloalkyl substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N; q is each independently selected from 0, 1, 2, 3 or 4; a is selected from 0, 1, 2, 3 or 4; b is selected from 0, 1, 2, 3 or 4; x is selected from 0, 1, 2, 3 or 4; Optionally, 1 to 10 H are replaced by D in the compound represented by general formula (A).
2. The compound according to claim 1 or its stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein the compound of general formula (A) is selected from the compounds represented by general formula (I), wherein 3. The compound according to claim 2 or its stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein the compound is selected from the compound represented by general formula (II), Ring X is selected from a 5-6 membered heteroaromatic ring or a 5-6 membered heterocyclic ring, wherein the heteroaromatic ring or heterocyclic ring contains 1 to 5 heteroatoms selected from O, S, and N; Or ring X is selected from an 8-10 membered cyclic heteroaromatic ring or an 8-10 membered cyclic heterocyclic ring, wherein the heteroaromatic ring or heterocyclic ring contains 1 to 5 heteroatoms selected from O, S, and N; R a1 、R a2 Each independently selected from H, halogen, cyano, OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, -SO2-C 1-6 Alkyl, -C(=O)C 1-6 Alkyl, -(CH2) q -C 3-10 Carbocyclic ring or -(CH2) q -3 to 12 membered heterocyclic ring, wherein said -CH2-, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, OH, cyanogen, Base, =O, C 1-6 Alkyl, halogen-substituted C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 substituted by a cycloalkyl group or a 3- to 10-membered heterocyclic ring containing 1 to 3 heteroatoms selected from O, S, and N; The definitions of the remaining groups are the same as those in FIG2.
4. The compound according to claim 3, or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, Y is selected from a bond, -O-, -N(R y )-、C 1-3 Alkylene, -OC 1-2 Alkylene-, -C 1-2 Alkylene O-, -C 1-2 Alkylene OC 1-2 Alkylene, -C 1-2 Alkylene S-, -C 1-2 Alkylene S(=O)2-, -N(R y )C 1-2 Alkylene-, -C 1-2 Alkylene N(R y )-、-C 1-2 Alkylene N(R y )-C 1-2 Alkylene, wherein the alkylene is optionally substituted by 1 to 4 groups selected from halogen, =O, =S, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a cycloalkyl substituent; R y Each independently selected from H, C 1-4 Alkyl or C 3-6 Cycloalkyl, wherein the alkyl or cycloalkyl is optionally substituted by 1 to 4 groups selected from deuterium, halogen, CF3, OH, cyano, NH2, C 1-4 Alkyl, C 1-4 Alkoxy, 3 to 8 membered heterocyclic group or C 3-6 The heterocyclic group is substituted by a cycloalkyl substituent, wherein the heterocyclic group contains 1 to 3 heteroatoms selected from O, S, and N; R x 、R a1 、R a2 Each independently selected from H, halogen, cyano, OH, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 1-4 Alkylthio, -SO2-C 1-4 Alkyl, -C(=O)C 1-4 Alkyl, -(CH2) q -C 3-6 Carbocyclic ring or -(CH2) q -3 to 6 membered heterocyclic ring, wherein said -CH2-, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, =O, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a cycloalkyl group or a 3- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms selected from O, S, and N; R b Each independently selected from H, halogen, cyano, OH, =O, C 1-4 Alkyl, C 1-4 Alkoxy, -(CH2) q -C 3-6 Cycloalkyl, wherein the -CH2-, alkyl, alkoxy or cycloalkyl is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, NH2, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 substituted by a cycloalkyl substituent; Ak1 and Ak2 are each independently selected from C 1-3 Alkylene, C 2-3 Alkenylene, C 2-3 Alkyne group, wherein Ak1 is optionally substituted by 0 to 4 R k1 The Ak2 is optionally substituted with 0 to 4 R k2 replace; R k1 、R k2 Each independently selected from halogen, cyano, OH, =O, NH2, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Carbocyclic or 4 to 7 membered heterocyclic rings, wherein the alkyl, alkoxy, carbocyclic or heterocyclic rings are optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, NH2, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 is substituted by a carbocyclic or 4- to 6-membered heterocyclic substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N; Alternatively, R k1 With R k1 、R k2 With R k2 、R k1 With R k2 Direct connection to form C 3-6 A carbocyclic ring or a 4- to 7-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, =O, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 The heterocyclic ring is substituted by a cycloalkyl substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N; Q1, Q2 are each independently selected from O, S, N (R q )、C(=O)、C(=O)N(R q )、N(R q )C(=O), S(=O)2; R q Each independently selected from H, C 1-4 Alkyl, wherein the alkyl group is optionally substituted by 1 to 4 groups selected from halogen, CF3, OH, cyano, NH2, C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent; Alternatively, R q With R k1 、R q With R k2 Directly connected to form a 4- to 7-membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, =O, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 The heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N.
5. The compound according to claim 4, or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, wherein: Ring X is selected from a pyridine ring, a pyrimidine ring, a pyrazine ring, a pyridazine ring, a thiophene ring, a thiazole ring, a furan ring, an oxazole ring, a pyrrole ring, a pyrazole ring or an imidazole ring; Or ring X is selected from triazine ring, benzothiazole ring, pyridothiazole ring, pyrimidothiazole ring, pyridazinothiazole ring, pyrazinothiazole ring, benzoxazole ring, pyridotoxazole ring, pyrimidotoxazole ring, pyridazinotoxazole ring, pyrazinotoxazole ring, pyridopyrrole ring, pyridopyrazole ring, pyrimidothiphene ring, pyrimidopyrazole ring, pyrimidopyrrole ring, pyrimidoimidazole ring, pyrimidotriazole ring, pyrimidofuran ring, pyrimidopyrrole ring, Quinoline ring, isoquinoline ring, pyrimidopyridine ring, triazole ring, triazolopyridine ring, triazolothiazole ring, triazolooxazole ring, triazoloimidazole ring, triazolopyrazole ring, R x 、R a1 、R a2 Each independently selected from H, F, Cl, Br, I, cyano, OH, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, -SCH3, -SCH2CH3, -SO2CH3, -SO2CH2CH3, -C(=O)CH3, -C(=O)CH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl, phenyl, pyridyl, thiazolyl, thienyl, oxazolyl, furyl, pyrrolyl, pyrazolyl, imidazole wherein the methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, -SCH3, -SCH2CH3, -SO2CH3, -SO2CH2CH3, -C(=O)CH3, -C(=O)CH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl, phenyl, pyridyl, thiazolyl, thienyl, oxazolyl, furyl, pyrrolyl, pyrazolyl, imidazolyl is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a cycloalkyl substituent; R b Each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl or isopropyl, wherein the methyl, ethyl, propyl or isopropyl is optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, NH2, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 substituted by a cycloalkyl substituent; Y is selected from a bond, -O-, -N(R y )-、-N(R y )C(=O)-、-C(=O)N(R y )-, -CH2-, -CH2CH2-, -CH2CH2CH2-, -OCH2-, -OCH2CH2-, -CH2O-, -CH2CH2O-, -CH2OCH2-, -CH2S-, -CH2CH2S-, -CH2S(=O)2-, -CH2CH2S(=O)2-, -N(R y )CH2-、-N(R y )CH2CH2-、-CH2N(R y )-、-CH2CH2N(R y )-、-N(R y )C(=O)CH2-、-CH2C(=O)N(R y )-, wherein CH2 is optionally substituted by 0 to 2 groups selected from H, =O, =S, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 substituted by a cycloalkyl substituent; R y Each independently selected from H, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, wherein the methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl is optionally substituted by 1 to 4 groups selected from deuterium, halogen, CF3, OH, cyano, NH2, C 1-4 Alkyl, C 1-4 Alkoxy, 3 to 8 membered heterocyclic group or C 3-6 The heterocyclic group is substituted by a cycloalkyl substituent, wherein the heterocyclic group contains 1 to 3 heteroatoms selected from O, S, and N; Ak1 and Ak2 are each independently selected from methylene, ethylene, propylene, vinylene, propenylene, ethynylene, and propynylene, wherein Ak1 is optionally replaced by 0 to 4 R k1 The Ak2 is optionally substituted with 0 to 4 R k2 replace; R k1 、R k2 Each independently selected from F, Cl, Br, I, cyano, OH, =O, NH2, NH(CH3), N(CH3)2, methyl, ethyl, propyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, azetyl, oxadiazolyl, oxadiazolyl, oxadiazolyl, pyridine, phenyl, the methyl, ethyl, propyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, azetyl, oxadiazolyl, oxadiazolyl, pyridine, phenyl, the methyl, ethyl, propyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, Heterobutyl, oxolane, oxacyclohexyl, pyridine, phenyl optionally substituted by 1 to 4 groups selected from halogen, OH, cyano, NH2, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 is substituted by a carbocyclic or 4- to 6-membered heterocyclic substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N; Alternatively, R k1 With R k1 、R k2 With R k2 、R k1 With R k2 Direct connection to form C 3-6 A carbocyclic ring or a 4- to 7-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, =O, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 The heterocyclic ring is substituted by a cycloalkyl substituent, wherein the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N; Q1, Q2 are each independently selected from O, S, N (R q )、C(=O)、C(=O)N(R q )、N(R q )C(=O), S(=O)2; R q Each is independently selected from H, methyl, ethyl; Alternatively, R q With R k1 、R q With R k2 Directly connected to form a 4- to 7-membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted by 1 to 4 groups selected from halogen, =O, OH, cyano, C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 The heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N.
6. The compound according to claim 5, or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, wherein L is selected from -N(R q )-Ak1-O-Ak2-, -O-Ak1-O-Ak2-, -O-Ak1-N(R q )-Ak2-、-N(R q )-Ak1-N(R q )-Ak2-, the left side is directly connected to the pyridazinone ring; Y is selected from a bond, -O-, -NHC(=O)-, -C(=O)NH-, -CH2-, -CH2CH2-, -CH2CH2CH2-, -OCH2-, -OCH2CH2-, -CH2O-, -CH2CH2O-, -NHCH2-, -NHCH2CH2-, -CH2NH-, -CH2CH2NH-, -NHC(=O)CH2-, -CH2C(=O)NH-, -N(CH3)C(=O)-, -C( =O)N(CH3)-, -CH2C(=O)NH-, -CH2C(=O)N(CH3)-, -N(CH2CH3)C(=O)-, -N(CH(CH3)2)C(=O)-, -N(CH2CH( CH3)2)C(=O)-, -N(cyclopropyl)C(=O)-, -N(CH2-cyclopropyl)C(=O)-, -C(=O)N(CH2CH3)-, -C(=O)N(CH(CH3)2)-, -C(=O )N(CH2CH(CH3)2)-, -C(=O)N(cyclopropyl)-, -C(=O)N(CH2-cyclopropyl)-, -C(=O)N(CD3)-, -C(=O)N(CH2-oxetanyl)-, -C(=O)N(CH2-oxolanyl)-, -C(=O)N(CH2-azetidinyl)-, -C(=O)N(CH2-pyrrolidinyl)-, -C(=O)N(CH2-cyclopentyl)-, -C(=O)N(CH2 CH2CH3)-, -C(=O)N(CH2CH(CH2CH3)2)-, -C(=O)N(CH2CH2CH2CH3)-, -C(=O)N(CH2CH2CH(CH3)2)-, -C(= O)N(CH2CH(CH3)CH2CH3)-, -C(=O)N(n-octyl)-, -C(=S)N(CH3)-, -C(=S)N(CH2CH3)-, -C(=S)N(CH2-cyclopropyl)-, -CH2S(=O)2-; R a2 Selected from H.
7. The compound according to claim 6, or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, L is selected from The left side is directly connected to the pyridazinone ring; R x Each independently selected from H, F, Cl, Br, I, cyano, OH, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, vinyl, ethynyl, methoxy, ethoxy, -SCH3, -SCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl, phenyl, pyridyl, thiazolyl, thienyl, oxazolyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, the methyl alkyl, ethyl, propyl, isopropyl, vinyl, ethynyl, methoxy, ethoxy, -SCH3, -SCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl, phenyl, pyridyl, thiazolyl, thienyl, oxazolyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, optionally substituted with 1 to 4 substituents selected from F, OH, cyano, methyl, ethyl, methoxy or ethoxy; R a1 is selected from H, F, Cl, Br, I, cyano, CF3, CHF2, CH2F, methyl, ethyl, propyl, isopropyl, ethynyl, methoxy, ethoxy, -SCH3, -SCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; Selected from R b Each is independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl or isopropyl.
8. The compound according to claim 7, or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, L is selected from The left side is directly connected to the pyridazinone ring; R a1 is selected from F, Cl, Br, CF3, CHF2, CH2F, methyl, cyano, cyclopropyl, isopropyl; R x Each is independently selected from H, F, Cl, Br, cyano, isopropyl, CD3, CF3, CHF2, CH2F, cyclopropyl, cyclobutyl; b is selected from 0, 1, 2, 3; x is selected from 1 and 2.
9. The compound according to claim 1 or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, W is selected from C(═O); Ring X is selected from C 3-10 Cycloalkyl, 4- to 10-membered heterocycloalkyl, phenyl, 5- to 6-membered heteroaromatic ring, 5- to 6-membered heterocycle, 8- to 10-membered paracyclic heteroaromatic ring, or 8- to 10-membered paracyclic heterocycle, wherein the heterocycloalkyl, heteroaromatic ring, or heterocycle contains 1 to 5 heteroatoms selected from O, S, and N; Preferably, ring X is selected from C 3-6 Monocyclic cycloalkyl, C 5-10 Cycloalkyl, C 5-11 Spirocyclic cycloalkyl, C 5-11 Bridged cycloalkyl, 4-7 membered monocyclic heterocycloalkyl, 5-10 membered cyclic heterocycloalkyl, 5-11 membered spirocyclic heterocycloalkyl, 5-11 membered bridged heterocycloalkyl, phenyl, 5-6 membered heteroaromatic ring, 8-10 membered cyclic heteroaromatic ring, wherein the heterocycloalkyl, heteroaromatic ring or heterocycle contains 1 to 5 heteroatoms selected from O, S and N; Preferably, ring X is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclobutylspirocyclobutyl, cyclobutylspirocyclopentyl, cyclobutylspirocyclohexyl, cyclopentylspirocyclopentyl, cyclopentylspirocyclohexyl, cyclohexylspirocyclohexyl, cyclobutylspiroazetidinyl, cyclobutylspiroazacyclopentyl, cyclobutylspiroazacyclohexyl, cyclopentylspiroazacyclopentyl, cyclopentylspiroazacyclohexyl, cyclohexylazaspirocyclohexyl, azetidinylspiroazacyclohexyl, azacyclopentylspiroazacyclopentyl, azacyclopentylspiroazacyclohexyl, azacyclohexylazaspirocyclohexyl, cyclobutyl and cyclobutyl ... Cyclopentyl, cyclobutylcyclohexyl, cyclopentylcyclopentyl, cyclopentylcyclohexyl, cyclohexylcyclohexyl, cyclobutylazetidinyl, cyclobutylazetidinyl, cyclobutylazetidinyl, cyclopentylazetidinyl, cyclopentylazetidinyl, cyclopentylazetidinyl, cyclohexylazetidinyl, azetidinylazetidinyl, azetidinylazetidinyl, azetidinyl, oxetyl, or ring X is as described in claim 5; The remaining groups are as defined in any one of claims 2 to 8.
10. The compound according to claim 9, or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, Selected from 11. The compound according to claim 1 or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, wherein the compound is selected from one of the structures shown in Table E-1.
12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11 or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, and a pharmaceutically acceptable carrier. Preferably, the pharmaceutical composition comprises 1 to 1500 mg of the compound according to any one of claims 1 to 11 or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof.
13. Use of the compound according to any one of claims 1 to 11, or its stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, for preparing a medicament for treating a disease associated with PARP7 activity or expression.
14. The use according to claim 13, characterized in that The disease is selected from tumors.
15. A method for treating a disease in a mammal, the method comprising administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 11, or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or cocrystal thereof, wherein the therapeutically effective amount is preferably 1 to 1500 mg, and the disease is preferably a disease related to PARP7 activity or expression.
